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ABSTRACT 
 
 Group A streptococci (GAS) are serious human pathogens that can cause a wide 
array of diseases ranging from pharyngitis to streptococcal toxic shock (STSS), which is 
caused by excessive cytokines responses triggered by streptococcal superantigens (Strep 
SAgs). SAgs interact simultaneously with HLA class II molecules on antigen presenting 
cells (APC) and with the T cell receptor beta chain variable elements (TCR Vß) and cause 
excessive stimulation of both cell types and massive release of inflammatory mediators.  
 The Strep SAgs include the streptococcal pyrogenic exotoxins (Spes), which play a 
crucial role in the pathogenesis of severe invasive streptococcal diseases, including Strep 
toxic shock syndrome (STSS). However, not all septic individuals infected with SAg-
producing GAS develop STSS. Our epidemiologic studies showed that individual HLA 
class II allelic variation plays a crucial role in modulating the severity of invasive GAS 
diseases.  Certain HLA class II alleles and haplotypes confer strong protection from STSS 
(DRB1*1501/DQB1*0602) or increase the risk for it (DRB1*1401/DQB1*0503 and 
DRB1*0701/DQB1*0202), whereas others behave in a neutral fashion with respect to 
disease severity.  The main aim of this thesis was to validate the direct role of HLA class 
II variation in modulating the severity of GAS sepsis and investigate molecular 
mechanisms underlying the differential effect of HLA class II variation on SAgs responses 
in vitro and in vivo. 
 We validated our epidemiological findings and confirmed the direct role of HLA 
class II allelic variation in modulating the severity of GAS sepsis using HLA transgenic 
(tg) mice expressing alleles of interest. Splenocytes from mice expressing the protective 
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HLA-DQB1*06 (DQ6) allele mounted significantly lower proliferative and cytokine 
responses to Strep SAgs, than splenocytes from mice expressing the neutral 
DRB1*0402/DQB1*0302 (DR4/DQ8) alleles. Furthermore, cross presentation of Strep 
SAgs to pure T cells by antigen presenting cells (APC) from these HLA-tg mice showed 
that presentation by HLA-DQ6 APC elicited significantly lower proliferative and 
inflammatory cytokine responses than by the HLA-DR4/DQ8 APC. These in vitro data 
were supported by in vivo findings, as the DQ6 mice showed significant resistance to 
GAS sepsis with lower inflammatory cytokine responses and longer survival, than the 
DR4/DQ8 mice.  
 Similarly, presentation of the Strep SAgs by human APC expressing STSS 
protective haplotypes elicited significantly lower proliferative and cytokine responses 
than by APC expressing neutral or high risk haplotypes, even when the responding APC-
depleted T cells came from different individuals with different TCR Vβ repertoires. 
Moreover, we screened SAgs responses over a panel of B lymphoblastiod cell lines 
(BLCL), expressing the most prevalent HLA class II haplotypes in populations with high 
incidence of STSS, using pure T cells from different individuals, and reproducibly 
observed significantly higher responses in the presence of the high-risk haplotypes or 
neutral than protective haplotypes. These data demonstrate a dominant role of individual 
HLA class II and not TCR Vß repertoire variation in determining the potency or type of 
responses to the Strep SAgs. 
 An important finding from the above studies is that the presentation of the Strep 
SAgs by the protective HLA class II haplotype (DR15/DQ6) elicits high levels of the 
regulatory cytokine IL-10, and thus may be actively suppressing inflammatory cytokine 
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production.  To further investigate this point and to determine if in the clinical setting, 
humans heterozygous for high risk and protective haplotypes would be protected or prone 
to STSS, we generated a panel of bare lymphocyte syndrome cells (BLS) (class II 
negative cells) expressing individual HLA-DR, DQ to delineate their relative contribution 
to the potency and type of Strep SAg responses. In addition to the mixture of M1T1 
SAgs, we also generated a panel of recombinant SAgs found in this mixture to investigate 
the interaction and relative contribution of variable HLA and SAg molecules to the 
overall response.  
 To ensure equimolar expression of HLA class II alleles on BLS cells, we utilized 
the novel technology of ‘self cleaving’ 2A peptide to generate multicistronic retroviral 
vectors. The constructs were cloned into pHSPG retroviral vector and packaged into 
HSPG viral particles that were used to transduce (BLS). DR or DQ α and β chains were 
expressed as a single message linked by 2A peptide resulting in coordinated expression 
of both chains that was confirmed by quantitative flow cytometric analysis of the 
transduced BLS cells.  
 Presentation of individual Strep SAgs by BLS cells expressing either of the 
protective alleles (DR15 or DQ6) induced significantly lower proliferative and cytokine 
responses than that by BLS cells expressing single alleles on the high-risk haplotypes. 
Reproducibly, higher levels of the immunosuppressive cytokine IL-10 were produced in 
the presence of the protective alleles. Thus, confirming our suggestion that protective 
alleles mediate their effects through active suppression of inflammatory cytokines 
production. 
 ix 
 In an attempt to understand the molecular basis, we investigated if differences in 
binding affinities between specific SAgs and HLA class II alleles affect response level. In 
general, there was a correlation between binding affinity of Alexa fluor 647-labeled SAgs 
to individual class II alleles and response levels, except for SmeZ1 binding to and 
presentation by DQ alleles, where an inverse correlation was observed. However, Ca flux 
studies demonstrated good correlation with the observed responses. These data indicate 
that individual class II alleles differentially bind and present Strep SAgs resulting in 
significantly different proliferative and cytokines responses. The inverse relation between 
SmeZ1 responses and its binding affinities to DQ alleles suggest that different 
combinations of SAgs-HLA alleles may trigger distinct signaling in T cells resulting in 
variable levels of response.  
 In conclusion, our study demonstrates a dominant and direct role of HLA class II 
in controlling Strep SAgs responses and resulting disease severity. The data indicate that 
each SAg-class II allele is unique with distinct behavior that cannot be extrapolated to 
others.  Future studies will investigate this point further and determine the interactions 
between high risk and protective HLA class II alleles, when expressed on the same APC.   
 x 
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Chapter 1. Introduction 
 
Group A Streptococci and Human Diseases 
 Group A streptococci (GAS), S. pyogenes, are β-hemolytic, facultative anaerobic, 
non-motile gram positive, catalase negative, chain forming cocci that normally colonize 
the skin and throat. However, when the bacteria penetrate the physical barrier of the skin 
or when the host immune system is compromised, GAS can cause many diseases of 
variable severity to the extent that they are often considered the most pathogenic member 
of the genus Streptococcus. GAS are strictly human pathogens with no other natural host 
(1, 2). Streptococci were first differentiated on the basis of hemolytic activity into α, β, or 
γ hemolytic (3). Subsequently the presence of a specific carbohydrate in the cell wall 
allowed for further division into groups A, B, C, F, and G (4). Finally, the M- and T- 
typing systems were established (5). These systems use serology to identify cell-wall-
associated M and T protein, respectively. Recently, molecular methods have been used to 
sequence the emm gene, which encodes the M protein, where nucleotide differences 
reflect the specific bacterial emm genotype. With the advent of sophisticated molecular 
approaches, additional classifications and subclassifications of a given M serotype or 
emm genotype can be made taking into account phages that have been acquired by the 
bacteria (6).  Detailed knowledge of the bacterial genome, transcriptome, regulome, 
lipidome and proteome etc. afforded a deeper insight into molecular mechanisms 
involved in bacterial virulence and its interaction with genetically distinct host to cause 
starkly different diseases (7, 8). This information allowed us to better understand and 
dissect host defenses engaged in different diseases caused by these important bacteria. 
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GAS pathogenesis 
 GAS are among the most versatile of human pathogens; they can potentially 
infect most human organs or tissues. These bacteria can be carried asymptomatically or 
cause mild self-limiting superficial illnesses such as pharyngitis, erysipelas and 
pyoderma. Also, they can invade normally sterile sites where they can initiate severe life-
threatening illnesses such as necrotizing fasciitis (NF) and streptococcal toxic shock 
syndrome (STSS) or nonsevere invasive disease such as bacteremia and cellulitis, 
depending mainly on host risk factors (9). In addition to causing these acute diseases, 
GAS are also associated with the post-infection autoimmune diseases, which may affect 
the heart, kidney skin, joints, central nervous system or the brain (10, 11). These 
nonsuppurative sequelae of GAS infection include acute rheumatic fever, acute 
glomerulonephritis, post-streptococcal reactive arthritis or neurological disorders. While 
most recover with no complications, others suffer chronic and debilitating autoimmune 
illnesses such as rheumatic heart disease, renal failure or Sydenham Chorea with possible 
neurologic and neuropsychiatric disorders (12-15). Each year worldwide, GAS cause 
more than 700 million cases of pharyngitis or skin infection and more than 650,000 
invasive infections, with associated mortality of 25% (16).  
 
Re-emergence of severe invasive GAS infections 
 The highly severe forms of acute invasive GAS infections were noted as early as 
the 1840’s and became a major concern during the 1920s epidemics where they were 
associated with high fatality rates. During the time between 1920's and late 1970's, the 
presentation of invasive GAS infections was mostly in the form of mild scarlet fever or 
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cellulitis.  In the early 1980’s, the severe forms of invasive GAS infections suddenly 
resurged after almost 40 years of decline (17-19).  The re-emergence of STSS and NF has 
been reported in several continents. STSS and NF are rapidly progressive diseases 
associated with high mortality rates despite prompt antibiotic therapy and surgical 
interventions. The speed by which the disease progresses in some patients, causing severe 
necrosis and flesh destruction, lead to the designation of ‘flesh eating disease’ (20, 21).  
 Although few distinct GAS serotypes, such as M1, M3, M12, and M28, were 
isolated from severe invasive GAS infections, the M1 serotype has been the most 
prevalent serotype isolated from both noninvasive and invasive infection cases (17, 22, 
23). Interestingly, the resurgence of severe invasive GAS infections coincided with the 
emergence of a particular subclone of the M1T1 serotype, the clonal M1T1 strain, that 
has globally disseminated and persisted for more than 25 years as the most prevalent 
isolate (24, 25).  Indepth genomic and proteomic studies provided valuable insight into 
how this virulent M1T1 clone prevails and revealed several features that distinguishes it 
from related strains. Comparative genomic studies by Aziz et al. (6) showed that the 
emerged M1T1 clonal strain is distinguished from its ancestral strain by the acquisition of 
two new prophages encoding important virulence factors; one carries the potent 
superantigen (SAg), streptococcal pyrogenic exotoxin A (SpeA), and the other carries a 
novel streptodornase that has the highest activity of all know GAS DNAses (6, 26).  This 
strain is also differentiated from its ancestral strain by acquiring from M12 strain a 36 kb 
chromosomal segment that carries two important virulence determinants: streptolysin O 
and DAD+ glycohydrolase (NADase), which demonstrated much higher expression and 
activity than their orthologs present in the ancestral strain but with undetectable activity 
 4 
(27). In vivo, this clonal M1T1 strain, unlike its ancestral strain, attains hypervirulence 
due to a host-imposed selection of mutants in a major two component regulator system 
(COVR/S) associated with increased expression and/or preservation of several major 
bacterial virulence factors, including Sda1 (28, 29)  
 In addition, recent studies have revealed novel features of the soluble M1 protein 
itself that may also contribute to the virulence and prevalence of the clonal M1T1 strain. 
M1/fibrinogen complexes were shown to induce vascular leakage (30) and M1 protein 
can also stimulate monocytes via TLR2 to produce high amounts of proinflammatory 
cytokines (31). Furthermore M1/fibrinogen/M1-specific IgG complexes activate platelets, 
initiating massive coagulopathy and pro-inflammatory state (32), and soluble M1 protein 
can act as a SAg thus contributing to the excessive T cell activation and inflammatory 
cytokines hyper-responsiveness underlying STSS (33). The superantigenic properties of 
M1 protein may explain the overrepresentation of M1T1 strain among other strains 
isolated from streptococcal severe invasive cases. Another M proteins (M5) demonstrated 
SAg-like activities (34), therefore further studies of other M proteins are required to 
explore whether they possess any of the M1 protein characters. 
 
GAS Virulence Factors 
 GAS possess an impressive arsenal of virulence determinants; some are cell 
associated and others are secreted (Fig. 1.1). These can be functionally subclassified into 
those involved in bacterial adhesion, invasion of host tissues, evasion of host defenses, 
and survival. Some bacterial components play overlapping roles in modulating host 
defenses. Certain virulence factors have been studied in vitro only and their actual role in 
 5 
 
Figure 1.1 Summary of the main GAS virulence factors. 
 
Phagocyte recruitment is reduced by peptidases C5a and SpyCEP that degrade the 
chemokines C5a and IL-8, respectively; Complement deposition is limited by M protein 
binding of host counter-regulatory factors C4BP and FH; phagocytic uptake is reduced by 
IdeS/Mac-1 binding of phagocyte Fc receptors and the by the M and F proteins; 
resistance to cationic antimicrobial peptides is afforded by D-alanyl modification of cell 
wall teichoic acid, streptococcal inhibitor of complement (SIC) and streptococcal 
pyrogenic exotoxin B (SpeB); SpeB also causes bacterial spread; SpeB-mediated 
degradation of M protein camouflages the bacteria from recognition by host defenses in 
the early stages of invasion; SIC is involved in inhibiting complemet-mediated killing;  
antibody-mediated opsonization is blocked by proteolytic inactivation of Ig by SpeB, 
Ides, and endoS;  DNase production facilitates escape from neutrophil extracellular traps, 
and the pore-forming cytolysins SLS and SLO exhibit lytic activity against host 
neutrophils and macrophages. (Adapted with permission from Mitchell TJ (2003) (35). 
The Pathogenesis of Streptococcal Infections: From Tooth Decay to Meningitis. Nat rev 
microbiol 1, 219-230.) 
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pathogenesis in not yet clear. I will focus on the well-established virulence factors.  
 
Cell-associated virulence factors 
 Cell-associated virulence factors play a role in bacterial adherence (e.g. M 
protein, fibronectin-binding proteins (FBP), lipoteichoic acid), invasion into host cells 
and tissues (e.g. hyaluronic acid (HA) capsule, FBP and M protein) or evasion of host 
immune responses (e.g. M protein, C5a peptidase, HA capsule and SpeB) (Table 1.1). 
Some of these factors are released in a soluble form from the bacterial surface and can 
still contribute to pathogenesis (e.g. M protein and glyceraldehyde 3-phosphate 
dehydrogenase).  
 
Secreted virulence factors 
 Secreted virulence factors include degrading enzymes such as proteases and 
DNases, leukocidal toxins such as the streptolysins O and S, proteins that inhibit 
complement activation and interfere with phagocytosis and killing (e.g. streptococcal 
pyrogenic exotoxin B (SpeB), EndoS, streptococcal inhibitor of complement (SIC) and 
immunoglobulin G degrading enzyme of S. pyogenes), proteins that promote 
dissemination (e.g. streptokinase, SpeB, DNase and hyaluronidase), proteins that 
suppress chemotaxis (e.g. C5a peptidase) and superantigens (SAgs) that induce systemic 
inflammatory responses and thus increase blood supply of nutrient for the bacteria (Table 
1.2).  Inasmuch as SAgs are central to our studies, the following section will present a 
detailed account of their properties, interaction with host cells and their role in certain 
disease manifestations particularly toxics shock syndrome. 
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Table 1.1 Cell-associated virulence factors. 
 
 
Virulence factor Mode of action 
 Lipoteichoic acid - Adhesin in initial binding process (36) 
 - Resistance to neutrophil killing and the antimicrobial peptides 
(AMP) through change in D-alanine content (37). 
 Hayluronic acid 
capsule 
- Resistance to phagocytic killing by serving as a physical 
barrier restricting access of phagocytes to the opsonins (38). 
- Plays a role in adhesion by binding to collagen (39) and in 
invasion by binding to host hayluronic acid receptor, CD44, on 
pharyngeal epithelial cells and inducing cytoskeleton 
rearrangement (40). 
 Fibronectin–
binding proteins 
(SfbII, Fbp54, M 
protein, SOF and 
Pfbp) 
- Adhesins for binding host tissues. Protein F (prtF1, sfbI) also 
binds Fc region of IgG, preventing antibody-dependent cell 
cytotoxicity by macrophages (41) and promote internalization 
into epithelial cells (42). 
- Bound fibronectin forms complex with collagen that generate 
large bacterial aggregates, which in turn mask opsonic epitopes 
and protect from phagocytosis (43). 
 C5a peptidase - Cleaves the complement-derived chemoattractant C5a (44). 
 S. pyogenes cell 
envelope 
protease 
  (SpyCEP) 
- Inhibits neutrophil recruitment and activation by degrading IL-
8, granulocyte chemotactic protein 2 (GCP-2) and growth-
related oncogene α (GROα) (45, 46). 
 HtrA serine 
protese 
- Resistance to oxidative and thermal stress (47). 
- Chaperone for SpeB and possibly other secreted virulence 
factors (48, 49). 
 M-protein - Inhibits complement-mediated opsonophagocytosis by 
impeding classical pathway (sequester the complement 
regulatory protein C4b binding protein from human serum (50) 
and alternative pathway (bind complement regulator factor H) 
(51, 52). 
- Resistance to neutrophil intracellular killing by inhibiting 
phagosome maturation (53). 
- Tissue adhesion and internalization (54, 55). 
- Camouflage bacteria and impair IgG-dependent complement 
activation by binding IgG through Fc region (56). 
 M-related 
protein 
- Like M-protein, they are antiphagocytic (57).  
 Collagen-binding 
protein 
- Acts as adhesin (58). 
 Heme-binding 
protein 
- Supply iron by acquiring and transporting heme from human 
blood (59). 
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Table 1.1 (continued) 
 
 
Virulence factor Mode of action 
 Collagen-like 
proteins 
- Adherence to epithelial cells and may act as a mask concealing 
the bacteria from immune surveillance (60). 
- Bind low density lipoproteinns (61). 
- Interact with integrin and thus enhance internalization and 
reemergence from epithelial cells (62).  
 Lipoprotein of 
S. pyogenes 
(LSP) 
- Involved in adhesion and internalization (63). 
 CD15s-related 
antigen 
- Adhesin and bacterial disguise from immune recognition  (64) 
 Serum opacity 
factor (SOF) 
- Adhesin (65). 
 Strep leucine-
rich protein  
- Evasion of innate immune response by inhibiting phagocytosis  
(66). 
 Protein H - Inhibits complement activation on bacterial surface by binding 
IgG-Fc element (67). 
 Glutathione 
peroxidase 
- Mediates resistance to phagocyte intracellular killing by 
allowing adaptation to oxidative stress (68).  
 Protein G-related 
α2-M-binding 
protein (GRAB) 
- Binds the human protease inhibitor α2-macroglobulin to 
protect important virulence factors from degradation by either 
the streptococcal or host proteases (69). 
  Plasmin(ogen) 
binding proteins 
- Gylceraldehyde-3- phosphate dehydrogenase, α-enolase and 
plasminogen binding group A streptococcal M-like protein 
(PAM) aid in the dissemination by breaking down fibrin barriers 
(70, 71). 
-Shedded glyceraldehyde-3-phosphate dehydrogenase can bind 
and inactivate the chemoattractant C5a (72). 
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Table 1.2 Secreted virulence factors. 
 
Virulence factor Mode of action 
Streptokinase 
(Ska) 
- Converts plasminogen to the proteolytically active plasmin that 
accumulates on the bacterial surface and contributes to bacterial 
dissemination (73, 74). 
EndoS - Impairs opsonophagocytosis by hydrolyzing conserved 
oligosaccharide from IgG preveting its recognition by phagocyte 
Fc receptors thus blocking classical complement activation (75). 
Hyaluronidases - Breaks down hyaluronic acid in host connective tissues allowing 
the organism or its toxins to spread (76). 
DNases - Degrade neutrophil extracellular traps (NETs) that capture and 
kill bacteria (77). 
SpeB  
(GAS major 
cysteine 
protease)  
- Cleaves IgG, IgM, and IgA impairing antibody-mediated 
opsonization (78). 
- When retained on bacterial surface, it degrades AMP LL-37 (79). 
- Activates matrix metalloproteases, releases biologically active 
IL-1β and kinins from their precursors and degrades vitronectin 
and fibronectin contributing to tissue damage and promoting 
bacterial spread (80-83). 
Immunoglobulin-
G degrading 
enzyme of S. 
pyogenes (Ides/ 
Mac-1) 
- Cleaves IgG, preventing phagocytosis (84).  
- Binds CD16 on neutrophils inhibiting phagocytosis and 
generation of reactive oxygen species (85). 
The 
streptococcal 
inhibitor of 
complement 
(SIC) 
- Inhibits complement-mediated killing by binding the membrane 
attack complex C5-7 (86). 
- Binds and inactivates the AMP α-defensins and LL-37 (87). 
- Resistance to neutrophils internalization (88). 
Leukocidal 
toxins 
- Streptolysin S (SLS) and Streptolysin O (SLO) exert cytocidal 
activity on neutrophils and confers resistance to phagocytic killing 
(89, 90). 
- SLO is required for NADase transport into epithelial cells (91). 
Sperantigenic 
Streptococcal 
pyrogenic 
exotoxins (Spes) 
Disrupt specific immune responses. They interfere with the 
adaptive immune response by driving profound Th-1 and 
suppressing Th-2 responses thereby preventing production of 
specific cytotoxic antibodies. Also, they may cause T cell anergy 
or deletion of T cells bearing SAg-specific Vβ elements (92, 93). 
SlaA - Phospholipase A2 that promote epithelial adhesion, colonization, 
tissue destructions and dissemination (96). 
SibA - Binds IgA, IgG and IgM; interfering with immune system 
recognition of the bacteria (94). 
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Table 1.2 (continued). 
 
Virulence factor Mode of action 
NAD+ 
glycohdrolase 
(NADase) 
- Inhibits chemotaxis by interfering with actin function (95). 
- Induces epithelial cells apoptosis promoting deeper tissue 
invasion (91). 
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Superantigens’ Structure, Function and Interaction with Immune Receptors 
 Superantigens (SAgs) are potent T cell mitogens that, at concentrations as low as 
0.1 pg/ml, can elicit uncontrolled stimulation of resting T cells resulting in fever, shock, 
and death (97-99). Because of this feature, SAgs are considered major culprits in GAS 
severe systemic diseases (SSD) (100-102). The best characterized SAgs are the 
staphylococcal enterotoxins (SEs), which include staphylococcal entertoxin A to E (SEA 
to SEE), SEG to SER, SEC-ovine, SEC-bovine, SEC-canine, SEU as well as toxic shock 
syndrome toxin 1 (TSST-1) (103-105) and the streptococcal SAgs that include several 
streptococcal pyrogenic exotoxins (Spes) such as SpeA, SpeB, SepC, SpeF, SpeG, SpeH, 
SpeI, SpeJ, SpeK, SpeL, SpeM, streptococcal SAg A (SSA), and streptococcal mitogenic 
exotoxin Z (SmeZ) (100, 106). The following section presents an overview of the general 
characteristics of staphylococcal and streptococcal SAgs as well as SAgs from other 
related bacteria.   
 For many years before the mode of action of SAgs was discovered, several 
laboratories were noticing proteins with unusual biological activities that were produced 
by S.aureus, S. pyogens, and Mycoplasma arthriditis with potent mitogenic and/or 
enterotoxic activity (107-110). These proteins, now designated SAgs, include several SEs 
and Spes. It was in the 1950s that the first bacterial SAg was discovered as a toxin 
produced by S. aureus and was given the name staphylococcal entertoxin A (SEA) due to 
its powerful enterotoxic activity (111). However, it was not until many years afterwards 
that Philippa Marrack and John Kappler elucidated the mechanism of immune 
stimulation by SEs and were the first to introduce the term ‘superantigens’ to describe 
proteins with exceptionally high potency to stimulate human T cells through 
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simultaneous interaction with both HLA class II molecules, normally involved in the 
presentation of processed antigenic peptides, and with variable elements within the β 
chain of the α/β T cell receptor (TCR) (112). To be described as a SAg, a protein has to 
meet three main conditions: (1) interacts reproducibly with specific TCR Vβ elements 
(each SAg has a unique Vβ signature); (2) depends on professional antigen-presenting 
cells (APC) expressing either autologous or allogeneic class II molecules (lack MHC 
restriction) to elicit potent T cell proliferation and inflammatory cytokine responses; (3) 
does not require complex processing by APC to be recognized by T cells. 
 
Conventional antigens (Ag) versus superantigens (SAg) 
  There are major differences between SAgs and regular antigens (Ags).  Although 
both bind to major histocompatibility complex class II (MHC II) molecules and to the T 
cell receptor (TCR), their mode of binding is quite different.  Conventional Ags must be 
processed into small peptides before being loaded onto the MHC molecules, and the 
processed antigenic peptides are recognized by specific T cell receptors in the context of 
self MHC II molecules (100, 103, 113). In contrast, SAgs bind as intact molecules to 
MHC II expressed on professional antigen presenting cells (APC), outside the Ag 
peptide-binding groove, and interact with the TCR at a site different from where regular 
Ag is bound (100, 103). Recognition of Ag by the TCR involves the combinatorial effect 
of 5 variable elements: Vβ, Dβ, Jβ, Vα, and Jα. SAgs, on the other hand bind to specific 
elements within the variable region of the T cell receptor β chain (TCR Vβ) (100, 103).  
 The human TCR repertoire comprises 25 types of Vβ elements known also as Vβ 
families. Each SAg has a characteristic TCR Vβ spectrogram, i.e. a characteristic set of 
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TCR Vβ elements that it interacts with, and this can range from 1-9 Vβ elements, 
depending on the SAg (100, 103).  Depending on how many TCR Vβs a given SAg 
interacts with and on the relative frequency of expression of these Vβ elements in a given 
person’s TCR repertoire, a SAg can activate anywhere from 5-20% of the resting T cell 
compared to only 0.00001% that would be stimulated by a conventional Ag (100, 103). 
This remarkable ability of SAgs to stimulate such a high numbers of T cells is unmatched 
by any other physiologic T cell stimulus, and if uncontrolled can cause serious pathology 
in the host. 
 
Discovery of streptococcal superantigens 
 Before the completion of S. pyogenes genome sequence, the gold standard for 
discovering Strep SAgs was by demonstrating the T cell-stimulating activity of bacterial 
culture supernatant from which they were purified and functionally characterized. 
 Showing that a molecule is mitogenic and showing that it is superantigenic are 
two different things. Malak Kotb and Mark Tomai were the first to provide evidence that 
GAS possess SAgs by demonstrating their interactions with HLA-II and their TCR Vβ 
specificity; they showed that pepM5 (M5 protein prepared by controlled pepsin digestion 
of M5 GAS) was a SAg and also characterized its TCR Vβ specificity and the TCR Vβ 
of other SAgs produced by GAS (34, 114). Although the superantigenicity of the pepM5 
protein was disputed and thought to be contaminated by Strep SAgs (115), recent data 
with M1 protein indicate that it does act as a SAg (33).  
 Another streptococcal toxin, the scarlet fever toxin or toxin A was suggested to be 
the cause of scralet fever-like manifestations (Dick reaction) noticed following injection 
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of filtered GAS cultures into healthy volunteers (116). Erythrogenic toxin B and toxin C 
were also identified in GAS culture supernatant (117). As pyrogenic activity was 
supposed to be the main effect of GAS toxins, these toxins were designated streptococcal 
pyrogenic exotoxin A (SpeA), SpeB, and SpeC (118). Other Strep SAgs identified 
experimentally are SSA and SmeZ. A consistent concern during the pre-genomic 
methods of superantigen identification was that SAg preparations were not all on the 
same level of purity, which lead to discrepancy in literature. For example, some studies 
showed that SpeB promoted T cell activation (119, 120) while others that used very 
highly purified SpeB argued that the initial findings were caused by SpeB contamination 
with unknown SAg (121). SpeB is regarded as the major GAS cysteine protease, and its 
superantigenic identity is still disputed. The general belief is that its expression in an 
unnatural host may not allow proper protein folding by HtrA, a GAS chaperon (48) thus 
affecting its biological functions. 
 The publication of the first S. pyogenes genome sequence marked the start of the 
post-genomic age of GAS SAgs discovery (122). Mining the DNA database for genes 
with family signature motifs shared by almost all SAgs lead to identification of several 
new genes encoding putative SAgs. The predicted genes were cloned, and recombinant 
proteins were used for functional studies. Novel SAgs were discovered and designated 
SpeG, SpeH, SpeI, SpeJ, and SpeM (123-125). The rapid discovery of new SAgs caused 
confusing nomenclature with the same SAg being given two different names. For 
example, SpeK discovered in the US is the same as SpeL found in Japan and New 
Zealand (126-128).  
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Superantigens produced by other bacteria  
 In addition to the well recognized SEs and Strep SAgs, other bacteria have been 
shown to produce SAgs that are implicated in infection pathogenesis. Group C 
streptococci (GCS) are regarded as commensals; however, several reports demonstrated 
their association with severe diseases (129-131). SAgs were found in two different GCS. 
The Streptococcus equi pyrogenic exotoxins (Sepe) H, I, L and M are homologous to 
their corresponding S. pyogenes pyrogeinc exotoxins (Spe) H, I, L and M (128, 132). 
Another two SAgs have been identified from S. dysgalactiae subsp. equisimilis called S. 
dysgalactiae derived mitogen SDM and SpeGdys that are most similar to SpeM and SpeG, 
respectively (133, 134).  
 Some Gram-negative bacteria were found to produce SAgs.  Yersinia 
pseudotuberculosis produces the Y. pseudotuberculosis mitogens (YPM) a, b and c, and 
Mycoplasma arthritidis produces the M. arthritidis mitogen (MAM). Interestingly, these 
Gram-negative SAgs differ from staphylococcal or Strep SAgs in many aspects including 
their TCR Vβ spectrum, their amino acid sequences and the absence of the conserved 
SAg signature sequence (135-138).  
 
Structural features of SAgs   
 SAgs of both S. pyogenes and S. aureus are soluble non-glycosylated molecules, 
most of which are 20-30kDa proteins. The majority of currently known Strep SAgs have 
been well characterized with respect to their structure, biological activity, and Vβ 
specificity (Table 1.3) (9, 100, 103, 123, 124, 128, 139-141). The crystal structure of 
several Strep SAgs (SpeA, SpeC, SpeH, SpeJ, SSA, and SmeZ-2) has been solved  
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Table 1.3 Biochemical and functional properties of streptococcal SAgs. 
 
SAg MW (kDa) 
Crystal 
Structure 
HLA II 
binding 
α/β 
chain 
Zinc 
dependent 
binding 
Chromosome
/Phage 
encoded 
Human TCR Vβ 
specificity 
SpeA 26 + +/− − −/+ 2.1, 12.1, 14.1, 15.1 
SpeBa 28 − ? ? +/− 8 
SpeC 24.4 + −/+ + −/+ 2.1, 3.2, 12.5, 15.1 
SpeFb 25.4 − ? − −/+ 2, 4, 8, 15, 19 
SpeG 24.6 − −/+ + +/− 2.1, 4.1, 6.9, 9.1, 12.3 
SpeH 23.6 + −/+ + −/+ 2.1, 7.3, 9.1, 23.1 
SpeI 26 − −/+ + −/+ 5.3, 6.9, 9.1, 18.1, 22 
SpeJc 24.6 + −/+ + +/− 2.1, 8 
SpeKd 27.4 − −/+ + −/+ 1.1, 5.1, 23.1 
SpeL 26.2 − −/+ + −/+ 1.1, 5.1, 23.1 
SpeM 25.3 − −/+ + −/+ 1.1, 5.1, 23.1 
SmeZ1 24.3 − −/+ + +/− 2.1, 4.1, 7.3, 8.1 
SmeZ2 24.1 + −/+ + +/− 4.1, 8.1 
SSA 26.9 − +/− − −/+ 1.1, 3, 15, 17 
 
a SpeB is the major Strep cysteine protease; however, its mitogenicity is debated.   
b SpeF is identical to DNase B (142). This molecule contains two separate domains, one 
responsible for DNase activity and the other involved in mitogenic activity. There is a 
dispute as to the superantigenicity of SpeF (143, 144). 
c M3 and M18 serotypes lack speJ gene suggesting that it is present in a less stable 
chromosomal region (145)   
d SpeK found in M3 strain from US is identical to SpeL identified in M3 strain from 
Japan and M89 from New Zealand (122, 126, 127). 
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(141, 146-149). Despite highly different primary amino acid sequences, SAgs show 
notable resemblance in their overall structure. Most SAgs show a conserved 3D structure 
built on two domains: a smaller N-terminal β-barrel domain, which is homologous to the 
oligosaccharide/oligonucleotide-binding fold (OB-fold) observed in other bacterial 
proteins and a larger C-terminal β-grasp motif separated from the other domain by long 
α-helix (103, 146, 148, 150). Such conserved folding implies an evolutionary pressure to 
preserve similar architecture and hence capacity to interact TCR and class II MHC (151). 
 Based on structural features and distinct modes of interaction with 
immunoreceptors, SAgs may be separated into five different groups (152, 153). TSST-1 
and TSST-ovine are the only members of group I. These toxins have unique amino acid 
sequence, but fold into the common SAg structure (154). TSST-1 exclusively binds HLA 
class II α-chain through the N-terminal, low-affinity OB-domain in a peptide-dependent 
manner (Fig. 1.2A) (155, 156). Group II includes staphylococcal SAgs (SEB, SEC, SEG 
and SEU) and Strep SAgs (SpeA and SSA) that contain cysteine loop of variable length 
(10-19 amino acids). Similar to TSST-1, these toxins use the N-terminal low-affinity 
domain to interact only with the class II α-chain; however, unlike TSST-1, in a peptide-
independent manner  (Fig. 1.2B) (157). Group III contains staphylococcal entertoxins A, 
D, E, N, J, H, O and P that are able to cross-link class II molecules by engaging class II 
α-chain through the N-terminal low-affinity site and class II β-chain by a C-terminal 
high-affinity zinc-dependent site in the β-grasp motif of the SAg (Fig. 1.3) (158-160). 
These toxins have cysteine loop that is exactly 9 amino acids long. Group IV includes 
Strep pyrogenic exotoxin C, G, J, K, L, M and SmeZ. Similar to group III, group IV 
SAgs possess the C-terminal high-affinity domain, 
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Figure 1.2 MHC-SAG-TCR ternary complexes showing different SAgs groups and 
distinct modes of SAg-HLA interactions. 
 
Tenary complexes mediated by   A.   TSST-1,   B.   SEB,   C.   SpeC, and   D.   SEK. 
Colors are as follows: MHC α subunit, green; MHC β subunit, blue; antigenic peptide, 
gray; TCR α chain, orange; TCR β chain, red; SAGs, yellow. For clarity, the MHC-SAG-
TCR complexes mediated by (c) SpeC and (d) SEK are rotated approximately 90° 
clockwise about the vertical axis of the page relative to those mediated by (a) TSST-1 
and (b) SEB. (Adapted with permission from Günther S. et al. (2007) (161). A Novel 
Loop Domain in Superantigens Extends Their T Cell Receptor Recognition Site. J Mol 
Biol 371, 210–221.) 
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Figure 1.3 Ribbon diagram of SEA quaternary complex (group III SAg).  
 
Crosslinking HLA class II α/β chains by SEA (group III SAg). Model of the two HLA 
(green)–SEA (white)–TCR (blue) quaternary complex. The complex has been produced 
by superposition of the SAgs in the crystal structure of SEAD227A–HLA-DR1 (160) 
representing the low-affinity-binding site and the crystal structure of SEH–HLA-DR1 
(159) representing the high-affinity-binding site. (Adapted with permission from K. 
Petersson, G. Frosberg and B. Walse (2004) (150). Interplay Between Superantigens and 
Immunoreceptors. Scand J Immunol 59, 345-355.) 
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 but lack the N-terminal low affinity class II binding site and the cycteine loop (Fig 1.2C) 
(162). Group V contains SEI, SEK, SEL, SEM, SEQ and SpeI that analogous to group 
IV, bind HLA class II through C-terminal domain high-affinity site (Fig 1.2D) (163); 
however, group V SAgs, are characterized by having 15 amino acids loop extension that 
is absent in other groups and is critical for T cell activation (153, 161) 
 Some Strep SAgs exhibit allelic variation. For SpeA, six alleles have been 
described. SpeA1, SpeA2 and SpeA3 differ by single amino acid while SpeA4 differs  
from SpeA1 by about 11% (164). Also, four synonymous and one nonsynonymous 
mutations differentiate speA5 differs from speA4, and one synonymous mutations 
distinguishes speA6 from speA1 (165). SmeZ distinctively exhibits much greater 
variation. SmeZ2 differs by approximately 8.1% from the very first published SmeZ 
protein, now known as SmeZ1 (124). Twenty-two additional smeZ alleles were identified 
through analysis of 37 GAS isolates (166). The functional activities of SmeZ were not 
affected by such wide allelic variation. However, these smeZ variants showed antigenic 
differences as indicated by highly variable neutralization responses of human sera (166).  
 
Interactions of SAgs with HLA class II molecules  
 Co-crystallization and mutagenesis studies revealed that SAgs have two distinct 
sites for engaging HLA class II molecules, one at the N-terminal domain called the 
generic or low affinity binding sit (KD ~10-5 M) that mediates class II α-chain binding and 
the other at the C-terminal domain known as the high affinity site (KD ~10-7 M), which 
mediates class II β-chain binding. The latter is dependent on Zn2+, which is held in a 
coordination complex via a His (H81) from HLA class II β-chain and three residues 
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 (two His and one Asp) from the SAg (103, 152).  
 To ensure they concentrate onto the surface of antigen presenting cells (APC) at 
the interface with T cells, SAgs have developed several ways for binding HLA class II, 
which is regarded as a critical aspect of SAgs function. SAg-HLA class II interactions 
can be categorized into three distinct modes. Mode I involves the SAg N-terminal low 
affinity region and a site on the α1 domain of HLA class II α-chain that entails extensive 
interactions with the bound antigenic peptide and reaches to make contacts with class II 
β-chain as in the case of group I SAgs (TSST-1) (155). This binding mode creates two 
protein-protein interfaces, which are SAg-HLA and SAg-TCR and prevents any direct 
contact between HLA and TCR (Fig 1.2A). HLA class-II bound antigenic peptide can 
influence the presentation of SAgs that utilize mode I (167, 168). Mode II is exemplified 
by group II SAgs that bind through the low affinity N-terminal domain to a site on HLA 
class II α-chain that is completely marginal to the bound antigenic peptide and thus 
blocks that bound peptide from affecting SAg responses (157, 168). Such binding mode 
creates three protein-protein interfaces namely SAg-HLA, SAg-TCR and HLA-TCR and 
precludes any contact between TCR and HLA-bound antigenic peptide (Fig 1.2B). 
Additionally, TCR-HLA contact acts cooperatively to enhance the weak HLA-SAg 
interaction to a degree sufficient for T cell activation (169). In the last mode, the SAg C-
terminal high affinity site interacts in a zinc dependent manner with the β1 domain of 
class II β-chain and contacts the bound antigenic peptide as illustrated by group IV and V 
SAgs (162, 163). Like mode I, there is no direct TCR-HLA contact and two interfaces 
exist: HLA-SAg and SAg-TCR and the class-II associated antigenic peptide may 
influence SAg binding (Fig 1.2C&D) (162). Importantly, such high affinity of SAg-HLA 
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interaction can compensate for poor SAg-TCR binding and allow HLA-SAg-TCR 
complex to attain efficient T cell activation (170). 
 SAgs that are able to crosslink HLA class II molecules on APC induce much 
more potent immune responses as they up-regulate cytokines and co-stimulatory 
molecules expression by APC (171-173). SAgs also exhibit different ways for cross-
linking class II antigens. For example, SEA cross-links class II molecules by binding one 
α-chain and one β-chain, and disruption of any of these interactions detrimentally affect 
T cell activation (173). Both interactions seem to allow SEA to attain the appropriate 
orientation for engaging certain TCR Vβ elements (174). Other SAgs cross-link class II 
by forming SAg-homodimers as in case of SED and SpeC; however, through distinct 
dimerization mechanisms. SED forms Zn2+-stabilized homodimers through C-terminal 
domains and engages two α-chains (171, 175) while SpeC forms homodimers through 
the N-terminal OB-fold domain and interact with two β-chains (139, 148). Furthermore, 
other SAgs demonstrate dimer formation; however, the biological relevance of such 
structural arrangement is not clear. For example, SpeJ crystal structure showed dimer 
formation. However, the dimerization was through the proposed TCR-binding face, 
implying two possible functions  normal class II and TCR binding or in the dimer 
mode, cross-linking class II molecules (141). Additionally, SSA was reported to exhibit 
monomeric and dimeric forms that occur through intermolecular cysteine bridge 
involving Cys 26 (176). Note worthily, dimer formation would block TCR interaction, 
which was reflected in the much higher activity of monomer. Such observation requires 
additional studies to clarify the role of dimer formation in SSA function. Analogously, 
crystal structure of SpeA1 dimer involved cysteine bridge between monomeric forms Cys 
 23 
90 (177). Even though the dimerization interface involved the TCR binding site, both 
forms were equally active in vitro, which suggested that flexibility of the dimer interface 
may permit different orientations than those observed in the crystal structure and thus 
allow TCR binding.   
 SAgs vary in their requirement to interact with HLA class II for recognition by 
and stimulation of T cells, and it appears that both the SAg and the TCR Vβ subset play a 
role in HLA-independent T cell activation. Kotb and co-workers’ studies showed that the 
requirement for class II-interaction could be bypassed if T cells receive appropriate 
costimulatory signals (178, 179) with TCR Vβ specificity preserved in case of pepM5 
(180) and altered in case of SEA (181). Moreover, SEE unlike SEA is entirely reliant on 
HLA for T cell activation, though; these SAgs are highly homologous (182). It seems that 
SAg-T cell direct interaction depends on TCR Vβ elements affinity for the SAg, For 
example, Vβ8 T cells fail to respond to SEB but not SEC due to much lower affinity for 
the former (183). 
 HLA class II isotypic and allelic variation can affect SAg responses. Distinct 
SAgs demonstrate differential binding and presentation by different class II alleles or 
isotypes that consequently influences biological reactions to the SAgs and explain the 
diversity of clinical manifestations observed in individuals infected with the same SAg-
producing organism (7). This aspect of HLA-SAg interaction will be discussed later 
under HLA polymorphism and SAg response. HLA class II associated peptide adds 
another layer of complexity to Class II-SAg interaction. The presentation of a given SAg 
by a distinct class II allele can be deeply affected by the characteristics of HLA-bound 
peptide (167, 184) as well as by co-factors involved in peptide antigen presentation such 
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as invariant chain and DM (185). As mentioned above this effect may be mediated 
through TSST-1 interaction with class II-associated peptide (167). However, even for 
SAgs that do not make contacts with the bound peptide such as SEA similar effects were 
observed (184, 186), which may be explained by the HLA-TCR interaction in the HLA-
SAg-TCR ternary complex. The effect of class II-bound peptide on SAg presentation was 
suggested to fine tune SAg responses by limiting the number of class II molecules that 
can bind and present the SAg and thus induce optimal T cell activation through low 
density and sustained signaling rather than much stronger and shorter signals induced if 
many more class II molecules were allowed to interact with the SAg (184, 187) 
 
Interaction of SAgs with TCR 
 SAgs stimulate T cells through specific interaction with particular Vβ elements of 
the TCR (188, 189). Therefore, SAgs are known to have a distinct TCRVβ signature. 
This explains the ability of SAgs overcome the usual specificity between MHC and TCR 
and activation of all T cells expressing the SAg-specific TCRVβ regardless their 
antigenic specificity. The TCRVα region may to some degree influence the SAg 
activation of T cells. However, this is probably an indirect effect caused by HLA class II 
β-chain interaction with TCRα-chain (Fig. 1.2B). SAgs’ affinities for TCRVβ are 
comparable to those for pMHC-TCR complexes (190). This allows relatively fast-
dissociation similar to that of pMHC-TCR complexes, which implies that T cell 
activation by SAGs may also involve serial triggering. 
 The different groups SAgs (mentioned above) also engage distinct hypervariable 
(HV) elements and complementarity determining regions (CDR) of TCRVβ domain. 
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TSST-1 (group I SAg) mainly interacts with CDR2 and the third framework region (FR3) 
(191). SEB and other group II SAgs primarily engage CDR2 and HV4 in a manner that 
depends mainly on the general conformation of the CDR2 and involves hydrogen bonds 
with the TCRVβ backbone atoms (192). Little is known about group III SAgs interaction 
with TCRVβ. SpeC, similar to other group IV SAgs, interacts with all TCRVβ 
hypervariable motifs including HV4, CDR1, 2, and 3. Additionally, abundant side chain 
hydrogen bonds are involved in SpeC-TCRVβ interaction. Group V SAgs (e.g. SpeI, SEI 
and SEK) engages CDR2 and FR3. Also, through their unique 15 amino acids loop, these 
SAgs interact with FR4 (161). It seems that SAg-TCR interaction specificity is achieved 
through increased side chain hydrogen bonds formation, engaging an enlarged set of 
hypervariable elements and contacting rare elements of TCRVβ region. Also, binding to 
CDR2 appears to be required for all SAg-TCR interaction, and the percentage contributed 
by CDR2 to SAg-TCR interface is the largest compared to that of any other CDR or FR.  
 In contrast to the accepted paradigm that SAgs interact with TCR primarily 
through the Vβ domain, SEH activate T cells in a Vα-specific manner expanding distinct 
TCRVα elements (193, 194). This finding demonstrates the significance of distinct 
modes of SAg-TCR interaction for a wider activation of T cells and the importance of 
having diverse SAgs to induce SAg response. Also, demonstrating skewed TCRVβ 
repertoire in a patient as an evidence for SAg-mediated disease may not be conclusive.  
 
 TCR-generated signaling response to SAgs 
 Originally, SAg-induced TCR signaling has been suggested to use the same 
pathway employed conventional antigen activation (195) that involves activation of CD4 
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associated Tyrosine kinase (TK) Lck through dephosphorylation of the inhibitory 
tyrosine residue by CD45 followed by its recruitment to TCR/CD3 complex (196). 
However, several lines of evidence suggest that SAg-triggered TCR signaling may 
involve an alternative pathway, where the use of HLA class II molecules as the primary 
receptors for SAg would entail CD4+ T cells to constitute the majority of responding T 
cells; however, several studies have indicated that CD8+ T cells also respond to some 
SAgs (197, 198), which suggests that CD4 is not essential co-receptor for SAg responses. 
Additionally, monoclonal antibodies blocking of CD4 and using CD4− T cell lines did 
not affect some SAgs responses (199, 200). Therefore, CD4 independent T cell responses 
to SAgs implies that Lck is also dispensable. This premise was supported by the 
discovery that some SAgs can stimulate T cells lacking Lck function (201, 202). By the 
use of various kinase inhibitors and Lck-defective T cells, it was found that the Lck-
dependent and -independent pathways meet at the ERK-1/2 activation step and that such 
T cells can mobilize Ca2+ in response to SEE stimulation but fail to respond when protein 
kinase C (PKC) was inhibited (200). Since phospholipase C-γ1 (PLC-γ1) is inhibited in 
the absence of Lck and it is the PL involved in the typical TCR-signaling trigerred by 
petide-HLA, it was suggested that a different PL is required for the alternative pathway 
utilized by SAgs. Indeed, It was found that PLC-β (which is regulated by the Gα-11 
family of G proteins) is involved in the SAg alternative signaling pathway. These data 
may help clarify certain SAg responses such as the ability of CD8 T cell to respond to 
some SAgs despite SAg recognition in the context of HLA class II molecules. Also, it 
was suggested that unlike Th2, Th1 responses are Lck-independent (203, 204), which 
explains the observed preferential SAg induction of Th1 cytokines (205, 206).  
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 Another aspect of T cell activation is the role of co-stimulation. Early work by 
Kotb and co-workers provided useful insights into co-stimulatory signals in T cell 
responses to SAg stimulation. It was shown that SAg and mitogen (e.g. 
phytohemagglutinin, PHA) induced distinct biochemical events during T cell activation 
(207) and that T cell responses to SAgs required both secreted and cell associated factors 
(178, 208, 209), where the latter was shown to be delivered by CD28 cross linking (179, 
210). Ohnishi et al. characterized the CD28 co-stimulatory pathway in SAg-mediated T 
cell activation (210). They were the first to provide direct evidence for the involvement 
of PKC in this pathway, and also showed that it involved PLC-γ1 activation and an 
instantaneous sustained rise in intracellular Ca2+ level. Interestingly, response sensitivity 
to cyclosporin A was reliant on the absence (sensitive) or presence (resistant) of phorbol 
myristate acetate, which suggested that Ca2+-dependent or -independent responses may be 
produced based on the co-stimulus character. Therefore, CD28 co-stimulation boosts 
SAg-triggered TCR signals by promoting the activation of PLC-γ1 and PKC in a 
cyclosporine A-sensitive pathway that is distinct from alternative SAg-induced TCR 
signaling pathway. On the other hand, B7 interaction with cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) dampened SAg-induced T cell activation (211, 212), 
suggesting that CTLA-4 regulatory activities are operative in SAg-TCR signaling.  
 
Superantigens in Human Disease 
 The unusual immune responses triggered by SAgs are believed to be responsible 
for the pathogenesis of SAg-associated diseases. These molecules can interact with a 
large spectrum of T cells and induce excessive inflammatory cytokines production. SAgs 
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have been implicated in the pathogenesis of several human diseases such as toxic shock 
syndrome (TSS), and autoimmune diseases (213, 214). 
 
Food poisoning 
 Food poisoning is an intoxication caused by consumption of SEs produced in food 
contaminated by toxin-producing staphylococci. Emesis is the primary symptom of this 
illness. The mechanism of SE-induced emesis is not clear because gastrointestinal tract 
receptors have not been yet discovered (215). An intact cysteine loop, mentioned above 
under structural features, is required but not sufficient for the emetic response because 
SpeA has this loop but is not emetic (216). Furthermore, the mitogenic activity of SE 
appears to be separable from the enterotoxic behavior (215, 217).  
 
Staphylococcal toxic shock syndrome (staphTSS) 
 StaphTSS is a severe illness that involves multiple organs. StaphTSS 
manifestations include hypotension, diffuse rash, fever, vomiting, diarrhea, and skin 
desquamation upon recovery (152). Not all staphylococcal SAgs are equally important in 
the production of TSS. Menstrual TSS is mainly caused by STSS-1 (109), whereas non-
menstrual TSS can be triggered by TSST-1 and other staph SAgs particularly SEB and 
SEC (218, 219). Support for the involvement of these toxins in non-menstrual TSS comes 
from their induction of TSS-like symptoms in animal models (99, 220). Interestingly, 
SEB, SEC, and TSST-1 interact only with class II α-chain through the low affinity site, 
and thus are expected to be less potent than SAgs that interact with class β-chain high 
affinity site. However, higher levels of these toxins may be produced in vivo (105). 
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Streptococcal toxic shock syndrome (STSS) 
 STSS, caused by S. pyogenes, is the most severe form of invasive streptococcal 
infections, with about 50% or more mortality rates. Although STSS shares many 
symptoms with staphTSS, there are important differences, which include disseminated 
infections, severe pain, tissue invasion, and bacteremia are usually associated with STSS 
(221, 222). Several lines of evidence support the involvement of Strep SAgs in STSS. 
First, the in vivo pattern of TCR Vβ repertoire expression in STSS patients was skewed, 
reflecting Vβ specificities of SAgs produced by the infecting GAS isolates (102). Also, 
passive administration of anti-Strep SAgs neutralizing antibodies to STSS patients 
significantly alleviated disease severity and reduced mortality (223, 224). Importantly, 
direct evidence was obtained from studies that demonstrated circulating SAgs in patients 
suffering from STSS (225), and SAgs expression in tissue biopsies from STSS cases 
together with increased infiltration of CD68 and CD4 cells producing high levels of TNF-
β and IFN-γ, which are typical of a SAg-induced response (101). Additionally, the direct 
ability of Strep SAgs to cause STSS has been confirmed in experimental models (226, 
227).  
 The pathogenesis of staphTSS and STSS is believed to result from the abnormal 
immune responses elicited by SAgs, which are potent inducer of inflammatory cytokine 
not only from the T cells bearing SAg-reactive Vβ elements, but also from the HLA class 
II APC (206, 228). Elevated cytokine production correlates with the physiological 
changes characteristic of septic shock (229, 230). TNF-α and -β induce capillary leakage 
that results in hypotension and multiple organ failure (213, 231). TNF-α also promotes 
the release of other cytokines such as IL-1, IFN-γ, and TNF-β that potentiate TNF-α 
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activity (232, 233). IL-1 has pyrogenic activity that causes fever and, at high levels, can 
trigger hypotension (234). IFN-γ upregulates HLA class II expression and thus provide 
SAgs with more receptors, which potentiates SAg-induced cytokine induction (235). 
 
Kawasaki syndrome (KS) 
 KS involves the development of systemic vasculitis that targets primarily young 
children and is known to be the principal cause of acquired heart disease in children. A 
growing body of data suggests SAgs involvement KS (236). First, KS shares clinical 
features and immunological reactions with StaphTSS and STSS (237). Also, early 
administration of intravenous immunoglobulins is highly effective, which points to a 
toxin as the causative agent. Importantly, several studies reported selective expansion of 
certain TCRVβ subsets, suggesting a possible involvement of SAgs (238, 239). 
Furthermore, elevated serum IgM specific for several SAgs has been observed in KS 
patients (240). 
 
Acute rheumatic fever (ARF) 
 ARF is a delayed sequel to GAS pharyngitis. Manifestations involve 
inflammation of several organs such as joints, heart and central nervous system (241). 
Cardiac rheumatic fever is believed to result from a cross-reactive immune response to 
the host’s cardiac tissue. SAg involvement in ARF was suggested by the observation that 
several ARF-associated serotypes were shown to harbor numerous Strep SAgs. SpeL 
gene was frequently found in serotypes M3 from USA and Japan (126, 127) and in M89 
from New Zealand (128). Also, SpeM gene was found in M18 from USA (242). 
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Importantly, sera from convalescent ARF patients showed higher titer of SpeM-specific 
antibodies than those from pharyngitis patients or healthy individuals (125).  
 
Role of Host Genetics in Infectious Diseases 
 
Host genetic involvement in the pathogenesis of infectious diseases 
 The effect of host genetics on the outcomes of infectious diseases is becoming 
more and more evident. Predisposition to and protection from infections vary among 
people exposed to certain pathogens (243, 244). Genetic contribution relative to the 
environmental and other factors is variable. Inasmuch as most infectious diseases have an 
underlying immunological component, it was not surprising that most genetic 
associations discovered were related to genes that regulate the immune responses. 
Extensive genetic polymorphism in immune response genes, especially HLA genes, is 
critical to the survival of human species because it ensure that some individuals with 
unique genetic makeup will be able to mount successful immune response to a highly 
mutable pathogen (243, 244). Exploring the immune response and the genetic makeup of 
susceptible and resistant individuals can shed more light on the disease process. 
Additionally, studying host genetic influence on infectious diseases offers new diagnostic 
tools, advances understanding of case definition and prognosis and induces novel 
prophylactic and therapeutic approaches.  
 Variations in immune receptors and associated signaling components, cytokine 
genes, genes that regulate cellular adhesion and homing patterns as well as genes 
encoding complement and HLA molecules have been shown to affect susceptibility to 
 32 
several infections (7, 245, 246). This section will discuss such variations and the 
associated disease outcomes. 
 It has been shown that Toll-like receptor-2 (TLR2) gene polymorphism is 
associated with increased risk for leprosy and tuberculosis (247). Similarly, TLR4 
variants with lower expression level are associated with Gram −ve bacterial infection and 
septic shock (248). Furthermore, polymorphism in complement component genes are also 
linked to increased susceptibility to certain infections. For example, FCγRIIa inefficient 
variants are linked to severe meningococcal disease susceptibility (249), which is also 
modulated by variations in mannose-binding lectin (250). 
 The classically known heterozygous sickle hemoglobin is not the only genetic 
variation that protects against malaria (251), but also the Duffy blood group that inhibits 
the expression of Duffy gene encodes a chemokine receptor on red blood cells, which is 
also the entry gate for P. vivax (252). Chemokine receptors variation is also involved in 
HIV infection; CCR5Δ32 deletion variant, a co-receptor for HIV, and CCR2-Ile64 
variant are associated with delayed progression to AIDS in heterzygotes and HIV-
protection in homozygotes (253, 254). Also, variants of RANTES (CCR5 ligand) (255), 
stromal cell-derived factor-1 (CXCR4 ligand) (256) and IL-10 (257) have been shown to 
play a role in progression to AIDS. 
 Cytokines orchestrate the immune responses and their genes polymorphism can 
affect infections outcomes. Variations in IL-4 and IL-10 have been shown to affect 
outcomes of hepatitis C virus (HCV) infections and progression rates of HIV infections 
(258-261). Additionally, polymorphisms that promote higher levels of IL-10 production 
are associated with adverse outcome of pneumococcal infection (262). Interestingly, the 
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same genotype (- 592 C) is also associated with hepatitis B virus (HBV) clearance (263). 
Several single nucleotide polymorphisms were reported in TNF-α; some of them are 
associated with altered secretion that affects sepsis outcome and susceptibility to cerebral 
malaria, HBV, HCV and leprosy (264-267). Cytokine gene mutations also can cause 
some otherwise healthy individuals to develop severe mycobacterial infections, though, 
by weakly pathogenic strains. These individuals have defective IFN-γ responses due to 
variations in IL-12 (268), IL-12 receptor (IL-12 R) (269), or IFN-γR (270). Not only the 
cytokine genes and receptors do play a role in such mycobaterial infections, but also the 
signaling pathways play a role where defects in STAT1 pathway involved in IL-12 and 
IFN-γ were reported (271, 272).  
 
The same GAS strain is associated with variable infection severity 
 It was noticed that individuals infected with GAS strains can develop different 
clinical manifestations; some suffer from severe sepsis, while others are colonized and 
never experience disease. Even among invasive cases, some develop NF and STSS; 
others have a mild bacteremia. This variation in clinical symptoms could be due to 
differences in the virulence of the infecting strains, differences in host susceptibility or 
both. We are mainly interested in studying host factors that may contribute to variable 
susceptibility. 
 The M1T1 clonal strain was isolated from individuals with starkly different 
symptoms ranging from uncomplicated pharyngitis to invasive infection cases with or 
without SSD (273, 274). Additionally, the inflammatory responses triggered by SAgs 
from the same M1T1 clone in different people can vary considerably, and there is a direct 
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correlation between the levels of inflammatory cytokine responses and the severity of 
invasive disease (101, 275, 276). These observations led to the suggestion that individual 
variations in immunogenetic factors that regulate SAg responses may be important 
determinants of infection severity, which is the fundamental hypothesis studied in this 
dissertation.  
 
Host risk factors for invasive streptococcal infections 
 Demographic factors such as age, gender and pre-existing conditions would be 
expected to affect the clinical outcome of invasive infection. Such factors can affect 
disease progression or confound case classification and should be carefully considered in 
the analysis of association studies. Both host and environmental factors can play a role in 
the susceptibility to invasive GAS infections (277-279). Drug abuse by injection, use of 
corticosteroid and chronic medical conditions such as diabetes, cancer, cardiovascular 
diseases and HIV infection are among the host factors, while household size and contact 
with children suffering sore throat are environmental factors that increase the risk for 
invasive GAS infections among adults over 18 years old. Furthermore, Varicella zoster 
virus infection, recent use of non-steroidal anti-inflammatory drugs and crowded 
household are associated with increased risk for developing invasive GAS infection; 
however, large home and, surprisingly, exposure to child with rhinitis are associated with 
decreased risk among children under 18 years old (278, 279). 
 Moreover, pre-existing levels of protective humoral immunity such as opsonic M 
type-specific antibodies (Abs) and SAgs-neutralizing Abs are critical factors. It was 
shown that low levels of these Abs were associated with increased risk for invasive 
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disease. However, there was no correlation between Ab levels and disease severity as 
both severe and non-severe cases had equally low levels of protective Abs (273). 
 
HLA association with infectious diseases 
 In humans, the major histocompatibility complex is known as the HLA system, 
which represents the most polymorphic genetic locus in the human genome. It includes 
three major classes of HLA, class I, class II and class III that are located on chromosome 
6 and play an essential role in developing and regulating immune responses to pathogens.  
 Both HLA class I and class II molecules present antigenic peptides to T cells, 
which afterwards mount antigen-specific immune responses. The class I molecules are 
HLA-A, -B and -C, while the class II molecules are HLA-DP, -DQ and -DR. Class I 
molecules are expressed on all nucleated cells, whereas class II molecules are expressed 
on professional APC whose primary function is to present processed foreign antigens to 
CD4 T cells. Both HLA class I and II consist of α and β heterodimers. Class I β-chain, 
β2 microglobulin, is monomorphic, whereas the α-chain is highly polymorphic. 
Similarly, class II DR α-chain is non-polymorphic, while both α- and β-chains of class II 
molecules (e.g. DRB1*, DQA1*, DQB1*) are highly polymorphic. Individual genes are 
referred to by a nomenclature that indicates locus and allelic designation. Thus, 
polymorphic HLA DR genes encode the DRβ polypeptide at a locus known as DRβ1. 
Individual alleles carry four digit designation that follows the locus name, i.e. 
DRB1*1501.  
 The extensive polymorphism in HLA molecules is generally concentrated in the 
peptide-binding groove, which allows highly diverse peptides to be efficiently bound and 
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presented by different HLA molecules. HLA remarkable polymorphism is thought to 
have evolved primarily through natural selection by pathogens (280, 281). Several genes 
that map to the HLA region have been implicated in a number of infectious diseases. 
HLA allelic variation has been associated with susceptibility or resistance to malaria, 
tuberculosis, leprosy, HIV progression, HBV and HCV persistence (280, 282). 
 Reports demonstrated that HLA allelic variation can influence malaria 
susceptibility where HLA-B53 and HLA DRB1*1302 are associated with protection. 
Schistosomiasis is another parasitic infection where HLA polymorphism plays a role in 
the development of post infection hepatic complications, for example HLA-A2 and -B12 
are associated with high-risk for S. mansoni-triggered hepatic fibrosis while HLA-DR2 is 
protective. Susceptibility to mycobacterial infections is also influenced by HLA 
polymorphism, for example HLA DR2 is associated with increased susceptibility to 
leprosy and tuberculosis. In case of viral infections, the phenotype influenced by HLA is 
progression to AIDS in HIV infections and persistence carriage in HBV and HCV 
infection. In HIV infection, HLA-B35 is associated with poor prognosis, whereas HLA-
B27 is associated with a better one. Similarly, HLA DRB1*1101 and HLA DRB1*1302 
are associated with resistance to persistent HCV and HBV, respectively. 
 Kotb and co-workers’ studies identified significant associations between specific 
HLA class II haplotypes and different manifestations of GAS sepsis and post-
streptococcal rheumatic heart disease (RHD) (275, 283). 
DRB1*0701/DQB1*02/DQA1*0201 haplotype was associated with increased risk for 
RHD while DRB1*13/DQB1*0603/DQA1*0103 haplotype was associated with 
protection (283). In invasive GAS infections, DRB1*1501/DQB1*0601 haplotype is 
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associated with strong protection from both STSS and NF, whereas 
DRB1*1401/DQB1*0503 haplotype is associated with high risk for STSS. Furthermore, 
it was found that DRB1*03/DQB1*0201 is protective from NF, while 
DRB1*11/DQB1*0301 is high-risk for NF (275). This was the first study to demonstrate 
that HLA polymorphism can influence the outcome of a Gram-positive infection and to 
present a plausible molecular basis for such association. The findings suggested that HLA 
class II allelic variation could shape the outcome of SAg-mediated infection through 
differential SAg-presentation by distinct class II alleles/haplotypes. Also, different class 
II associations with STSS and NF supported the view that these are two different clinical 
manifestations with distinct underlying mechanisms and require different interventional 
approaches.  
 
HLA class II polymorphism and SAg responses 
 HLA class II molecules on APC serve as receptors for SAgs that present them to 
the T cells. Although some SAgs can interact directly with T cells in the absence of HLA 
class II molecules (182, 183), CD28 crosslinking was required to induce T cells to 
proliferate (179, 180, 209, 210).  These observations suggested that the requirement for 
HLA class II molecules in SAg responses is to bring T cells and APC in close proximity 
to allow productive interactions between CD28 and B7 molecules as well as other 
receptors/ligands on both types of cells (179, 180, 209, 210). Therefore, the ability of 
SAgs to bridge HLA molecules on APC and TCR on T cells is essential for effective 
intercellular communication and for subsequent generation of biochemical signals and 
activation of both cell types.  
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 The presence of more than one class II isotype (DR, DQ, DP) and their extensive 
polymorphism is expected to influence SAgs binding and presentation and thus their 
biological activities. Indeed, several studies have shown that HLA class II allelic 
variation can affect the type of signaling transduced through the MHC and TCR receptors 
and affect the magnitude of SAg response (185, 284-288). These studies support the view 
that not all class II isotypes or alleles bind or present a given SAg the same way and that 
the ensuing response depends on both the SAg and the class II allele. While most 
S.aureus SAgs are presented better by HLA DR than by HLA DQ, streptococcal SAgs 
vary in their preference for HLA DR or HLA DQ, where SpeA and SpeB are 
preferentially presented by DQ alleles, whereas SpeC shows superior presentation by DR 
than DQ alleles (287-289). Thus, Some SAgs are presented better by DR than by DQ and 
vise versa, and the type of DR or DQ allele can make a big difference. The preferential 
presentation of different SAgs by distinct class II alleles could be explained in some, but 
not all, cases by differential binding affinity (284, 288, 289). The lack of correlation 
between binding and presentation of some SAgs may be related to the stability of the 
ternary complex of HLA-SAg-TCR which is derived from the combined strengths of 
HLA-SAg, TCR-SAg and HLA-TCR interactions. The high affinity of the TCR Vβ 
subsets to a given SAg may stabilize poor SAg-HLA interaction and thus T cells can 
react to a particular SAg-HLA combination, even though the later cannot be easily be 
revealed by simple binding studies compared to much more sensitive functional studies. 
 The effect of class II allelism on SAg responses was also shown in vivo in 
experimental models (226, 227, 290). HLA DQ8 (DQB1*0302/DQA1*0301) transgenic 
(tg) mice developed SSD and mounted significantly higher responses to SpeA than other 
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HLA-tg mice or non-tg mice (227). Direct evidence for the effect of HLA class II allelic 
variation on SAg presentation is also demonstrated in results presented in this dissertation 
and from previous studies done in our lab (275, 288).  
 
Specific Aims 
 Host genetic factors are important determinant of susceptibility to infectious 
diseases. GAS can cause a large diversity of diseases ranging from uncomplicated 
pharyngitis and mild skin infection to NF and STSS caused by excessive inflammatory 
cytokine release triggered by Strep SAgs that have been shown to play a crucial role in 
the pathogenesis of such SSD. Thus, GAS offer an excellent model for elucidating the 
role of host factors in infection. Previous work in our laboratory showed that not all 
individuals with invasive infection develop SSD and the same GAS strain can be isolated 
from patients with starkly different clinical manifestations. These observations pointed to 
a strong involvement of certain host factors in shaping the outcome of GAS infections.  
 Several host factors may contribute to differences in disease manifestation, 
particularly HLA class II as these molecules are receptors for the SAgs and their 
polymorphism influence the disease outcome by controlling the inflammatory response to 
SAgs. Epidemiological studies showed that specific HLA class II alleles 
(DRB1*15/DQB1*0602) conferred strong protection from SSD, while others 
(DRB1*14/DQB1*0503) increased the risk for SSD. This argues strongly for a role of 
HLA class II allelic variation in contributing to differences in the severity of invasive 
GAS disease. 
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 The hypothesis investigated in this dissertation is that the differential presentation 
of SAgs by protective or high risk alleles is related to variation in the binding affinity or 
conformational changes resulting from the combined interaction of the tri-molecular 
complex, composed of the T cell receptor, HLA class II and SAg; this variation may 
account for the differences in the biochemical signals that follow the bridging of the TCR 
and HLA class II by the SAg. This hypothesis is supported by the observation that the 
proliferative and the inflammatory cytokine responses to SAgs differ quantitatively and 
qualitatively when the same SAg is presented by the protective versus the high risk or 
even the neutral class II alleles.  
 The specific aims of this study can be summarized as follows: 
1.    To use an animal model to validate the finding of our epidemiological studies 
demonstrating the critical role of HLA class II allelic variation as the primary 
controller of Strep SAg responses and infection severity. 
2.    To determine whether the HLA class II effect on GAS SAg responses is related to a 
specific SAg or a particular mix of GAS SAgs, or it is the same for all GAS SAgs. 
Some Strep SAgs are more potent than others.  It is important to determine which 
ones are differentially affected by the protective and high-risk alleles because these 
SAgs are likely to be the ones contributing to SSD. Such studies will help develop a 
sensitive system with minimum number of variables that can be used for the rest of 
our studies.  
3.    To investigate possible molecular mechanisms underlying the differential effect of 
HLA class II polymorphism on SAgs responses by investigating any differences in 
the binding affinity of the SAg to the class II alleles or differences in the 
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biochemical events that follow the initial interaction of SAg with its receptors on T 
cells and APC. 
 Our study may help more thorough understanding of the effects of HLA class II 
allelism on the SAg-driven responses and better predicting the outcome of SAg-
associated disease in a given patient. Possibly, treatment strategies can be customized 
depending on patient’s HLA class II haplotype. Similar to other clinical conditions, 
specific interventions can produce more effective results than general therapeutic 
approaches. For example, the use of IVIG in treating GAS SSD has been reasonably 
effective in reducing morbidity and mortality (224, 291). However, in the US and other 
parts of the world IVIG is expensive and sometimes unavailable. Our observations could 
recognize patients at low risk for SSD, thus IVIG can be secured for those at high risk. 
Also, we will be able to determine if a particular SAg or combination of SAgs can induce 
the most extreme responses. Such information will be useful at several levels. If a 
particular SAg or SAgs combination are the main cause for the observed HLA 
associations and for SSD, thus we can get an explanation for the resurgence of SSD by 
tracing the introduction of such SAg(s) before and after 1980 when SSD reappeared. 
Additionally, therapeutic approaches can be tailored to block this particular SAg or SAgs 
combination. On the other hand, if all studied SAgs are equivalent, then we will examine 
other factors that may have played a role in SSD reappearance and develop more generic 
therapies that block all SAgs activities.   
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Chapter 2. HLA Transgenic Mice Provide Evidence for a Direct and Dominant Role 
of HLA Class II Variation in Modulating the Severity of Streptococcal Sepsis∗ 
 
Introduction 
 Group A streptococci (GAS) are strictly human pathogens that cause a wide 
spectrum of diseases ranging from mild skin infections and uncomplicated pharyngitis to 
very severe life-threatening infections, e.g., streptococcal toxic shock syndrome (STSS) 
and necrotizing fasciitis (NF) (221, 292). In genetically susceptible individuals, GAS 
infections can sometimes trigger autoimmune disorders such as rheumatic fever, 
rheumatic heart disease, glomerulonephritis and possibly a number of neurological 
disorders (9, 100, 283, 293). Since the early 1980s, there has been a sharp resurgence of 
severe invasive GAS infections such as STSS and NF (292). GAS produce many 
virulence factors that contribute to their pathogenesis, but the streptococcal pyrogenic 
exotoxins (Spes), which belong to the family of microbial superantigens (SAgs), play a 
crucial role in STSS and NF (100-102, 275, 294). As SAgs, the Spes bind to both MHC 
class II and TCR molecules triggering very potent inflammatory cytokine responses, 
which in certain individuals leads to severe systemic diseases (SSD) manifested by STSS 
and multiple organ failure (100, 275). Our previous studies have provided conclusive 
evidence that GAS SAgs play a pivotal role in the pathogenesis of severe invasive 
illnesses (101, 102, 224, 275), however; we noted that only a few individuals infected 
                                                
∗ Adapted by permission of American Association of Immunologists from Nooh MM., 
El-Gengehi N., Kansal R., David CS., Kotb M. (2007). HLA Transgenic Mice Provide 
Evidence for a Direct and Dominant Role of HLA Class II Variation in Modulating the 
Severity of Streptococcal Sepsis. J Immunol 178, 3076-3083. 
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with SAg-producing GAS develop SSD (224, 274, 275). One possible explanation for the 
differences in the severity of invasive disease is the fact that some GAS strains are more 
virulent than others. Another mutually non-exclusive possibility is that the disease 
outcome is modulated by host immunogenetic variations.  
 Although there are over 100 known serotypes of GAS, the resurgence of severe 
invasive infection coincided with the emergence or re-emergence of virulent strains 
belonging to ancient serotypes that have apparently acquired genetic material via 
horizontal transfer (6, 24). In particular, a specific subclone of the M1 strain that has 
disseminated globally, persisting as the most frequently isolated clone from clinical cases 
over the last 25 years seemed to have acquired two unique prophages, each encoding 
virulence factors that are not found in the ancestral M1 strain (6). However, we showed 
that the same M1T1 clonal strain causes starkly different manifestations in different 
individuals, and was in fact isolated from cases with SSD, STSS, NF, non-severe 
invasive disease as well as from individuals with uncomplicated pharyngitis (274). 
Similar findings are observed with other prevalent serotypes, e.g. the M3 serotype (295). 
These findings provided a compelling argument that despite the resurgence of virulent 
strains, host factors must be contributing significantly to modulating the outcome of 
invasive GAS infections. 
 We and others have shown that the magnitude of inflammatory responses 
triggered by the same SAg can vary considerably in vitro as well as in vivo in different 
responders (275, 276, 289). A logical explanation for these findings is that variations in 
certain host immunogenetic factors modulate responses to the SAgs and, accordingly the 
severity of the systemic disease. Indeed, our epidemiological studies demonstrated a 
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significant association between specific alleles of the HLA class II and the severity of 
invasive GAS infection (275). While the haplotype DRB1*15/DQB1*06 (DR15/DQ6) 
conferred strong protection from SSD, the haplotype DRB1*14/DQB1*05 (DR14/DQ5) 
was associated with predisposition to SSD and other haplotypes, e.g. 
DRB1*04/DQB1*0302 (DR4/DQ8) were neutral with respect to the disease outcome. 
We also showed that inflammatory responses to the M1T1 SAgs, in the presence of the 
protective haplotype, were much attenuated as compared to the high-risk and neutral 
haplotypes (275). 
 To provide an in vivo validation to these findings, we needed an appropriate 
animal model for SAg-mediated GAS pathogenesis. Animal models have contributed 
significantly to the knowledge of the mechanisms involved in gram-positive bacterial 
toxic shock, however, regular mice are much less sensitive to SAg-mediated effects than 
humans (99, 296, 297). This difference relates, in part, to the lower binding affinity of 
SAgs to murine MHC class II as compared to human HLA class II (298). The advent of 
the HLA class II transgenic (HLA-tg) mice provided an opportunity to study the 
pathogenesis of GAS in a readily manipulated animal model with a sensitivity to SAgs 
similar to that of humans (226, 227, 299-301). Indeed several studies have shown that 
HLA-tg mice mount potent responses to GAS SAgs(226, 227, 290, 297, 302). 
 In this study, we examined the in vitro and in vivo responses to GAS SAgs in 
HLA-tg mice expressing HLA-DQ6 (SSD protective allele) or HLA-DR4/DQ8 (SSD 
neutral alleles). The work presented here provides evidence that HLA class II allelic 
variation contributes directly to streptococcal invasive disease outcome and confirms our 
previous epidemiological findings of the protective effect of the HLA-DQ6 allele.  
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Materials and Methods 
 
Transgenic mice 
 HLA transgenic, MHC class II deficient (H-2 Abo), mice expressing human 
DR4/DQ8 and DQ6 alleles were generated in the laboratory of Chella S. David (Mayo 
Clinic, Rochester, MN)(303-305). Mice were bred and maintained in accordance with the 
guidelines established by our institutional animal care committee. We confirmed the 
presence of the appropriate HLA class II transgenes by PCR-based genotyping using the 
following allele specific oligonucleotide primers: DQ6 sense 5’-AGG ATT TCG TGC 
TCC AGT TTA AGG CCA TG-3’ and DQ6 antisense 5’-TCT GCA AGA TCC CGC 
GGA ACG CC-3’, DQ8 sense 5’-AGG ATT TGG TGT ACC AGT TTA AGG GCA T-
3’ AND DQ8 antisense 5’-TGC AAG GTC GTG CGG AGC TCC AA-3’, DR4 sense 5’-
GTT TCT TGG AGC AGG TTA AAC A-3’ and DR4 antisense 5’- CTG CAC TGT 
GAA GCT CTC AC-3’. We also confirmed expression of HLA class II molecules on 
mice splenocytes by flow cytometry using monoclonal antibodies (mAb) specific to 
HLA-DQ (FITC, Leu-10, Catalog. No. 347453) or to HLA-DR (L227) followed after 
washing by FITC-goat F(ab`)2 specific to mouse IgG (Accurate Chemical & Science 
Corp., Westbury, NY). Analysis was conducted on a FACSCalibur (Becton Dickinson). 
 
Preparation of partially purified streptococcal SAgs from GAS culture supernatants 
 We used two representative invasive isolates of the clonal M1T1 strain to prepare 
a partially purified mixture of the native secreted streptococcal SAgs. Isolate 5622 
(isolate A) was from a severe invasive case and isolate 6021 (isolate B) from a non-
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severe invasive case. Previous studies determined that these two isolates are genetically 
indistinguishable, belonging to the global M1T1 strain (274). The bacteria were streaked 
on blood agar plates, subcultured in Todd-Hewitt broth (THB) supplemented with 1.5% 
yeast extract, and grown overnight at 37°C under static conditions. The recovered culture 
supernatants were mixed with ice-cold absolute ethanol (1:3 v:v) and incubated at -20°C 
overnight for complete precipitation of the secreted proteins, which include the SAgs. 
The precipitate was dissolved in distilled water containing 0.5 mM of the protease 
inhibitor PMSF and subjected to extensive dialysis against deionized water at 4°C. The 
dialysate was filter-sterilized with a 0.2 µm syringe filter (Sarstedt, Germany) and treated 
with polymyxin B agarose to remove any traces of endotoxin, as previously described 
(206). Aliquots of the dialyzed, LPS-depleted and sterilized native mixture of M1T1 
SAgs were stored at –20 °C until used.  
 
Generation of recombinant GAS superantigens 
 Recombinant SpeA2 (rSpeA2), rSmeZ1, rSpeG and rSpeJ were expressed as 
histidine-tagged fusion proteins according to the manufacturers’ recommendations 
(Promega, Madison, WI. and Qiagen Inc. Valenica, CA). Primer pairs used for the 
cloning were as follows: SpeA2 (672bp-5’G AGG CCT CAA CAA GAC CCC GAT C 3’ 
forward and 5’G AAG CTT ACT TGG TTG TTA GGT AGA CT3’ reverse), Smez1 
(645bp-5’G AGG CCT TTA GAA GTA GAT AAT AAT TC3’ forward and 5’CA AAG 
CTT AGG AGT CAA TTT C3’ reverse), SpeG (630bp-5’ T AGG CCT GAT GAA AAT 
TTA AAAG3’ forward and 5’ C AAG CTT CTA GTG CGT TTT TAA3’ reverse) and 
SpeJ (630bp-5’ G AGG CCT ATG AAA AGA ATA ATA AAA ACA A 3’ forward and 
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5’ G AAG CTT ATT TAG TCC AAA GGT AA 3’ reverse).  The forward and reverse 
primers contained Stu1and HindIII restriction sites, respectively.  The amplified PCR 
products were purified, subcloned in pGEM-T Easy vector (Promega Corporation, 
Madison, WI, USA), and sequenced (UTHSC Molecular Resource Center). The correct 
cloned inserts were digested with Stu1 and HindIII, moved to the pQE30Xa vector 
(Qiagen), propagated in DH5α Escherichia coli cells and subsequently used to transform 
M15 E. coli cells.  Recombinant SAg (rSAg) protein expression was induced with 1 mM 
IPTG (isopropyl-b-D-thiogalactopyranoside) for 3 h. Proteins in the bacterial cell lysate 
were resolved by SDS-PAGE, and the specific expression of each rSAg protein was 
determined by immunoblotting with RGS-His HRP Conjugate Kit (Qiagen) and specific 
rabbit polyclonal anti-Spe Ab. rSAgs were purified as His-fusion proteins using Ni-NTA 
superflow according to manufacturer’s recommendations (Qiagen) and their purity was 
confirmed by resolving the eluted fractions on SDS-PAGE and silver staining to detect 
any contaminating proteins. The purified rSAgs were treated with polymyxin B agarose 
(Boehringer Mannhiem, Indianapolis, IN) to remove any contaminating endotoxin. The 
activity and Vβ specificity of our rSmeZ1 was found to be comparable to rSmeZ1 that 
was kindly provided by Dr. Proft (University of Auckland, New Zealand). 
 
T cell proliferation assays 
 Spleens were aseptically removed from the HLA-tg mice and dispersed into 
single-cell suspensions. The cells were treated with NH4Cl red blood cells lysis buffer, 
washed three times in Hank’s balanced salt solution (HBSS), and resuspended to 
2X106cells/ml in RPMI 1640 with 5% (v/v) heat-inactivated FBS, 4 mM L-glutamine, 25 
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mM Hepes, 50 U/ml penicillin/ 50µg/ml streptomycin, and 50 µM 2-mercaptoethanol 
(RPMI complete medium). The cells were seeded at 2Χ105/well into U-bottom 96-well 
microtiter plates (Costar Corp., Cambridge, MA) and stimulated with optimal 
dilutions/doses of (a) mixture of native secreted M1T1 SAgs, (b) individual rSAgs 
produced by the clonal M1T1 strain (0.1–100 ng/ml rSpeA2, rSpeG, rSpeJ or rSmeZ1), 
or (c) Con A 1 µg/ml. After incubation for 72h at 37 °C in a 5% CO2 and 95% humidity, 
the cultures were pulsed for the final 6 h with 1 µCi/well [3H]thymidine (specific 
activity= 6.7 Ci/mmol; Dupont, Wilmington, DE), harvested onto glass fiber filters, 
washed, and the [3H]thymidine uptake was measured by counting on a Matrix 97 direct 
ionization β-counter (Packard Instruments Co., Meriden, CT). All samples measurements 
were performed in triplicates, and the data were presented as mean cpm [3H] thymidine 
uptake ± SD. Each experiment was repeated at least three times. 
 
Crisscross SAg presentation assays 
 Mouse APC-depleted T cells were purified from splenocytes by negative selection 
using the mouse pan T cell magnetic isolation kit and AutoMax according to the 
manufacturer’s instructions (Miltenyi Biotech, Auburn, CA). Pure APC-depleted T cells 
were cultured in RPMI complete medium, and their purity was confirmed physically by 
flow cytometry and functionally by the lack of response to stimulation by M1T1 SAgs. 
Experiments in which pure T (cultured alone without any APCs) cells showed a response 
to Con A or SAgs were discarded. We prepared APCs from each HLA-tg mouse strain by 
treating whole splenocytes with mitomycin C (Sigma) 50 ug/5X107 cell/ml for 20 min at 
37°C, washing them five times with HBSS, and suspending them in RPMI complete 
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medium. The efficacy of mitomycin C treatment was established by the non-
responsiveness of APCs to stimulation with Con A or M1T1 SAgs. Pure, APC-depleted T 
cells (1X105 /well) from a specific HLA-tg mouse strain were co-cultured in U-bottom 
96-well microtiter plates, with either autologous APCs (5X104 /well) or with the same 
number of APCs from the other HLA-tg mouse. Proliferation assays were conducted as 
described above. 
 In similar assays, pure human T cells were used as responders instead of the pure 
murine T cells. To prepare human T cells, we used ficoll hypaque gradient centrifugation 
to obtain the peripheral blood mononuclear cells (PBMCs) from healthy donors’ blood. 
We purified the T cells from PBMCs by one cycle of erythrocyte rosetting followed by 
negative selection using the human pan T cell magnetic isolation kit and AutoMax 
(Miltenyi Biotech, Auburn, CA). The purity of the APC-depleted T cells was confirmed 
by flow cytometry and by the lack of response to PHA or the M1T1 SAgs as detailed 
above. 
 
Cytokine measurement 
 Splenocytes were cultured as described under the proliferation assays (see above). 
Culture supernatants were collected from the individual wells after 24, 48, and 72 h of 
incubation, cleared of cells by centrifugation, and stored at –80 °C for subsequent 
analysis.  The cytokines IL-2, IFN-γ, and TNF-α were simultaneously quantified using 
the mouse cytometric bead array (CBA) kit (Pharmingen, San Diego, CA) according to 
the manufacturer’s instructions. A FACSCalibur (Becton Dickinson) was used to 
determine the fluorescence intensity and the assay results were analyzed using the BD 
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CBA software (Becton Dickinson, San Jose, CA). The amounts of cytokines produced in 
pg/ml were assessed by comparison to standards run in parallel with the test samples. 
Where human T cells were the responding population, we used the human cytokine 
Lincoplex kit (Linco Research, St Charles, CA.).  
 
Analysis of the T cell receptor Vβ (TCR Vβ) repertoire by flow cytometry 
 Relative quantitative analysis of TCR Vβ repertoire was conducted by flow 
cytometry using the mouse Vβ TCR screening panel kit (BD Pharmingen, Catalog No. 
557004). CD3-PE-Cy5 conjugate (BD Pharmingen Catalog No. 555276) was used as an 
additional marker to enable proper gating on T cells only. Approximately 5X105 
splenocyte/tube in 100 ul PBS containing 1% BSA were stained with mAbs for different 
Vβ according to the manufacturer's instructions. Using a FACSCalibur flow cytometer 
(Becton Dickinson), we gated on the CD3-PE-Cy5 cells and analyzed individual TCR Vβ 
per tube. The data were analyzed using FlowJo software (Tree Star, Inc. Ashland, OR 
97520). A minimum of 30,000 cell events was acquired for each analysis. 
 
In vivo infection studies 
 In preparation for infections, a representative isolate of the clonal M1T1 strain 
was grown for 17h at 37 ˚C without shaking in THB supplemented with 1.5 % yeast 
extract. The bacteria were washed twice in sterile PBS and diluted to the appropriate 
cfu/ml in PBS. DQ6 and DR4/DQ8 mice (n=10) were infected with 5 X 106 cfu/mouse in 
250 µl PBS bacteria via the tail vein. Mouse survival was monitored twice daily over 7 
days. We also assessed the systemic inflammatory responses elicited as a result of the 
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GAS infection by collecting heparinized blood (∼150 µl) at 24 h post infection from the 
retro-orbital plexus. The levels of inflammatory cytokines TNF-α and IFN-γ were 
determined as describe above. Bacteremia was determined by plating serial dilutions on 
blood agar plates. For assessing bacterial load in the organs, infected mice were killed by 
CO2 asphyxiation and bacteria were evaluated by preparing organs homogenates in PBS 
and plating 10-fold serial dilutions on blood agar plates. β hemolytic colonies were 
counted after incubation at 37°C for 24h.  
 
Statistical analysis 
 Data are expressed as mean of triplicates or quadruplicates ± SD. Statistical 
differences were calculated on original values using the nonparametric Mann Whitney U 
test. Kaplan-Meier survival curves were generated to compare mice survival following 
infection and the significant differences in survival curves were calculated by employing 
the log rank test. A value of p < 0.05 was considered significant.  
 
Results 
 
Differential in vitro response of HLA-tg mice splenocytes to M1T1 SAgs 
 To determine the effect of HLA class II variation on the response to GAS SAgs, 
spleen cells from mice expressing different HLA class II alleles were stimulated in vitro 
with partially purified mixture of native SAgs secreted by two different M1T1 isolates: 
isolate A from severe invasive STSS case, and isolate B from non-severe invasive case of 
mild bacteremia. Mice expressing the high-risk haplotype/alleles DR14/DQ5 are not yet 
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available and thus we compared mice expressing the protective DQ6 allele to mice 
expressing the DR4/DQ8 alleles that are neither associated with protection nor with high-
risk for SSD, i.e. neutral. As expected, the response to M1T1 SAgs from both isolates 
was comparable, reflecting the clonality of this strain. However, the proliferative 
response of splenocytes with DQ6 or DR15 alleles, both of which are present on the 
protective HLA class II haplotype in our epidemiological studies, was significantly lower 
(p<0.001) than that of splenocytes expressing the neutral DR4 and/or DQ8 alleles (Fig. 
2.1A). These differences were specific to the SAgs response inasmuch as the Con A 
responses were similar regardless the type of the HLA class II alleles expressed on mice 
splenocytes (Fig. 2.1A). Splenocytes from the non-tg background mice strains failed to 
respond to the M1T1 SAgs (data not shown). 
 In support of the proliferation data, splenocytes from the DQ6 mice produced 
significantly lower levels of TNF-α, IFN-γ, and IL-2 than those from the DR4/DQ8 mice 
in response to the same M1T1 SAgs (Fig. 2.1B). Cytokine responses peaked at the 72 h, 
those of the DQ6 mice were 6, 30, and 60-fold lower than those of the DR4/DQ8 mice 
for TNF-α (p < 0.001), IFN-γ (p < 0.01), and IL-2 (p< 0.001), respectively. 
  To further confirm that the response is specific to the M1T1 SAgs, we also 
compared the proliferative response of the splenocytes from the DR4/DQ8 and DQ6 mice 
to rSpeA2, rSpeG, rSpeG and rSmeZ1, individually as well as in a mixture. The pattern 
of the response to rSAgs mixture reflected that obtained with the native partially purified 
mixture of SAgs where the response of the DQ6 splenocytes was consistently and 
significantly less than that of DR4/DQ8 splenocytes and both responses were higher than 
the responses of the traditional inbred background mice splenocytes (Fig. 2.2). 
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Figure 2.1 HLA allelic variation affects in vitro response to M1T1 SAgs.  
 
In vitro stimulation of spleen cells from various HLA-tg mice with M1T1 SAgs  
A.   Proliferative responses of the indicated HLA-tg mice to the native mixture of M1T1 
SAgs. Spleen cells (2X105/well) were stimulated in triplicates by an optimal dilution 
(1:500) of the mixture of partially purified native SAgs secreted by M1T1 streptococcal 
isolate A from a severe invasive case, isolate B from a non-severe invasive case, or by 
Con A (1ug/ml).   B.   Cytokine responses of splenocytes from the indicated of HLA-tg 
mice to native M1T1 SAgs mixture. DQ6 or DR4/DQ8 spleen cells were incubated with 
the SAgs mixture in triplicates, and at the indicated times points the culture supernatant 
was collected and analyzed for the production of IL-2, TNF-α and IFN-γ. Each point 
represents the mean of triplicate ± SD; shown is a representative of one from at least four 
independent experiments. P<0.01: **, P<0.001: *** based on all experiments using the 
Mann-Whitney U test. 
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Figure 2.2 Proliferative response of splenocytes from tg and non-tg mice to individual or 
a mixture of rSAgs produced by the clonal M1T1 strain.  
 
Spleen cells (2X105/well) from DQ6 or DR4/DQ8 mice were stimulated with the 
indicated concentrations of individual rSAg (0.1-100 ng/ml) as well as a rSAg mixture. 
Individual rSAgs were mixed in equal amounts and 0.1-100 ng/ml of this mixture was 
used to stimulate mouse spleen cells. Spleen cells from the non-tg ancestral background 
mice were similarly stimulated with the same rSAgs mixture. 
Each point represents the mean of triplicate ± SD; shown is a representative of one from 
at least four independent experiments. 
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This was not related to differences in HLA allele expression inasmuch as flow cytometric 
analysis showed comparable expression of DQ6 and DQ8 (Table 2.1). DR4 expression 
was lower than that of DQ6 and DQ8 because cDNA was used for the generation of the 
DR4-mice, and genomic DNA was used to create the DQ6 and DQ8 tg-mice (303, 304, 
306).  
 The enhanced responsiveness of the DR4/DQ8 mice compared to DQ6 and DR15 
mice was unrelated to expression of double versus single alleles because as demonstrated 
in Figure 2.1A, mice expressing DQ8 only were also significantly higher responders to 
the M1T1 SAgs as compared to DR15 and DQ6 mice. 
 
Dominance of the effect of HLA allelic variation in potentiating M1T1 SAgs 
responses 
 The possibility that TCR Vβ repertoire variability may be a major factor in the 
stark differences in responses between the various mice was addressed. We found the Vβ 
repertoire in DQ6 and DR4/DQ8 to be quite comparable with few exceptions (Fig. 2.3). 
The percentage of T cells expressing TCR Vβ 5 was higher in the DQ6 mice while 10 
and 14 were higher in the DR4/DQ8 mice but these elements are not specific to any of 
the SAg produced by the M1T1 strain (103, 307). The expression of TCR Vβ11 and 12, 
which are specific for SmeZ1 was higher in the DQ6 mice, yet these mice were low 
responders. Thus we conclude that variation in the TCR Vβ repertoire does not account 
for the enhanced responsiveness of DR4/DQ8 mice to M1T1 SAgs. 
 To further confirm this, we performed crisscross SAg presentation assays, where 
pure T cells from the DQ6 or the DR4/DQ8 mice were stimulated with the same  
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Table 2.1 Percentages of splenocytes expressing respective HLA class II transgenes and 
the mean fluorescence intensity (MFI) of the expression a. 
 
% DQ % DR DQ MFI DR MFI HLA tg-mice 
± SD 
HLA-DQ6 36 ± 4.3 − 273 ± 24.7 − 
HLA-DR4/DQ8 37 ± 2.6 21.9 ± 1.6 292.4 ± 30.5 101.2 ± 6.6 
 
 a Analysis of HLA class II expression in tg mice.  Spleen cells from 4-5 naïve DR4/DQ8 
or DQ6 mice were analyzed by flow cytometry for surface expression of the transgene 
DR4, DQ8 and DQ6 as described in material and methods. The data are presented as the 
mean ± SD. 
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Figure 2.3 Comparison of the TCR Vβ repertoire of the DQ6 and DR4/DQ8 mice.  
 
Splenocytes from age-matched DR4/DQ8 and DQ6 tg mice (n = 3 mice /strain) were 
stained for CD3 and TCR Vβ-specific fluorochrome-conjugated antibodies and analyzed 
by flow cytometry. Each bar represents the mean ± SD of the percentages of cells 
expressing a specific TCR Vβ subfamily within the CD3+ population. 
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M1T1 SAgs, presented either by their autologous HLA class II-expressing APC or by 
APC from the other HLA-tg mouse. The presentation of the M1T1 SAgs by DQ6-
expressing APC resulted in a two-fold lower proliferative response than the presentation 
by the DR4/DQ8-expressing APC (p<0.01), regardless the source of the responding T 
cells (Fig. 2.4A). The dominant effects of the HLA class II allelic variation on the 
response was also reflected in TNF-α, IFN-γ, and IL-2 responses, where in the presence 
of the DQ6 APC there was respectively 2 (p<0.01), 13 (p< 0.01), and 3-fold (p< 0.001) 
lower cytokine level compared to cultures containing the DR4/DQ8 APC (Fig. 2.4B). 
These data demonstrate that T cells from the DQ6 mice are perfectly capable of mounting 
potent responses to the streptococcal SAgs, if presented by the DR4/DQ8 APC, but that 
the magnitude of the response is governed mainly by the HLA class II allele type 
expressed on the presenting APC. 
 To further confirm the dominant role of class II allelic variation in modulating the 
SAg response we investigated the effect of different human HLA class II alleles 
expressed by murine APC on the SAg response of pure human T cells. Similar to the 
murine T cells, human T cells proliferative (Fig. 2.5A) and cytokine (Fig. 2.5B) 
responses to the same M1T1 SAgs were significantly (p< 0.01) lower in the presence of 
the DQ6 APC as compared to the DR4/DQ8 APC. 
 
HLA class II allelic variation directly modulates the severity of systemic disease and 
mouse survival following infection with M1T1 GAS 
 We have shown that individuals carrying the protective DR15/DQ6 alleles are 
significantly more protected against SSD in invasive infection, compared to others 
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Figure 2.4 Cross-presentation of the M1T1 SAgs by APC from DQ6 and DR4/DQ8 mice 
to each other’s T cells reveals that variation in HLA class II is the main controller of the 
magnitude of SAg.  
 
A.   Proliferative responses. DQ6 (protective) and DR4/DQ8 (neutral) T cells were 
separated from their autologous APC. The native mixture of M1T1 SAgs (at 1:500 
dilution) was presented to the pure T cells (1X105/well) from DQ6 or DR4/DQ8 mice by 
mitomycin C-treated APC (0.5X105/well) from either DQ6 or DR4/DQ8 mice.    
B.   Cytokine response of pure T cells from DQ6 mice to native M1T1 SAgs presented by 
APC from either DQ6 or DR4/DQ8 mice. The culture supernatants were collected at 24, 
48, and 72h culture and analyzed for of IL-2, TNF-α and IFN-γ production. Differences 
in cytokine levels are in support of the observed proliferative responses. The results 
shown represent one out of four separate experiments. 
P< 0.05: *, P< 0.01:**,  P< 0.001: *** based on all experimental results using Mann-
Whitney U test.  
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Figure 2.5 Differential proliferative and cytokine responses of APC-depleted human T 
cells to native M1T1 SAgs presented by APC from DQ6 or DR4/DQ8 mice.  
 
A.   Pure human T cells (1X105/well) were stimulated with 1:500 dilution of M1T1 SAgs 
in the context of mitomycin C-treated APC (0.5X105/well) from DQ6 or DR4/DQ8.   
B.   Human T cells were stimulated in the same way as above and culture supernatants 
were collected at 24, 48, and 72h culture, and analyzed for IL-2, TNF-α and IFN-γ 
expression using the human. Each data set represents mean ± SD of triplicates. Shown are 
the results representing one of three independent experiments. P<0.05:*, P<0.01:**,  
P<0.001: *** based on results from all experiments using Mann-Whitney U test. 
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infected with the same GAS strain, but who are not carrying those alleles (275). 
Therefore, it was important to compare in vivo responses of DQ6 and DR4/DQ8 mice and 
see if they are comparable to what we found in humans and whether the significant 
differences observed in our in vitro studies would translate to considerable biologic 
variation in vivo. Accordingly, we infected the HLA tg-mice i.v., with 5X106 CFU of the 
M1T1 bacteria, and recorded their mortality over a period of 7 days. DR4/DQ8 mice 
started to succumb to the infection within 48h with a mortality rate of 80% by day 4 after 
inoculation. By contrast none of the DQ6 mice died during the observation period (Fig. 
2.6A).  
 The differential susceptibility of the HLA tg-mice to infection with M1T1 
bacteria was also reflected in the systemic levels of the inflammatory cytokines TNF-α 
and IFN-γ. Plasma levels of TNF-α and IFN-γ at 24 h post i.v., infection with M1T1 
bacteria were significantly lower in the DQ6 mice than in the DR4/DQ8 mice (p< 0.01 
and p <0.05, respectively) (Fig. 2.6B). In contrast to the significant difference in the 
survival and systemic inflammatory cytokines results, both mice strains had comparable 
bacteremia at 24h post infection as well as comparable bacterial load in the liver at 24 
and 48h post infection (Fig. 2.6C). However, DR4/DQ8 spleens showed significantly 
higher bacterial load than those of DQ6 only at 24h post infection (P= 0.03); but there 
was no significant difference at the 48h in both strains. These observations underscore the 
role of HLA class II as a major controller of the inflammatory cytokine response and 
hence the severity of invasive GAS infection. 
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Figure 2.6 Class II allelic variation directly modulates systemic disease severity and 
survival following infection with M1T1 GAS. 
 
A.   In vivo differential susceptibility of HLA-tg mice to M1T1 GAS sepsis. (5X106 CFU) 
live M1T1 bacteria in 250 ul PBS were injected i.v. into DQ6 () or DR4/DQ8 () 
mice. Mice survival was monitored twice daily and death was recorded over 7 days.   B.   
IFN-γ and TNF-α levels in plasma of HLA-tg mice, 24h post infection.   C.   Bacterial 
load in the blood, liver, and spleen of DQ6 () or DR4/DQ8 () mice i.v. infected with 
5 X106 CFU bacteria . P<0.05:*, P<0.01:** 
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Figure 2.6 (continued). 
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 Discussion 
 The resurgence of invasive GAS infection pandemic in the 1980’s, with 
aggressive manifestations such as STSS and NF, has been receiving much attention for 
the past 25 years (221, 292, 308, 309). Throughout this pandemic, the clonal M1T1 strain 
was the most frequently isolated strain from severe and non-severe invasive cases (25, 
310, 311). Among the many virulence factors produced by the bacteria, the streptococcal 
SAgs are mainly responsible for triggering potent inflammatory responses, which 
mediate the systemic effects seen in patients with STSS (100, 214, 312). Our previous 
work provided evidence that certain individuals are prone to be high responders to GAS 
SAgs, whereas others mount moderate or low inflammatory responses (275, 276). We 
also found that among patients who recovered from invasive GAS infections, those who 
are prone to be high responders to GAS SAgs in vitro were the ones who had developed 
severe invasive systemic disease and STSS and mounted very high inflammatory 
cytokine response during the acute infection; whereas, those who developed mild 
invasive disease were consistently low responders. Differences between the high and low 
responders reflected host genetic variations that were found to be associated with the 
HLA class II locus. Specifically, the strongest association was with DRB1*15/DQB1*06 
haplotype, which seemed to confer strong protection from the severe manifestations of 
the invasive disease (275). However, there was still a question of whether the observed 
association is directly related to HLA class II allelic variation or to other genes that are in 
linkage disequilibrium with these HLA haplotypes. In this study we provide evidence for 
direct role of HLA class II allelic variation in modulating the severity of GAS sepsis, and 
demonstrate the dominant effect of the protective alleles in attenuating SAgs responses. 
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 Although well-designed epidemiological association studies have an advantage of 
being carried out in patients with clear clinical outcomes, these studies are limited by the 
inability to design certain controlled experimentation to delineate disease pathogenesis. 
Despite limitations, animal models for diseases remain indispensable to address such 
drawbacks. Regular mice are generally not a model of choice for STSS because they 
respond poorly to SAgs, particularly to the streptococcal SAgs (99, 296, 297). To elicit 
appropriate responses in these mice, investigators have resorted to using doses of SAgs 
that are much higher than physiologic (124, 313), have augmented SAg effects by co-
administering LPS (296, 314), or treated the mice with D-galactosamine to prolong the 
biologic half-life of cytokines by delaying their hepatic clearance (99). Whereas these 
models provided valuable information, these manipulations may not represent actual 
events of the human disease.  
 By contrast, the humanized HLA class II-tg mice have shown high sensitivity to 
bacterial SAgs; T cells from these mice respond vigorously to bacterial SAgs in a way 
similar to human T cells without any manipulation, suggesting a SAg presentation pattern 
comparable to that in humans (227, 300). Several studies have used HLA-tg mice to 
investigate immune responses to SAgs and SAg-producing bacteria (227, 297, 300, 301). 
We were particularly interested in HLA-tg mice carrying the HLA class II alleles 
associated with protection or high-risk for SSD, as identified in our epidemiological 
study (275). However, as mentioned earlier, mice carrying the high-risk alleles are not yet 
available so we compared responses to M1T1 SAgs of mice carrying the neutral alleles 
DR4 and/or DQ8 alleles, to mice carrying the protective DQ6 allele.  
 Our previous studies showed that PBMCs isolated from healthy individuals or 
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recovered patients expressing HLA alleles associated with protection from STSS 
mounted significantly lower proliferative and cytokine responses to SAgs than PBMCs 
from individuals carrying neutral or high-risk alleles (275). In a nicely reproducible 
manner, the in vitro responses of HLA tg-mice splenocytes to M1T1 SAgs were 
markedly lower for the DQ6 mice than for the DR4/DQ8 mice. Also, in human invasive 
GAS infections, we showed that patients with SSD who lack the DR15/DQ6 protective 
alleles mount significantly higher levels of inflammatory cytokine responses, in both 
acute and convalescent phase of the disease, than those with mild non-severe disease 
(275, 276). We found the same pattern in the HLA tg-mice, where splenocytes from the 
DQ6 mice mounted significantly lower levels of the inflammatory cytokines TNF-α and 
IFN-γ in vitro and in vivo than those of the DR4/DQ8 mice. In addition, the DQ6 mice 
were highly resistant to GAS sepsis, while the DR4/DQ8 mice were susceptible and quite 
overwhelmed by the infection despite having comparable bacterial load in liver and 
spleen. These findings emphasize the overriding role of HLA class II in governing the 
outcome of invasive GAS infection by modulating the systemic inflammatory cytokine 
responses to SAgs. Additionally, the SAgs-crisscross presentation assays where APC 
from one HLA-tg mouse were used to present the SAgs to T cells from the other mouse 
or to human T cells, showed reproducibly and significantly lower proliferative and 
cytokine responses in the context of DQ6 APC as compared to the DR4/DQ8 APC. Thus, 
results from the HLA-tg mice paralleled our findings in humans and confirmed a direct 
and dominant role of HLA class II allelic variation in controlling the magnitude of 
response to streptococcal SAgs, with little or no impact of variability in host T cells on 
disease severity. The dominance of the protective effect of the DQ6 allele seen in 
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humans was also confirmed in these HLA-tg mice.  
 Differences in proliferative and inflammatory cytokine responses to the M1T1 
SAgs when presented by DR4/DQ8 as compared to DQ6 or DR15 alleles may be 
attributed to difference in binding affinities or to the ensuing cellular signals in the APC 
and T cells. Our previous studies (288) indicated no correlation between binding affinity 
and response level. However, ongoing studies in our lab are addressing this possibility in 
greater depth as well as examining if differences in the stability of the trimolecular 
complex (composed of Class II-SAg-TCR) taken as a whole may establish the overall 
strength of the response. Although our present study point to the HLA class II molecule 
as the principal controller of the SAg-induced response, we still cannot rule out the 
likelihood that associated polymorphism in other host genes could contribute to 
susceptibility to STSS  
 These findings should facilitate our ongoing studies of the temporal events that 
take place in the pathogenesis of invasive GAS infection and will help us identify specific 
molecular and cellular mechanisms involved in regulating SAg responses in the presence 
of distinct HLA class II alleles in vivo.  
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Chapter 3. HLA Allelic Variants Dictate the Overall Cytokine Profile Elicited by 
Superantigens: Streptococcal Toxic Shock Protective Alleles Elicit IL-10 Production 
and Diminish Inflammatory Responses 
 
Introduction 
 Host genetic variability can profoundly affect resistance/susceptibility to 
infectious diseases as well as control the severity of disease associated clinical 
manifestations (244, 246, 315). Group A Streptococci (GAS) are important human 
pathogens that can cause a wide spectrum of diseases ranging from superficial infections 
to life threatening streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis 
(NF). Furthermore, in genetically susceptible individuals, GAS infections can lead to 
post-streptococcal autoimmune diseases, including acute rheumatic fever, 
glomerulonephritis, carditis, arthritis or neurological disorders (10, 293, 316). The severe 
forms of invasive GAS infections, including STSS and NF resurged in the 1980s after 
almost 60 years of decline (221, 292). Coincidental with the resurgence of severe 
invasive GAS disease was the emergence of a particular subclone of the M1T1 serotype, 
which exhibited increased virulence, global dissemination and persistence for over 25 
years (22). The increased virulence of this M1T1 clone is in part attributed to the 
acquisition of 3 unique prophages, one carries the potent SAg SpeA2, and the other two 
carry DNases, including a novel and highly potent streptodornase (Sda1) (6). Despite its 
increased virulence, this M1T1 strain was isolated from individuals with starkly different 
clinical manifestations, thereby underscoring the critical role of host factors in 
modulating outcomes of GAS infections (273-275).  
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 Although GAS possess a large battery of virulence factors that can trigger potent 
inflammatory responses in the host (9, 317, 318), the superantigenic streptococcal 
pyrogenic exotoxins (Spes) are the main players in severe invasive GAS infections, 
including GAS sepsis and STSS (100, 275). SAgs bridge HLA class II molecules on 
antigen presenting cells (APC) and the TCR on T cells, thereby forcing these cells to 
interact regardless of the antigenic specificity of the TCR. In addition, SAgs utilize these 
receptors to trigger excessive activation of both cell types, causing massive T cell 
proliferation and inflammatory cytokines production. However, several studies have 
shown that not all class II isotypes or alleles present a given SAg equally — some SAgs 
are presented better by DR than by DQ and vice versa (285, 287-289). 
 The magnitude of inflammatory responses triggered by the same Strep SAg in 
different individuals can also vary considerably (206), and there is a direct correlation 
between the levels of inflammatory cytokine responses and severity of invasive disease 
(275, 276). These observations suggested that variations in host immunogenetic factors 
involved in regulating SAg responses are important determinants of infection severity. 
Indeed, we identified significant associations between specific HLA haplotypes and 
different manifestations of GAS sepsis. Specifically, the HLA DRB1*1401/DQB1*0503 
(DR14/DQ5) and DRB1*0701/DQB1*0202 haplotypes were associated with the severe 
forms of GAS sepsis, namely STSS, whereas the HLA DRB1*1501/DQB1*06 
(DR15/DQ6) haplotype conferred strong protection from STSS even in septic patients 
(275). Biological validation studies in vitro and in vivo using animal models of GAS 
sepsis demonstrated that disease-modulatory effects are directly mediated by HLA allelic 
variation and not by other genes in linkage disequilibrium on the same haplotype (275, 
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319).  However, SAg responses are also influenced by the interaction with its other 
receptor on T cells. SAgs interact with specific TCR Vβ elements of the β chain of the 
αβ TCR with little contribution from the other variable elements of the TCR (313, 320, 
321). Humans have about 25 major Vβ families (322). Each SAg has a distinct, signature 
TCR Vβ specificity and can interact with T cells expressing those Vβ elements regardless 
of the Ag specificity of their TCR. Therefore, the response to particular SAg could be 
affected by the relative abundance of SAg-reactive TCR Vβ families and the frequency 
of T cells expressing those families in a given individual’s repertoire.  
 In this study we determined the relative contribution of variations in the 
individual’s HLA class II and TCR Vβ repertoire on host responses to Strep SAgs 
derived from the prevalent M1T1 strain and we investigated the molecular basis for the 
protective effect of the DR15/DQ6 against STSS. We found a dominant role of HLA 
class II variability in controlling the magnitude of Strep SAgs responses, with little to no 
effect of TCR Vβ variation on the overall SAg response. Additionally, we show that 
alleles associated with protection from STSS seem to diminish proliferative and 
inflammatory cytokine responses to the Strep SAgs by inducing the production of high 
levels of the regulatory cytokine, IL-10. 
 
Materials and Methods 
 
Preparation of partially purified Strep SAgs from GAS culture supernatants 
 Bacterial culture supernatants were prepared from overnight cultures of GAS 
isolates by ethanol precipitation followed by extensive dialyses, as detailed 
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elsewhere(319). We have previously shown that these partially purified culture 
supernatants are good sources of the SAgs mixture produced by the clinical isolates (274, 
319).  
 
Cells  
 We isolated peripheral blood mononuclear cells (PBMC) from various individuals 
as previously described (323).  T cells were purified by subjecting freshly isolated PBMC 
to one cycle of erythrocyte resetting, followed by using the human pan T cell isolation kit 
and autoMACS according to the manufacturer’s instructions (Miltenyi Biotec, Auburn, 
CA). To remove any residual APC, we incubated the purified cells overnight at 37°C in 
RPMI 1640 supplemented with 5% (v/v) FBS, 4 mM L-glutamine, 25 mM Hepes, 50 
U/ml penicillin/ 50µg/ml streptomycin (RPMI complete medium). In each experiment, 
the purity of the APC-depleted T cells was confirmed phenotypically by flow cytometry 
and functionally by the lack of response to PHA or the M1T1 SAgs. Experiments in 
which purified T cells (cultured alone without any APC) showed a response to PHA or 
SAgs were discarded.  
 The E-rosette-negative fraction, enriched in B cells and monocytes, were used as 
APC in cross presentation assay, and their purity (T cell depletion) was determined in 
each experiment by their non-responsiveness to PHA or the M1T1 SAgs.  
 B cell lines homozygous for the high risk DRB1*1401/DQB1*0503 or the 
protective DRB1*1501/DQB1*0602 haplotypes were obtained from the European Cell 
Culture Collection (UK).  To use these cells in presenting SAgs, we treated them with 
mitomycin C (25 ug/1X107 cell/ml, Sigma) for 30 min at 37°C followed by extensive  
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washing with Hank’s balanced salt solution. The efficacy of mitomycin C treatment was 
checked by [3H]thymidine uptake and compared to untreated cells. 
 
T cell proliferation assay 
 PBMC (2X105/well) or pure T cells (105/well) were cultured in RPMI complete 
medium in 96 well plate. T cells were cultured with the indicated numbers of autologous 
or allogeneic APCs, or with mitomycin C-treated B cell lines (0.5X105/well). Cells were 
stimulated with either PHA (1µg/ml) or several dilutions of the mixture of native secreted 
M1T1 SAgs. The amount of M1T1 SAgs used was predetermined in titration assays to 
select SAg dilutions within the linear proliferation curve and not the plateau area. This is 
important to allow detection of differences in responses due to either HLA or TCR 
variations. In some experiments exogenous recombinant human IL-10 (3ng/ml)(R &D 
systems) was added to individual “B” PBMC or to T cells co-cultured with B cell line 
homozygous for the high-risk haplotype. After incubation for 72h at 37 °C in a 5% CO2 
and 95% humidity, the cultures were pulsed for the last 6h with 1 µCi/well [3H]thymidine 
(specific activity= 6.7 Ci/mmol; Dupont, Wilmington, DE). All samples measurements 
were performed in triplicates, and the data were presented as mean cpm [3H] thymidine 
uptake ± SD. Each experiment was repeated at least three times. 
 
Cytokine assays 
 Culture media were collected from the individual wells at 24, 48, and 72h post-
stimulation, cleared of cells by centrifugation, and stored at –80 °C for subsequent 
analysis. The cytokines IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α were simultaneously 
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quantified, using the human cytokine LINCOplex kit (Linco Research Inc., St. Charles, 
MO). TNF-β was analyzed by ELISA kit from R&D Systems (Minneapolis, MN). The 
assays were performed according to the manufacturer’s instructions, and the 
concentrations were calculated from standard curves run in parallel with the test samples. 
All samples measurements were performed in triplicates and data are presented as mean 
concentration ± SD.  
 
Analysis of the T cell receptor Vβ (TCR Vβ) repertoire by flow cytometry  
 Quantitative analysis of TCR Vβ repertoire was conducted by flow cytometry 
using the IOTest Beta Mark TCR Vβ repertoire Kit (Beckman Coulter, cat # IM3497). 
CD3-PC5 conjugate was used to enable proper gating on T cells only. Approximately 
5X105 lymphocyte/tube in 100ul PBS containing 1% BSA were stained with mAbs for 
different Vβ according to the manufacturer's instructions. Using a FACSCalibur flow 
cytometer (Becton Dickinson), we gated on the CD3-PC5 cells and analyzed three 
different TCR Vβ specificities per tube. The data were analyzed using FlowJo software 
(Tree Star, Ashland, OR 97520). A minimum of 30,000 cell events was acquired for each 
analysis. 
 
Flow cytometric assessment of HLA DQ and DR expression level   
 We used monoclonal antibody (mAb) labeled with phycoerythrin (PE) (Catalog. 
No. 347367, BD) specific to HLA-DR and primary unlabeled mAb specific to HLA-DQ 
(MCA379G, serotec) followed by PE-labeled secondary Ab (STAR12A, serotec). 
Analysis was conducted on a FACSCalibur (Becton Dickinson). 
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Statistical analysis 
 Analysis of variance (ANOVA) or a two-tailed Student’s t test was used to 
determine the significance of the data. A p value of <0.05 was considered significant.  
 
Results 
 
HLA Class II allelic variation plays a dominant role in determining the magnitude 
and type of Strep SAg responses  
 In initial studies, we selected two individuals, one individual “A” expresses the 
DR15 and DQ6 alleles associated with strong protection from STSS and the other, 
individual “B” expresses the DR7 and DQ5 alleles associated with high risk for it, and 
analyzed the relative contribution of HLA class II allelic variation to responses elicited 
by Strep SAgs produced by the prevalent M1T1 GAS strain.  Although we had shown 
that the same strain causes disease of different severity in genetically distinct individuals, 
we decided to test the response of both individuals to two invasive M1T1 GAS isolates: 
isolate 1 was recovered from an STSS case and isolate 2 was from a non-severe invasive 
case. We compared proliferative responses of PBMC from individuals “A” and “B” to the 
SAgs produced by these isolates, and found that both isolates elicited the same level of 
response in both individuals; however, there were significant differences in the level of 
response between these individuals. Individual “A” reproducibly mounted significantly 
(p<0.01) lower proliferative responses to the M1T1 SAgs than individual “B” (Fig. 3.1).  
This difference was SAg specific because both individuals had comparable PHA 
responses. Furthermore, differences in response levels of both individuals were not due to 
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Figure 3.1 Proliferative responses of PBMC from individual “A” (protective haplotype) 
and “B” (risk haplotype) to the native mixture of partially purified M1T1 SAgs.  
 
PBMC (2X105/well) from individual “A” (expresses STSS protective HLA class II 
alleles) and individual “B” (expresses STSS high-risk HLA class II alleles) were 
stimulated in triplicates with serial dilutions (1:100, 250, 500 and1000) of the SAgs 
mixture produced by isolate 1 from a severe invasive case, isolate 2 from a non-severe 
invasive case, or by PHA (1ug/ml). The experiments were repeated at least three times, 
and the presented data are means ± SD. Statistical significance was assessed by ANOVA 
(*** P<0.001, ** P<0.01, * p<0.05). 
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variable expression level of DQ or DR because both individuals expressed comparable 
levels of these antigens as determined by flow cytometry (Table 3.1).   
 To determine the relative contribution of T cells versus APC in controlling SAg 
response levels, we performed experiments where we separated the T cells and APC from 
PBMC of each individual and tested their response to the M1T1 SAgs in cross 
presentation studies. The presentation of the Strep SAgs to pure T cells from the high 
responder, individual “B” by APC from individual “A” who carries the protective 
DR15/DQ6 alleles resulted in a significantly reduced proliferative response compared to 
that in the presence of his own APC (Fig. 3.2A). Likewise the responses of T cells from 
the low responder (individual “A”) were significantly increased when the SAgs were 
presented by APC from the high responder, expressing the high-risk alleles (Fig. 3.2A).   
 To rule out the possibility that there is something peculiar about the APC and/or T 
cells from individual “A” or “B”, we compared the response of pure T cells from both 
individuals to the M1T1 SAgs presented by two B cell lines, one homozygous for the 
STSS protective DRB1*1501/DQB1*0602 haplotype and the other for the high risk 
DRB1*1401/DQB1*0503 haplotype. As predicted, the presentation by cells expressing 
the protective DR15/DQ6 haplotype elicited significantly lower proliferative and 
cytokine responses to the M1T1 SAgs than by cells expressing the DR14/DQ5 haplotype 
(Fig. 3.2B). The data shown in Figure 2B indicate that when T cells from individual “A” 
are presented with the M1T1 SAgs in the context of the high risk alleles, they mounted a 
response that is as potent or even more potent than that of individual “B”. The response 
of T cells from both individuals was diminished in the presence of the DR15/DQ6 
expressing cell line (Fig. 3.2B).   
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Table 3.1 Percentages of PBMC expressing HLA DR or DQ and the mean fluorescence 
intensity (MFI) of the expression a. 
 
Individual % DQ % DR  DQ MFI DR MFI 
A 15.7 ± 3.4 18.3 ± 2.3 356.9 ± 23.4 962.6 ± 45.7 
B 16.6 ± 3.7 19.5 ± 3.7 334.2 ± 30.2 1059.2 ± 34.3 
 
a PBMC from Individual A (with protective alleles) or B (with high-risk alleles) were 
analyzed by flow cytometry for expression level of DR and DQ. Analysis was performed 
at each experiment and the data are shown as mean ± SD.  
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Figure 3.2 T cell responses to the M1T1 SAgs are governed by the type of HLA class II 
alleles expressed by autologous or allogeneic APC expressing STSS protective or high- 
risk HLA class II haplotypes.   
 
Pure T cells (1X105/well) from individuals “A” (protective haplotype) or “B” (high risk 
haplotype) were stimulated with PHA (1 µg/ml) or an optimal dilution (1:500) of the 
native mixture of M1T1 SAgs presented by:   A.   Autologous or each other’s allogeneic 
APC (0.5X105/well) in a criss-cross design, or   B.   Immortalized B lymphoblastoid cell 
lines homozygous for either the STSS protective or high-risk haplotypes as indicated. 
Proliferative responses were determined as described in Figure 1. The data represent 
mean cpm ± SD of at least three independent experiments after normalization for any 
variability in HLA expression level on the APC. Statistical significance was assessed by 
ANOVA (*** P<0.001, ** P<0.01, * p<0.05). 
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 The above data demonstrate that SAg responses are governed primarily by the 
type of HLA class II alleles expressed on the APC with minimal or no contribution from 
TCR Vβ repertoire variability. To investigate this possibility further, we compared the 
TCR Vβ repertoire of both individuals and analyzed them in the context of the Vβ 
specificity of the M1T1 SAgs.  The globally disseminated M1T1 strain harbors the 
SpeA2, speF, speG, speJ, and SmeZ1 genes. Although these SAgs overlap in their 
specificity to certain Vβ elements, they also have unique signature TCR Vβ specificities 
(103, 114).  It was therefore of interest to determine if the heightened response of 
individual “B” to the M1T1 SAgs is related to over-expression of M1T1 SAgs-reacting 
TCR Vβ elements in this individual repertoire.  
 The TCR Vβ repertoires of individual “A” and “B” were comparable, with 
several exceptions (Fig. 3.3). The relative expression of TCR Vβ 1, 3, 5.1, 8 and 11 was 
higher in the repertoire of the low responder individual “A” than in individual "B", 
however none of these Vβ elements are specific to the M1T1 SAgs listed above (100, 
106). By contrast, expression of TCR Vβ8, which is specific for SmeZ1, was higher in 
individual A, yet this individual is the low responder. These data are consistent with the 
conclusion that individual variations in the TCR Vβ repertoire have little or no effect on 
the magnitude of SAgs responses. Although certain TCR Vβ elements (e.g. Vβ6.9, 7.3, 
10, 15, 19, 24 and 25) are not included in our analysis, some of these (Vβ10, 24 and 25) 
are not specific to any known Strep SAgs (Table 1.3). Also, Vβ7.3 is reactive to SpeH, 
however, this SAg is not produced by the clonal M1T1 strain. Furthermore, Vβ6.9 is 
specific to SpeG, but it is not a major taraget for this SAg (106). Similarly, Vβ 15 is not a 
major target for SpeA, and Vβ15 and 19 are reactive to SpeF that is disputed as a SAg. 
 84 
 
Figure 3.3 Comparison of the TCR Vβ repertoire of individual “A” (protective 
haplotype) and “B” (risk haplotype).  
 
PBMC from both individuals were stained with fluorescently labeled antibodies against 
CD3+ and a panel of antibodies directed to the 24 indicated Vβ subfamilies, as described 
in Methods, then analyzed by flow cytometry. Each bar represents the mean of the 
percentages of cells expressing a specific TCR Vβ subfamily within the CD3+ population. 
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In addition, the cross presentation results (mentioned above) exclude variation in the 
unstudied TCR Vβ elements as a factor contributing to disparate SAg responses.   
 
DR15/DQ6 alleles diminish SAg responses by inducing high levels of IL-10 
 In agreement with the proliferation results, cytokine responses to the Strep SAgs 
were also affected by the type of HLA class II alleles expressed by the presenting APC.  
The levels of IL-2, IL-6, TNF-α, and notably IFN-γ and TNF-β, which are typical SAg-
induced inflammatory cytokines, mounted by individual “A” PBMC, were significantly 
lower than by individual “B” (p<0.001-0.05; Fig. 3.4A). Interestingly, however, 
individual “A” (low responder) produced significantly higher levels of the anti-
inflammatory cytokine IL-10 than individual “B” (p<0.01; Fig. 3.4A). IL-4 responses 
were undetectable in either individual (data not shown).   
 IL-2, IL-6, TNF-α, TNF-β and IFN-γ responses were also significantly lower 
when the M1T1 SAgs were presented by the B cell line expressing the protective 
haplotype DR15/DQ6 as compared to that expressing the high-risk DR14/DQ5 haplotype 
(p<0.001-0.05; Fig. 3.4B). Importantly, IL-10 levels were significantly higher in the 
presence of the DR15/DQ6 expressing cells than in the presence of the DR14/DQ5 
haplotype at all time points tested (p<0.001-0.05; Fig. 3.4B).   
 
Exogenous IL-10 diminishes SAgs responses induced by high-risk alleles 
 The lower proliferative responses coupled with higher level of the anti 
inflammatory IL-10 in the presence of the protective DR15/DQ6 alleles compared to the 
high-risk alleles suggested that SAg presentation by the protective alleles may be  
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Figure 3.4 The HLA type of the APC determines the type and magnitude of cytokine 
responses to the Strep SAgs.   
 
A.   Cytokine responses of PBMC from both individuals to native M1T1 SAgs mixture. 
Cells (2X105/well) were stimulated with the native M1T1 Strep SAg mixture in 
triplicates, and at the indicated times points, culture supernatants were collected and 
analyzed for the production of TNF-β, IFN-γ, IL-6, TNF-α, IL-2 and IL-10   B.   Pure 
APC-depleted T cells (1X105/well) were stimulated with an optimal dilution of native 
M1T1 SAgs mixture presented by B cell lines (0.5X105/well) homozygous for either the 
STSS protective or high risk HLA- Class II haplotypes. Culture supernatants were 
collected at the indicated times points post stimulation, and analyzed for the production 
of TNF-β, IFN-γ, IL-6, TNF-α, IL-2 and IL-10.  Each data set represents mean ± SD. 
Significant differences were evaluated by ANOVA (*** P<0.001, ** P<0.01, * p<0.05). 
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Figure 3.4 (continued). 
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eliciting signals that actively suppress SAgs responses rather than merely eliciting a weak 
response. We tested this possibility by comparing the proliferative response of individual 
“B” in the presence or absence of added human rIL-10 (3ng/ml) to that of individual “A” 
PBMC stimulated with the same Strep SAgs mixture (Fig. 3.5).  The chosen  
concentration of IL1-10 was based on the amount produced by the low responder, 
individual “A”.  
 As shown in Fig. 3.5, the response of PBMC from the high responder (individual 
“B”) to the Strep SAgs was reduced down to the same level of the low responder 
(individual “A”) when IL-10 was added. Similarly, when pure T cells from either 
individual were stimulated with the same SAgs in the context of the B cell line 
homozygous for the DR14/DQ5, the response was comparably elevated in the absence of 
added IL-10 and similarly reduced in the presence of this regulatory cytokine (Fig. 3.5).  
Thus, in all combinations and regardless of the T cell donor, higher proliferative 
responses seen in the presence of the high-risk alleles were significantly diminished by 
the addition of IL-10 (Fig. 3.5).  
 
Discussion 
 The role of HLA allelic variation in modulating host responses to Strep SAgs and 
determining the outcomes of GAS sepsis has been first identified through 
epidemiological genetic association studies (275) and later validated biologically, in vitro 
and in vivo, using HLA transgenic mouse models (319). In this study we showed that 
HLA class II allelic polymorphism is the main determinant of the type and magnitude of 
the SAg response and, unlike common belief, we found little to no effect of individual 
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Figure 3.5 Active suppression of Strep SAgs-driven proliferative responses by IL-10.   
 
PBMC from individual “B” (high responder) (2X105/well) were stimulated as described 
in Figure 3.1 legend in the presence or absence of rIL-10 (3ng/ml). Pure T cells 
(1X105/well) from individual “A” or “B” were stimulated as described in Figure 3.2 
legend with or without rIL-10 (3ng/ml) added to cultures containing B cell lines 
(0.5X105/well) homozygous for either the STSS protective or high risk HLA Class II 
haplotypes.  PBMC from individual “A” or pure T cells co-cultures with B Cell line 
expressing the protective haplotype were used as a reference for low response. The data 
represent the mean and SD of three experiments. ( ** P< 0.01, * P< 0.05). 
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variations in TCR Vβ repertoire.  This finding is particularly interesting in the context of 
our earlier studies where we showed that although certain SAgs can interact directly with 
T cells in the absence of HLA class II presentation, CD28 crosslinking was needed to 
induce T cells to proliferate (179, 180, 209, 210).  These observations had lead us to 
believe that the requirement for HLA class II molecules in SAg responses is to bring T 
cells and APC in close proximity to allow productive interactions between CD28 and B7 
molecules as well as other receptors/ligands on both types of cells (179, 180, 209, 210). 
Several studies have shown that allelic variation in HLA class II molecules can affect the 
type of signaling transduced through the MHC and TCR receptors and affect the 
magnitude of SAg response (172, 185, 284-288, 324, 325). The data presented here show 
an even more important role for HLA class II molecules in SAg presentation — different 
allelic variants not only control the magnitude of SAg responses, but clearly they also 
affect the overall type of cytokines produced by the SAg stimulated T cells. 
 In our previous studies, the presentation of SAgs produced by the prevalent M1T1 
clonal strain of GAS by the STSS-protective HLA DR15/DQ6 haplotype or by individual 
alleles on this haplotype elicited significantly lower proliferative and inflammatory 
cytokine responses than the presentation by haplotypes/alleles associated with high-risk 
for STSS (DR14/DQ5 halptoype) or haplotypes that are neither associated with-risk nor 
protection from STSS (neutral haplotypes) (275, 319). This was thought to be due to 
weaker presentation of the SAgs by the protective haplotype.  However, the present study 
shows that presentation by the protective haplotype elicits high levels of IL-10, which 
possibly contributed to suppression of the inflammatory responses and reduction of T cell 
proliferation. Thus, the protective effect of the DR15/DQ6 haplotype may not be an 
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entirely passive action as we previously thought. Rather, an active IL-10-mediated 
suppression of the Strep SAgs-triggered inflammatory responses may play a part in this 
process.  We will further address this hypothesis by using anti-IL-10 Ab in vitro and in 
vivo in HLA-tg mice infected with prevalent M1T1 GAS strain.  
 Inflammatory cytokines play a central role in shaping the systemic manifestation 
of sepsis (326, 327). Our previous studies have demonstrated that patients with severe 
systemic manifestation of GAS sepsis have a propensity to produce high levels of 
inflammatory cytokine responses in either acute or convalescent phases of infection (275, 
276). In agreement with these reports, we observed that PBMC from individual “A” 
(expressing protective alleles) produced significantly lower pro-inflammatory cytokines 
than those from individual “B” (expressing high-risk alleles), when both were stimulated 
with the same SAgs.  In the cross-APC presentation studies, we found that the T cells 
from either individual can mount the same level of response if the SAgs were presented 
by the same APC from either individual or by B cell lines homozygous for the protective 
or high risk haplotype. This provides further support for the pivotal role of HLA class II 
allelic variation in governing SAgs responses and determining the severity of GAS 
sepsis.  
 It is well established that SAgs signal through MHC class II and TCR receptors 
and that these signals elicit a cascade of molecular events that result in the production of 
high levels of inflammatory cytokines including IL-2, TNF-α, TNF-β, IL-1, IL-6 and 
IFN-γ etc (276, 324, 328-331). Although several studies have investigated the nature of 
biochemical signals that ensue SAg interactions with MHC and TCR receptors, few have 
compared the effect of variability in either receptor (286, 332, 333).  In this study we 
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found insignificant contribution of TCR Vβ repertoire variability, but clearly HLA class 
II allelic variability has a dramatic influence on the magnitude and profile of responses to 
the same SAgs. We are unaware of any previous studies demonstrating that SAgs elicit 
differential higher levels of IL-10 than inflammatory cytokine (e.g. IFN-γ and TNF-β).  
From the data presented here, it appears that the ability of SAgs to elicit high levels of IL-
10 production is only seen when presentation is by the DR15/DQ6 haplotype. At present 
it is not clear how the interactions of the same SAgs with different alleles can result in 
such significant difference in the overall response, but we are actively investigating 
molecular and biochemical events responsible for these stark differences in SAg 
responses in the presence of distinct HLA alleles.   
 IL-10 is produced by monocytes and lymphocytes and has multiple effects in 
immunoregulation and inflammation (334, 335). It downregulates the expression of 
several inflammatory cytokines as well as inducible or constitutive expression of HLA 
class II and costimulatory molecules (335, 336).  The role of IL-10 in gram-negative and 
gram-positive sepsis has been thoroughly examined and it appears that this regulatory 
cytokine plays a more important role in the latter type of sepsis (337). Administration of 
IL-10 in several experimental and clinical studies showed benefit (338, 339), but the 
effect can vary considerably depending on the type of infection, the timing of IL-10 
administration and the relative levels of other inflammatory and anti-inflammatory 
mediators.  Whereas the initial production of inflammatory in infection is needed to help 
initiate protective immune responses, uncontrolled overproduction of cytokines like IFN-
γ and TNF-α can be detrimental, causing host-mediated pathogenesis vascular collapse 
and organ damage (340). On the other hand, overexpression of regulatory cytokines like 
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IL-10 may induce overt immunosuppression and thus increase mortality in bacterial 
sepsis (341, 342).  Therefore, any imbalance in the production of pro- or anti-
inflammatory cytokines can lead to pathological consequences (343, 344).  It would be of 
interest to measure IL-10 production in STSS patients carrying the STSS protective 
haplotype (DR15/DQ6) and compare it to those carrying the high-risk (DR14/DQ5 and 
DR7) alleles. More importantly it will be important to determine the overall balance 
between the inflammatory and anti-inflammatory cytokines in these patients. Although 
the vast majority of GAS sepsis patients with the DR15/DQ6 haplotype were protected 
against the severe form of the disease, few developed STSS (275). It will be of interest, 
therefore to determine if additional polymorphisms affecting IL-10 production in GAS 
sepsis can either confer increased protection or increase the risk for STSS. IL-10 
expression is regulated by other cytokines and can be affected by polymorphisms within 
its own gene (345). For example, allelic differences in position −1082 of the IL-10 
promoter have been shown to affect its production (346, 347). 
 Although our data support a direct and dominant effect of HLA molecules on 
SAg-induced responses, we should take into account effects of other polymorphic genes 
that may also be involved in regulating immune responses to the SAgs as well as to other 
bacterial components besides the SAgs that are likely to contribute to the pathogenesis of 
GAS sepsis as well. To this end we have recently adopted a forward genetics approach to 
investigate the role of multiple interactive genes and pathways in modulating host 
susceptibility and severity of infection with GAS as well as other pathogens (348) 
(Abdeltawab, N.F. et al. in press). Eventually, with these combined approaches we aim to 
translate our findings to the bedside, where it will become possible to predict the 
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outcomes and progression of specific infections based on combinations of genetic and 
soluble biomarkers to allow judicial intervention and customized patient management.  
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Chapter 4. Molecular Basis for HLA Class II Differential Presentation of 
Streptococcal Superantigens Involved in GAS Sepsis 
 
Introduction 
 The frequency of Group A streptococcal severe invasive manifestations, such as 
streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis (NF), have increased 
remarkably during the last two decades (221, 292). These manifestations are rapidly 
progressive infections with high mortality rates despite prompt antimicrobial therapy. 
Group A streptococci (GAS) cause more than 19.7 million cases of severe invasive 
infections each year worldwide, resulting in over 0.5 million yearly deaths (16). 
 Despite the presence of over 100 GAS serotypes, the resurgence of such severe 
systemic diseases (SSD) was associated with emergence of a globally disseminated 
subclone of M1T1 serotype. This clonal M1T1 strain is characterized by the acquisition 
prophages encoding distinctive virulence determinants such as the powerful DNase 
streptodornase 1 (Sda1) and the pyrogenic exotoxin A2 (SpeA2) (6). Moreover, recent 
studies revealed that M1 protein has superantigenic activities that may explain the 
overrepresentation of clonal M1T1 among isolates from SSD cases (33).  
 Although GAS possess a vast array of virulence factors that promote adhesion, 
invasion, survival and immune evasion, the systemic effects seen in patients with SSD 
are primarily triggered by inflammatory mediators induced in response to streptococcal 
pyrogenic exotoxins (Spes) (9, 318). Clonal M1T1 GAS express numerous Spes, 
including SpeA2, SpeF, SpeG, SpeJ, and streptococcal mitogenic exotoxin Z1 (SmeZ1) 
(100, 124, 143, 166).  Spes are superantigens (SAgs), which are by far the most potent 
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mediators of pro-inflammatory responses, and have therefore been implicated as pivotal 
players in the pathogenesis of STSS (214, 349). SAgs bind simultaneously to HLA class 
II molecules on antigen presenting cells (APC) and to distinct variable elements of TCR 
Vβ chain on T cells (98), bridging these critical immune receptors and triggering 
excessive activation of both cell types resulting in massive release of inflammatory 
cytokines.  Class II allelic variation has been shown to affect SAg responses (275, 287-
289, 319). Evidence for SAgs association with SSD came from investigations 
demonstrating TCR Vβ repertoire alterations in patients during acute infection (102), 
detection of SAgs in patients sera and tissue biopsy (101, 225) and animal models where 
SAgs triggered systemic manifestations similar to those observed in human infections 
(226, 227, 297, 319).  
 A direct correlation between pro-inflammatory cytokines level and invasive GAS 
infection severity was observed (101, 276). Patients’ propensity to produce higher or 
lower cytokine levels correlated with the development of severe or non-severe invasive 
infection, suggesting involvement of certain host immunogenetic factors in regulating 
SAgs responses (276). This hypothesis was also supported by our epidemiological study 
demonstrating that HLA class II polymorphism influenced the outcome of invasive GAS 
infections (275). HLA class II haplotypes associated with protection from SSD presented 
GAS SAgs in a way that resulted in significantly lower cytokines and proliferative 
responses. This was partly explained by our recent finding, which demonstrated that the 
protective haplotype preferentially induced higher levels of the anti-inflammatory 
cytokine IL-10 (chapter 3). However, SAgs interaction with the immune system is 
multifaceted.  We undertook this study to get a better understanding of how HLA class II 
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polymorphism affects SAgs responses and modulates GAS infection outcome. We 
explored the molecular basis of the differential interaction between HLA class II and 
Strep SAgs. 
 In this report, we generated a battery of bare lymphocyte syndrome (BLS) cell 
lines expressing single HLA class II alleles, and used it to delineate the contribution of 
individual class II alleles to Strep SAgs responses. Because of the quantitative nature of 
our studies, it is critical to ensure coordinated and balanced expression of both class II α 
and β subunits on BLS cells. Thus, we used a picornavirus-like ‘self-cleaving’ 2A 
peptide sequences to link class II α- and β-chains. The extremely rare 2A peptide 
conserved motif (2A: Asp-Val/Ile-Glu-X-Asn-Pro-Gly-[//]-2B: Pro, Fig. 1) impairs 
normal peptide bond formation between the Gly and Pro without affecting the translation 
of 2B (the protein on the C-terminal of the 2A peptide) (350). The 2A peptide, also 
known as cis-acting-hydrolase, mediates this cleavage through posttranslational 
processing that requires no viral or host proteinase (351). 
 
Materials and Methods 
 
GAS superantigens  
 Recombinant SpeA2, SpeG, SpeJ and SmeZ1 were expressed in E. coli and 
purified as His fusion proteins as described previously (323). The purified rSAgs were 
treated with polymyxin B agarose (Boehringer Mannhiem, Indianapolis, IN) to remove 
any contaminating endotoxin. 
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 Native secreted SAgs mixture was prepared from the supernatant of overnight 
cultures of GAS clinical isolates by ethanol precipitation followed by extensive dialyses, 
as detailed elsewhere (319).  
 
Generation of HLA class II multicistronic vectors 
 Genes encoding class II α and β chains were cloned from B lymphoblastoid cell 
lines (BLCL) homozygous for the appropriate haplotype. 2A peptide-linked constructs 
were generated by recombinant PCR as detailed elsewhere (352), using scheme shown in 
Figure 4.1 and the primers in Table 4.1. The constructs were cloned into the retroviral 
vector pHSPG. A trinucleotide GSG spacer was included between class II β chain and the 
2A peptide to maximize cleavage efficiency. Since the HLA DR α-chain is 
nonpolymorphic, the DRB1*1401-P2A-DRA1*0101 construct was generated with 
Bstz17I recognition sequence inserted between DRβ chain and the P2A peptide, so that it 
could be used together with EcoRI to digest DRB1*1401 out of the construct and replace 
it with β chain for the other DR alleles.  
 
Virus preparation, transduction and cell sorting 
 The retroviral vector pHSPG has GFP marker gene driven by phosphoglycerate 
kinase promoter (pGK). To prepare viral particles, pHSPG-class II allele plasmids were 
co-transfected into 293T cells with gag/pol and VSVg vectors by the calcium phosphate 
method. Viral supernatants were collected 48 and 72h post transfection and 0.48 µ 
filtered. Transductions by spin inoculation were performed by suspending BLS cells in 
fresh viral supernatants at 0.5X106/ml in the presence of 8µg/ml polybrene  
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Figure 4.1 Generation of 2A-linked HLA Class II constructs.  
 
A.   Schematic of the pHSPG retroviral vector containing the 2A linked Class II 
constructs, DRB1-P2A-DRA1 and DQB1-T2A-DQA1 produced by recombinant PCR. 
The constructs were cloned into a CMV-based retroviral vector that contains enhanced 
GFP driven by phosphoglycerate kinase (PG) promoter. The position and direction of 
primers used is shown.   B.   Amino acid sequence of 2A peptide of porcine teschovirus-1 
(P2A) and Thosea asigna (T2A). Conserved residues are boxed. The cleavage point 
between the 2A and 2B peptides, and thus the NH2- and COOH-terminal cisterons, is 
indicated by the arrow.   C.   The oligonucleotide sequences used for generation of 
DRB1*1401-P2A-DQA1*0101 ,as an example for primers used for PCR, are shown.  
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Table 4.1 Primers used to clone different class II alleles and to link the α- and β-chain by 
2A peptide. 
 
Gene Primer sequence 
DRA1*0101 
Fwd    5’-GCC ACG AAC TTC TCT CTG TTA AAG CAA GCA GGA GAC GTG 
           GAA GAA AAC CCC GGT CCC ATG GCC ATA AGT GGA GTC CCT 
           GTG C-3’ 
Rev    5’-G CTC GAG TTA CAG AGG CCC CCT GCG TTC TG-3’ 
DRB1*1401 
Fwd    5’-G GAA TTC ATG GTG TGT CTG AGG CTC CCT GG-3’ 
Rev    5’-TGC TTG CTT TAA CAG AGA GAA GTT CGT GGC TCC GGA ACC 
          GTA TAC GCT CAG GAA TCC TCT TGG CTG AAG TC-3’ 
DRB1*1501 Fwd    5’-G GAA TTC ATG GTG TGT CTG AAG CTC CCT GG-3’ Rev    5’-G GTA TAC GCT CAG GAA TCC TGT TGG CTG AAG-3’ 
DRB1*0402 Fwd    5’ G GAA TTC ATG GTG TGT CTG AAG TTC CCT GGA G-3’  Rev    5’-G GTA TAC GCT CAG GAA TCC TGT TGG CTG AAG-3’ 
DQB1*0602 
Fwd    5’-G GAA TTC ATG TCT TGG AAA AAG GCT TTG CGG-3’ 
Rev    5’-CC GCA TGT TAG CAG ACT TCC TCT GCC CTC ACC GCT ACC  
          GTG CAG GAG CCC TTT CTG ACT CCT G-3’ 
DQB1*0503 
Fwd    5’-G GAA TTC ATG TCT TGG AAG AAG TCT TTG CGG ATC C-3’ 
Rev    5’-CC GCA TGT TAG CAG ACT TCC TCT GCC CTC ACC GCT ACC 
           GTG CAG AAG CCC TGC TGG TGG-3’ 
DQA1*0104 
Fwd    5’-GAG GGC AGA GGA AGT CTG CTA ACA TGC GGT GAC GTC 
          GAG GAG AAT CCT GGC CCA ATG ATC CTA AAC AAA GCT CTG 
          CTG CTG G-3’ 
Rev    5’-G CTC GAG TCA CAA TGG CCC TTG GTG TCT GG-3’ 
DQB1*0202 
Fwd    5’-G GAA TTC ATG TCT TGG AAA AAG GCT TTG CGG-3’ 
Rev    5’-CC GCA TGT TAG CAG ACT TCC TCT GCC CTC ACC GCT ACC 
          GTG CAG GAG CCC TTT CTG ACT CCTG-3’ 
DQA1*0201 
Fwd    5’-GAG GGC AGA GGA AGT CTG CTA ACA TGC GGT GAC GTC GAG 
          GAG AAT CCT GGC CCA ATG ATC CTA AAC AAA GCT CTG ATG  
          CTG GG-3 
Rev    5’-G CTC GAG TCA CAA GGG CCC TTG GTG TCT GG-3 
 
(1) Italicized, underlined sequence indicates the GSG spacer. 
(2) Bold sequences are the restriction enzymes recognition sequences. 
(3) Bold underlined sequence indicates the start of the gene on 2A peptide C-terminus. 
(4) The primers for DRB1*0701 are the same as DRB1*1501 primers. 
(5) The primers for DQA1*0102 are the same as DQA1*0104 primers. 
(6) The primers for DQB1*0202/DQA1*0102 are the same as DQB1*0301/DQA1*0501 
primers. 
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followed by centrifugation at 2000Xg for 3 h. Transduction was repeated on two 
consecutive days to increase infection efficiency. Following one week of culture, stably 
transduced cells were sorted for GFP expression. FACS analysis showed that GFP and 
class II expression is 95% stable for at least two months following sorting (not shown). 
 
Cells 
 We used Ficoll-Hypaque density-gradient centrifugation to isolate the peripheral 
blood mononuclear cells (PBMC) from healthy donors blood. APC-depleted T cells were 
prepared by subjecting the recovered PBMC to one cycle of erythrocyte rosetting. These 
enriched T cells were further purified by using the human pan T cell isolation kit and 
autoMACS according to the manufacturer’s instructions (Miltenyi Biotec, Auburn, CA). 
To remove any residual APC, we did overnight adherence to polystyrene plate at 37°C in 
RPMI 1640 supplemented with 10% (v/v) heat-inactivated FBS, 4 mM L-glutamine, 25 
mM Hepes, and 50 U/ml penicillin/ 50µg/ml streptomycin (RPMI complete medium). 
The purity of T-cells was confirmed phenotypically by flow cytometry and functionally 
by the lack of response to PHA and/or to rSAgs. Experiments in which purified T cells 
(cultured alone without any APC) showed a response to PHA or SAgs were discarded.  
 A panel of EBV transformed B lymphoblastoid cell lines (BLCL) homozygous 
for HLA class II haplotypes prevalent in areas with high STSS incidence (275) (Table 
4.2) were tested together with untransduced BLS cells (HLA class II negative cells) or 
BLS cells transduced with single HLA DR or DQ alleles (Table 4.3). These cells were 
used as APC for presenting Strep SAgs. To block cellular division, the cells were treated 
with mitomycin C (Sigma) 50 µg/5X107 cell/ml for 20 min at 37°C,  
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Table 4.2 Human B lymphoblastoid cell lines expressing prevalent HLA class II 
haplotypes. 
 
Name DRB1* DQB1* DQA1* DQ MFI DR MFI 
MGAR(b) 0102 0501 01012 523 ± 15 2471 ± 167 
HHKB 0301 0201 0501 710 ± 49 2376 ± 154 
JVM 0401 0301 0301 560 ± 49 2243 ± 147 
VAVY 0401 0302 03 590 ± 39 2714 ± 62 
MADURA 07 03032 0201 678 ± 38 2111 ± 126 
PMG0705 0701 0202 0201 754 ± 50 2221 ± 149 
WBD001816 0801 0402 0401 614 ± 40 2574 ± 180 
1349-8636 1102 0301 0501 650 ± 34 2407 ± 126 
BM14 1301 0603 0103 605 ± 39 2459 ± 160 
MOU(c) 1401 0503 0104 505 ± 29 2381 ± 157 
31227ABO(d) 1501 0602 0102 583 ± 21 2308 ± 83 
 
a The cells lines were analyzed by flow cytometry for DR and DQ expression level that is 
assessed by mean fluorescence intensity. Analysis was done with each experiment. The 
data are presented as mean ± SD 
 
Cells express alleles associated with  
 (b) protection from STSS and NF. 
 (c) predisposition to STSS and NF.  
 (d) predisposition to STSS. 
 
 
 
 
 
 
 103 
Table 4.3 BLS cells transduced with different HLA class II DR or DQ alleles a. 
 
Allele designation Serological  designation 
DQ MFI DR MFI 
DRB1*0401/DRA1*0101 DR4 − 1655 ± 142 
DRB1*0701/DRA1*0101 DR7 − 1357 ± 98 
DRB1*1401/DRA1*0101 DR14 − 1534 ± 112 
DRB1*1501/DRA1*0101 DR15 − 1852 ± 168 
DQB1*0202/DQA1*0201 DQ2 765 ± 57 − 
DQB1*0301/DQA1*0501 DQ7 628 ± 68 − 
DQB1*0503/DQA1*0104 DQ5 702 ± 57 − 
DQB1*0602/DQA1*0102 DQ6 844 ± 77 − 
 
 a BLS cell lines were analyzed for the HLA DR or DQ expression level as determined by 
mean fluorescence intensity (MFI). Analysis was done with each experiment and the data 
are presented as mean ± SD. 
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extensively washed with HBSS then suspended in RPMI complete medium at a final 
concentration of 1x106/ml. The mitomycin C treatment efficacy was confirmed by 
minimal [3H]thymidine uptake compared to untreated cells. 
 
Assessment of HLA DQ and DR expression level  
 Using flow cytometry, we analyzed the expression level of HLA DR and DQ 
molecules on the eleven BLCL homozygous for prevalent Class II haplotypes as well as 
on the generated cell lines expressing single HLA DR or DQ alleles. This is essential to 
normalize the data for any difference in class II expression level. When variable 
expression level was observed, the data were mulitplied by a factor = highest MFI/MFI 
for each cell line. We used monoclonal antibody (mAb) labeled with phycoerythrin (PE) 
(Catalog. No. 347367, BD) specific to HLA-DR and primary unlabeled mAb specific to 
HLA-DQ (MCA379G, serotec) followed by PE-labeled secondary Ab (STAR12A, 
serotec). Analysis was conducted on a FACSCalibur (Becton Dickinson). 
 
T cell proliferation assays 
 Pure T cells (1X105 /well; 96-well plate), from different healthy donors, were co-
cultured with mitomycin C-treated B cell lines (0.5X105 /well) expressing the prevalent 
HLA class II haplotypes (Table 2) or single class II alleles (Table 3) in RPMI complete 
medium. Cells were stimulated with an optimal dilution of partially purified native 
secreted M1T1 SAgs mixture from clonal M1T1 clinical isolate, individual rSAgs (1 
ng/ml or 10 ng/ml) or PHA (1µg/ml). After 72h incubation, the cultures were pulsed with 
1 µCi/well [3H]thymidine, harvested and counted as previously described (319, 323). All 
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samples measurements were performed in triplicates or quadruplicates, and the data were 
presented as mean cpm [3H]thymidine uptake ± SD.  
 
Cytokine assays 
 Lymphocytes were cultured as described above. Culture media were collected 
from the individual wells after 24, 48, and 72h of stimulation, cleared of cells by 
centrifugation, and stored at –80 °C for subsequent analysis. The cytokines IL-2, IL-4, 
IL-6, IL-10, IFN-γ, TNF-α were simultaneously quantified by using the human cytokine 
LINCOplex kit (Linco Research Inc., St. Charles, MO). TNF-β was analyzed by ELISA 
kit from R&D Systems (Minneapolis, MN). The assays were performed according to the 
manufacturer’s instructions, and the concentrations were calculated from standard curves 
run in parallel with the test samples. Data are presented as mean concentration ± SD.  
 
SAgs labeling and binding assay 
 rSpeG, rSpeJ and rSmeZ1 were labeled with Alexa Fluor 647 according to 
manufacturer’s instructions (Molecular Probes, Eugene, OR). Binding assays were 
performed by incubating106 cells/tube with serial two-fold dilutions (1nM-1µM) of 
labeled rSAg for 4 h at 4 °C or 37 °C. After incubation, cells were washed and examined 
for bound SAg by flow cytometry using FACSCalibur. A total of 30000 cells within the 
healthy lymphocyte gate were analyzed. SAg binding was assessed as mean fluorescence 
intensity (MFI) of cells.  
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Calcium mobilization studies 
 Changes in T cells intracellular calcium [Ca2+]i were monitored by flow cytometry 
using cells loaded with the Ca2+ -sensitive fluorescent dye, indo-1. Indo-1 loading was 
done by incubating Jurkat or purified T cells (3X106 cells/ml) with 3 µM indo-1/AM 
(Molecular Probes) in RPMI complete medium with 5% FBS at 37 °C for 45 min. The 
indo-1 loaded cells were washed with HBSS, resuspended at 106 cells/ml in serum free-
RPMI complete medium and warmed to 37 °C prior to stimulation. BLS cells expressing 
different DR or DQ alleles (1X106/ml RPMI complete medium) were incubated overnight 
with 0.5µg/ml rSmeZ1 at 37 °C. Baseline fluorescence ratios were collected for 45 sec, 
followed by stimulation with SmeZ1-loaded APC. Samples were analyzed using LSR II 
flow cytometer (BD) with excitation at 350 nm and relative ratios of fluorescence emitted 
at 450 and 530 nm were monitored over time. The acquired data were analyzed with 
FlowJo kinetics platform (Tree Star, Inc. Ashland, OR). 
 
Statistical analysis 
 Analysis of variance (ANOVA) or a two-tailed Student’s t test was used to 
determine the significance of the data. A p value of <0.05 was considered significant.  
 
Results 
 
Relative effects of prevalent HLA class II haplotypes on M1T1 SAgs responses 
 To determine how allelic differences between HLA class II molecules affect the 
immune response to M1T1 GAS SAgs, we analyzed the presentation of native SAgs 
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mixtures by a panel of eleven BLCL homozygous for HLA class II haplotypes listed in 
Table 2 that are prevalent in Ontario Canada where increasing incidence of Strep SSD 
cases has been reported (20, 353). The SAg mixture was presented by this panel to pure 
APC-depleted T cells prepared from healthy donors. The highest response was in the 
presence of cells expressing the two haplotypes associated with high-risk for STSS HLA 
DRB1*1401/DQB1*0503 and HLA DRB1*0701/DQB1*0201 while the lowest response 
was in the presence of cells expressing the protective HLA DRB1*1501/DQB1*0602 
haplotype (Fig 4.2A). Significantly higher proliferative responses were detected in the 
presence of cells expressing not only high-risk but also neutral haplotypes HLA 
DRB1*0401/DQB1*0301 and HLA DRB1*0401/DQB1*0302  (neither associated with 
high-risk nor protection from STSS) as compared to the cell expressing the protective 
haplotype (p<0.001-0.05, Fig 4.2A). The observed variations in SAg stimulation could 
not be attributed to the level of surface expression of class II molecules on the cells, since 
flow cytometric analysis of these APC showed equivalent levels of HLA DR or DQ 
alleles (Table 4.2). Interestingly, the presentation of the M1T1 SAgs by the NF protective 
haplotype HLA DRB1*0301/DQB1*0201 was higher than by the NF risk haplotype 
HLA DRB1*1102/DQB1*0301, supporting previous reports that these two severe 
manifestations of invasive GAS infections differ in their pathogenic mechanisms. The 
observed different responses were SAg-specific since all cell lines promoted comparable 
PHA responses (Fig. 4.2B).  
 In the course of in vivo infection, one or more of M1T1 SAgs may be produced. 
Therefore, we investigated the presentation pattern of individual M1T1 rSAgs by the 
same panel of BLCL homozygous for prevalent class II haplotypes (Table 2),  
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Figure 4.2 Differential presentation of clonal M1T1 SAgs by prevalent HLA class II 
haplotypes. 
 
Pure APC-depleted T cells (1X105/well) from healthy donors were co-cultured with 
mitomycin C-treated BLCL (0.5X105/well) homozygous for the indicated class II 
DRB1*/DQB1* haplotypes. The cells were stimulated with:   A.   An optimal dilution of 
native secreted SAgs mixture (1:500),   B.   PHA (1ug/ml),   C.   rSpeA2,   D.   rSpeG,   
E.   rSpeJ   or  F.  rSmeZ1 (10 ng/ml, for all tested rSAg). Proliferative responses were 
determined by [3H]thymidine uptake. The data represent mean cpm ± SE of three 
independent experiments. Significant differences were tested by ANOVA (*** P< 0.001, 
** P<0.01, * P<0.05). 
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Figure 4.2 (continued). 
 110 
using pure T cells from several healthy volunteers. In agreement with the results for 
native SAgs mixture, proliferative responses to all tested individually rSAgs were 
significantly higher when presented by APC homozygous for the STSS high-risk 
haplotypes DR14/DQ5 or DR7/DQ2 than by the APC homozygous for the STSS-
protective haplotype DR15/DQ6 (p<0.001-0.05; Fig .4.2C-F). Thus, supporting our 
findings with the mixture of native purified SAgs and confirming that the observed 
differential SAg response was not due to any other component that might have 
contaminated the native partially purified SAg mixture. Reproducibly, presentation of all 
M1T1 rSAgs by DR3/DQ2 NF-protective haplotype resulted in higher proliferative 
responses than by the NF high-risk haplotype DR11/DQ8 confirming that NF, unlike 
STSS, is not SAg-mediated disease. 
 
Preferential presentation of individual M1T1 rSAgs by HLA DR or DQ alleles  
 HLA class II molecules are inherited together and expressed as either 
homozygous or heterozygous sets of two DP, DQ and DR molecules. Therefore, it is 
impossible to test the effect of single HLA class II alleles polymorphisms on the 
inflammatory response to a particular SAg. To achieve this goal we analyzed the 
presentation of rSpeA2, rSpeG, rSpeJ and rSmeZ1 by BLS cells transduced with distinct 
HLA DR or DQ alleles (Table 3), using APC-depleted T cells from healthy individuals. 
For the HLA class II alleles and rSAgs studied, the HLA DR14 or DQ5 consistently 
promoted significantly higher SAg-induced proliferative responses than did the HLA 
DR15 or DQ6, respectively (p<0.01-0.05, Fig. 4.3). Additionally, for the DR alleles, 
HLA DR14 was always associated with the highest responses, followed by HLA DR7;  
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Figure 4.3 Proliferative response to individual M1T1 GAS rSAgs presented by single 
class II alleles.  
 
Pure T cells from healthy volunteers were stimulated with the individual rSAg: SpeA2, 
SpeG, SpeJ and SmeZ1 (10 ng/ml) or PHA (1 ug/ml) presented by untransduced BLS 
cells or transduced with the indicated HLA DR or DQ alleles. The experiments were 
repeated at least 3 times and the data presented are mean proliferative responses ± SE, 
after normalization for any variability in HLA expression level. Significance was 
evaluated by ANOVA.  
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whereas the HLA DR15 was consistently associated with lowest responses compared to 
high risk or even neutral alleles. These data are in perfect agreement with our 
epidemiologic data, where we found that both HLA DR14 and DR7 are associated with 
high risk for STSS, whereas HLA DR15 conferred strong protection from it (275). 
Similar observations held true for the HLA DQ alleles. Presentation of all tested rSAgs 
by the HLA DQ6 allele consistently elicited the lowest response, while presentation by 
the HLA DQ5, which is part of the high-risk haplotype, consistently elicited the highest 
response with one exception. The presentation of rSpeG by HLA DQ7 resulted in higher 
responses than by HLA DQ5. This latter finding support previous reports showing that 
certain SAgs may interact with different HLA class II alleles in a unique fashion (288). 
Also, in agreement of our earlier studies, the overall presentation of SpeA2 by HLA DQ 
alleles was relatively superior to that by HLA DR alleles (288). As expected, the class II-
negative, BLS cells failed to promote SAg-induced proliferation. These experiments 
demonstrate that differences in the presentation of Strep SAgs are not related to 
differences in APC (BLCL or transduced BLS cells), but rather depend on the APC-
expressed class II allele and on the interacting SAg. Furthermore, the results suggest that 
single alleles, which are part of haplotypes associated with protection or susceptibility to 
STSS, can present SAgs in a manner analogous to these original haplotypes and hence 
individuals with such alleles may be protected or predisposed to SSD apart from being 
homozygous or heterozygous.    
 Cytokine responses were also assessed in cultures containing rSmeZ1 presented 
by HLA DR14 versus DR15 and HLA DQ5 versus DQ6. In agreement with the 
proliferative results, presentation of rSmeZ1 by the high-risk HLA DR14 or DQ5 alleles 
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induced significantly higher levels of the pro-inflammatory cytokines IL-2, IL-6, TNF-α, 
TNF-β, and IFN-γ than presentation by the protective HLA DR15 or DQ6 alleles, 
respectively (p<0.001-0.05; Fig 4.4). However, significantly higher levels of the anti-
inflammatory cytokine IL-10 were induced by HLA DR 15 or DQ6 alleles than by HLA 
DR14 or DQ5 alleles (p>0.01-0.05, Fig 4.4). These results are in agreement with our 
previous finding of higher IL-10 production by PBMC from individuals carrying 
protective alleles or by BLCL homozygous for the protective haplotype DR15/DQ6 and 
further support our hypothesis that protective haplotype/alleles may mediate their effects 
partly through active suppression of SAg-induced immune response by promoting high 
levels of the immunosuppressive cytokine IL-10.  
 
Binding affinity of rSpeG, rSpeJ and rSmeZ1 to different HLA class II alleles  
 Although, co-stimulatory molecules on both T cells and APC are involved in T 
cell activation by SAgs, binding to HLA class II plays a major role in this process. 
Therefore, we investigated whether differences in the presentation of rSAgs were due to 
variations in class II alleles binding affinity. Our binding studies demonstrated a 
correlation between the observed preferential SAg presentation by HLA DR or DQ 
alleles and binding affinity, where cells expressing high-risk alleles DR14 or DQ5 
showed significantly higher SAg binding than cells expressing protective alleles DR15 or 
DQ6 for all of the tested SAgs (Fig. 4.5A&B), except for SmeZ1 (Fig. 4.5C). Binding of 
rSmeZ1 to DQ alleles inversely correlated with the proliferative responses such that HLA 
DQ6-expressing cells showed significantly higher rSmeZ1 binding than HLA DQ5-
expressing cells. This suggests that although SmeZ1 binds more avidly to DQ6 
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Figure 4.4 Cytokine responses to SmeZ1 presented by the indicated HLA DR or DQ 
alleles. 
 
The cultures and stimulation were set up as indicated in Figure 4.3 legend. At the 
specified times points the culture supernatants were collected from cultures containing:  
A.   HLA DQ5 or DQ6 and   B.   HLA DR14 or DR15. Supernatants were analyzed for 
the production of IL-2, IL-6, IL-10, TNF-α, TNF-β and IFN-γ. The experiments were 
repeated at least three times, and the presented data are means ± SE. Statistical 
significance was assessed by ANOVA (** P<0.01, * p<0.05). 
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Figure 4.4 (continued). 
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Figure 4.5 Differential binding of SpeG, SpeJ or SmeZ1 by distinct HLA class II alleles. 
 
BLS cells (106/tube) expressing the indicated alleles were incubated with serial dilutions 
of Alexa fluor 647-labeled:  A.   SpeG,   B.   SpeJ or    C.   SmeZ1. After washing, cells 
with bound SAg were analyzed by flow cytometry and expressed as mean fluorescence 
intensity (MFI). Shown is a representative of three independent experiments. Statistical 
significance was assessed by ANOVA (*** P<0.001, ** P<0.01, * p<0.05). 
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Figure 4.5 (continued).
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but it binds in a manner that does not allow T cell stimulation. Moreover, cells expressing 
neutral alleles demonstrated intermediate SAg binding with the exception of rSpeG, 
which in agreement with the observed proliferation results that exhibited higher binding 
to DQ7- than to DQ5-expressing cells. These observations support the view that each 
SAg interacts distinctively with HLA DR or DQ alleles. Additionally, differential binding 
affinity of SAgs to distinct class II alleles cannot always be the underlying mechanism for 
the observed preferential presentation. 
 
Changes in [Ca2+]i levels in response to stimulation with rSmeZ1 
 To this end, we have examined SAg-driven responses at the initial stages (binding 
to class II molecules on APC) as well as the final steps (T cell proliferation). However, 
SmeZ1 contradicting behavior in the context of HLA DQ alleles (binding inversely 
correlated with proliferative responses) prompted us to investigate SmeZ1-induced 
changes in intracellular calcium level [Ca2+]i, an important signaling intermediate in the 
SAg-driven T cell activation that may provide novel insight into preferential SAg 
presentation. As expected, SmeZ1 presentation by DR15 allele had the lowest effect on 
the magnitude of the Ca2+ response (Fig. 4.6). Interestingly, SmeZ1 presentation by HLA 
DQ6 induced the weakest Ca2+ response. Therefore, changes in kinetics of T cells Ca2+ 
mobilization may be influenced not only by differences in SAg-class II binding affinity 
but also by the stability of the trimolecular complex of TCR-SAg- HLA class II. Possibly, 
the presence of a high affinity TCR could stabilize an apparently weak interaction 
between SmeZ1 and HLA DQ5 molecules, and the formation of such ternary complex 
would lead to more efficient T cell activation.  
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Figure 4.6 Calcium mobilization studies.  
 
BLS cells (106/ml) expressing the indicated HLA DR or DQ alleles were loaded with 
SmeZ1 (0.5 ug/ml) and incubated overnight at 37 ˚C. Indo I-loaded T cells (106/tube) 
were used to establish a baseline before stimulation with SmeZ1-loaded APC. The data 
are representative of three independent experiments. 
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Discussion 
 HLA class II molecules function as receptors for SAgs; therefore interaction with 
these molecules is a primary step in SAg-mediated responses (100, 354). Several studies 
have shown that allelic variations in HLA class II can influence SAgs presentation (288, 
289). Accordingly, HLA class II polymorphisms can govern the extent of SAg-driven 
inflammatory immune response and subsequent immunopathology and ultimately 
influence the outcome of SAg-induced illness (275, 276). A deeper understanding of this 
process can help us figure out the reasons for diverse manifestations of SAg-mediated 
diseases in different individuals and develop effective treatment policies. 
 Our previous studies indicated a direct and dominant influence of HLA class II 
allelic variation on the magnitude of cytokine and proliferative responses induced by 
Strep SAgs (275, 276, 288, 319) (Chapter 4). However, these studies were narrow in 
terms of the limited class II haplotypes/alleles investigated. Thus, in the present study we 
utilized a panel of eleven BLCL homozygous for class II haplotypes prevalent in places 
with high STSS incidence. The application of this panel allowed us to simultaneously 
study the relative abilities of several distinct HLA class II haplotypes to present Strep 
SAgs. The data presented here indicate that individual or mixed M1T1 SAgs are 
preferentially presented by class II haplotypes associated with STSS high-risk 
DR14/DQ5 or DR7/DQ2 or even by neutral haplotypes DR4/DQ8. 
 Since these BLCL express all class II isotypes DR, DQ and DP, they are 
unsuitable for in depth studies to further dissect SAgs-driven responses at the level of 
single class II allele, to delineate the contribution of polymorphism of individual alleles 
to variable SAgs responses and to perform biochemical studies with more defined system 
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with less variables. To attain this objective we generated a panel of eight BLS lines 
expressing distinct HLA DR (four) or DQ (four) alleles (Table 3). By using this panel of 
APC, we found that individual alleles, which are part of STSS-protective or high risk 
haplotypes, presented individual M1T1 SAgs in a manner equivalent to that of the 
original haplotypes.  
 Our previous studies showed that HLA class II association with NF are distinct 
from that with STSS (275). This observation suggested that STSS and NF are different 
manifestations of Strep SSD. In agreement with this view, NF-high risk haplotype/alleles 
reproducibly promoted lower SAg responses than NF-protective haplotype/alleles. This 
finding suggests that NF might be a SAg-independent manifesataion and thus may 
require distinct therapeutic approaches.  
 SAgs have highly variable primary amino acid sequence; however, solved crystal 
structures for many staphylococcal and Strep SAgs show that they share a conserved 
three-dimensional structure with two domains, a C-terminal β-grasp motif and an N-
terminal β-barrel domain (103, 354). Such conserved folding may explain the 
consistently high or low responses to individual M1T1 SAgs in the context of the high-
risk or protective HLA class II alleles, respectively. However, solved or computer-
generated SAg-HLA class II complex structures have indicated that SAgs bind HLA class 
II in distinct ways that may affect SAg responses. Some SAgs bind the α-chain through a 
low affinity N-terminal binding site, others bind the β-chain by high affinity C-terminal 
zinc ion coordinated binding site and a third group bind both chain and thus crosslink 
class II molecules on APC and induce more potent responses (103, 150). Despite these 
variable ways of interaction with HLA class II molecules that affect SAg potency, all of 
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the studied M1T1 SAgs bind to the β chain with the exception of SpeA2, which binds 
exclusively to the α-chain (106, 150). Even, this difference in class II binding did not 
affect the consistent high response induced by high-risk alleles.  
 The most logical explanation for the superior SAg responses in the presence of 
high-risk alleles is the enhanced binding of SAgs to such alleles and therefore an 
increased ligand concentration available for presentation to T cells. The binding results 
for rSpeG, rSpeJ and rSmeZ1 supported this hypothesis. However, in case of rSmeZ1, 
there was a lack of correlation between the ability of HLA DQ5 to bind SmeZ1 and the 
ability of SmeZ1-HLA DQ5 complex to stimulate T cells. This result may suggest that T 
cell stimulation under these conditions depends primarily on the formation of a ternary 
complex of TCR-SAg-HLA class II, with the stability of HLA DQ5-SmeZ1-TCR 
complex being greater than that of HLA DQ6-Smez1-TCR complex. A TCR with 
stronger affinity for SAg-HLA may be able to stabilize ineffective interaction between 
SAg and HLA molecule and thus T cells can react to a particular SAg-HLA combination, 
even though the last cannot easily be revealed by simple binding studies. 
 As we and others found, binding affinity of a specific SAg to a given HLA class 
II allele did not always correlate with the ability of that class II allele to present the SAg 
(284, 288, 289). In an attempt to explain the observed disagreement between SmeZ1 
binding to and presentation by HLA DQ alleles, we examined T cells Ca2+ influx as one 
of the early signals initiated following engagement of the T cell receptor. Ca2+ serves as a 
general second messenger in many cells including immune system cells such as T and B 
cells, monocytes and macrophages. In these cells, Ca2+ plays a crucial role in activation, 
effector functions, gene expression or differentiation (355, 356). Qualities of the 
 123 
generated Ca2+ signal such as strength and duration may shape T cell responses to 
activation (357, 358). Interestingly, our results show that SmeZ1 presentation by DQ5 
(associated with STSS high-risk, poor SmeZ1 binding but more efficient presentation) 
induced about three fold more Ca2+ influx than presentation by DQ6 (associated with 
STSS protection, stronger SmeZ1 binding, but inefficient presentation). These results 
suggest that the molecular requirements and biochemical pathways leading to T cell 
activation may vary depending the nature of the SAg and the type of HLA class II 
molecule and T cells.  
 The results obtained from this study may promote more thorough understanding 
of the effects of HLA class II allelism on the SAg-driven responses and better predicting 
the outcome of SAg-associated disease in a given patient. Possibly, treatment strategies 
can be customized depending on HLA class II haplotype. Similar to other clinical 
conditions, specific interventions can produce more effective results than general 
therapeutic approaches.  
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Chapter 5. Streptococcal Mitogenic Exotoxin Z, SmeZ, Is the M1T1 Streptococcal 
Superantigen Most Susceptible to Degradation by the Streptococcal Cysteine 
Protease, SpeB∗ 
 
Introduction 
 Group A streptococci (GAS) are Gram positive bacteria responsible for human 
diseases with varying severity (9, 100). The outcome of these infections is affected by a 
complex interplay between several surface-associated and secreted bacterial virulence 
factors, and host immune defenses (275, 318).  Streptococcal pyrogenic exotoxins (Spes) 
are well known for their ‘super’-antigenic activity and have been shown to be pivotal in 
the pathogenesis of streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis 
(NF, the flesh eating disease) (101, 102). SAgs are unusual bacterial toxins that play an 
important role in the pathogenesis of several diseases including food poisoning, 
autoimmunity, and toxic shock syndrome (TSS) (100, 349).  A major feature of SAgs is 
that they bind directly to human leukocyte antigen (HLA)-class II molecules and to the T-
lymphocyte receptor (TCR) causing the activation of larger numbers of T-lymphocytes, 
almost 1000-fold more than those activated by regular antigens (100). This 
unconventional mode of activation causes excessive production of pro-inflammatory 
cytokines that can lead to disseminated intravascular coagulation, shock, and multiple 
organ system failure (100, 214, 349). While all GAS isolates examined thus far secrete 
                                                
∗ Adapted by permission of American Society for Biochemistry and Molecular Biology 
from Nooh MM, Aziz RK, Kotb M, Eroshkin A, Chaung WJ, Proft T, and Kansal R. 
(2006). Streptococcal Mitogenic Exotoxin, SmeZ, is the Most Susceptible M1T1 
Streptococcal Superantigen to Degradation by the Streptococcal Cysteine Protease, SpeB. 
J Biol Chem 281, 35281-35288.  
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one or more SAg, different strains can produce very different spectra of the >24 
streptococcal SAgs.  One of the most clinically relevant strains, the M1T1 strain, whose 
appearance coincided with the resurgence of severe streptococcal infections around the 
world in the 1980s, has the following SAg-encoding genes: speA2, speF, speG, speJ, and 
SmeZ1 (274).  SpeA2, a horizontally acquired SAg, that has been recently introduced into 
this strain, has been shown to be a major player in the pathogenesis of STSS. Another 
streptococcal superantigen, SmeZ1, was shown to play an important role in streptococcal 
pathogenesis (226, 359). 
 M1T1 isolates obtained from patients with invasive GAS disease of varying 
severity carry identical spe genotypes but may differ in their SAg expression phenotype 
(274). Whereas the disease severity could not be correlated to a particular M1T1 SAg, 
there was a highly significant inverse correlation between severity of the invasive 
infection and the expression of the streptococcal cysteine protease, which is an important 
GAS virulence factor. SpeB modifies host proteins like matrix proteins thereby 
facilitating bacterial invasion, and it can post-translationally cleave and activate 
precursors for several cytokines and important components of the coagulation pathway 
(360, 361). However, SpeB can also modify and/or inactivate several important GAS 
virulence proteins, including the anti-phagocytic M protein, the anti-chemotactic C5a 
peptidase as well as many secreted virulence proteins (360-363). The activity of SpeB 
seems to be specific as certain bacterial proteins resist its proteolytic activity (363).        
 We demonstrated that the expression of SpeB significantly reduces the immune- 
stimulating activity of secreted native M1T1 SAgs (363). However, we never saw 
complete loss of the superantigenic activity, even in the presence of high concentrations 
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of secreted or added rSpeB.  The partial loss of proliferative activity and the fact that the 
SAgs responsible for the expansion of SmeZ1 specific T cells with TCRVβ4, TCRVβ7, 
and TCRVβ8 was blocked in the presence of SpeB while the expansion of T cells 
expressing TCRVβ2 was unaffected, suggested that SpeB selectively degrade some but 
not all SAgs produced by M1T1 GAS. 
 The present study was designed to examine the effect of SpeB on the 
streptococcal SAgs individually or in combination, as they exist in their native form 
during infection. We demonstrate a significantly higher susceptibility of SmeZ1 to SpeB-
proteolysis that was correlated to the presence of an exposed loop on the surface of this 
protein, as revealed by bioinformatics and structural analysis. 
 
Materials and Methods 
 
Generation of recombinant GAS superantigens 
 rSpeA2, rSmeZ1, rSpeG and rSpeJ were expressed as histidine-tagged fusion 
proteins containing a factor Xa protease site according to the manufacturers’ 
recommendations (Promega, Madison, WI. and Qiagen Inc.) Primer pairs used for the 
cloning were as follows: SpeA2 (672bp-5’gaggcctcaacaagaccccgatc 3’ forward and 
5’gaagcttacttggttgttaggtagact3’ reverse), SmeZ1 (645bp-5’gaggcctttagaagtagataataattc3’ 
forward and 5’caaagcttaggagtcaatttc3’ reverse), SpeG (630bp-5’ 
taggcctgatgaaaatttaaaag3’ forward and 5’ caagcttctagtgcgtttttaa3’ reverse) and SpeJ 
(630bp-5’ gaggcctatgaaaagaataataaaaacaa 3’ forward and 5’ gaagcttatttagtccaaaggtaa 3’ 
reverse).  The forward and reverse primers contained Stu1and HindIII restriction sites, 
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respectively.  The amplified products were purified, subcloned in pGEM-TEasy vector 
(Promega Corporation, Madison, WI, USA), and sequenced (UTHSC Molecular 
Resource Center).  The correct cloned inserts were digested with Stu1 and HindIII, 
subcloned into the pQE30Xa vector (Qiagen Inc.), propagated in DH5α Escherichia coli 
cells and subsequently used to transform M15 Escherichia coli cells. rSAg protein 
expression was induced with 1 mM IPTG (isopropyl-b-D-thiogalactopyranoside) for 3 h. 
Proteins in the bactrerial cell lysate were resolved by SDS polyacrylamide gel 
electrophoresis (PAGE), and the specific expression of each rSAg protein was 
determined by immunoblotting with RGS-His HRP Conjugate Kit (Qiagen Valenica, CA) 
and specific rabbit polyclonal anti-Spe antibodies. rSAgs were purified as His fusion 
proteins using Ni-NTA superflow according to manufacturer’s recommendations 
(Qiagen, Valenica, CA). The purity of rSAgs was confirmed by SDS-PAGE and silver 
staining. The purified rSAgs were treated with polymyxin B agarose (Boehringer 
Mannhiem, Indianapolis, IN) to remove any contaminating endotoxin.  Enzymatically 
active rSpeB was generated by one of us (Woei-Jer Chaung) and expressed and purified 
as detailed earlier (363). 
 
Polyclonal rabbit anti-Spe antibodies 
 Specific polyclonal rabbit antibodies to SpeA were generated as previously 
described (273). Antibodies to SmeZ, SpeG and SpeJ were generated by one of us (T. 
Proft). 
 
 
 128 
Effect of SpeB on rSAgs 
 Each of the rSAgs (200µg/ml) was incubated with the pre-activated rSpeB 
(200µg/ml) at 370C.  We generated the enzymatically active form of rSpeB by incubating 
the 40-kDa precursor for 8h at 370C in the presence of 5mM dithiothreitol and EDTA.  
To monitor the kinetics of the effect of rSpeB on rSAgs, we aliquoted samples at 0.5, 1, 
2, 4, 8, and 18h post incubation.  We stopped the SpeB enzymatic activity immediately at 
each time point by adding the cysteine protease inhibitor E-64 (Roche) at a final 
concentration of 28 µM.  The samples were frozen at –200C until further analyses. To 
check the specificity of SpeB’s proteolytic activity, we also included a control where its 
activity was inhibited from the start of incubation by adding E-64. The digestion mixtures 
(rSAgs + rSpeB) were separated by SDS-PAGE and transferred onto nitrocellulose paper.  
We analyzed the proteolytic degradation of the rSAgs following incubation with rSpeB 
by Western blots using specific anti-Spe antibodies. 
 
Proteomic analysis of the SAg mixture 
 The four recombinant M1T1 SAgs (SpeA2, SpeG, SpeJ, and SmeZ1) were mixed 
in equal amounts (10µg/ml) and treated with 20 or 200 µg/ml of pre-activated SpeB.  The 
cysteine protease inhibitor, E-64 (final concentration of 28 µM) was used to stop the 
reaction after 8h. Prior to isoelectric focusing (IEF), the SAg mixture, with and without 
active SpeB, was lyophilized to dryness, then resuspended in 125µl rehydration buffer 
composed of 7 M urea, 2 M thiourea, 4% CHAPS, 20 mM dithiothreitol and 0.16% of 
40% Bio-Rad 3-10 ampholytes (Bio-Rad) IEF was performed in a Protean IEF cell, and 
the second dimension SDS electrophoresis was run on a Protean Minigel Dodeca 
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apparatus (Bio-Rad) as detailed elsewhere (362). Protein spots, visualized by silver 
staining, were cut from the gels, destained, and digested with trypsin.  The tryptic 
peptides were extracted with 60% acetonitrile/5% trifluoroacetic acid (TFA), purified on 
micro-C18 columns (Ziptips-Millipore), and finally eluted in the matrix solution (alpha-
cyano-hydroxycinnamic acid dissolved in 50% acetonitrile/0.1% TFA). To identify these 
proteins, we analyzed their tryptic peptides’ masses by MALDI-TOF MS using a 
Voyager DE RP (ABI) in the Stout Neuroscience Laboratory (UTHSC proteomic facility) 
and then we used the Aldente software (http://us.expasy.org/tools/aldente/) to match the 
peptide masses to proteins in the databases. 
 
N-terminal sequencing of the Strep SAg following incubation with rSpeB 
 N-terminal protein sequencing (Edman degradation) was performed by Midwest 
Analytical, Inc. (St Louis).  
 
Bioinformatics analysis of SAg sequence 
 We used several bioinformatics tools to analyze the amino acid sequences of the 
four M1T1 SAgs as well as their secondary and tertiary structures. We aligned the 
primary sequences using the ClustalW analysis tool (364) in VectorNTI suite 
(Invitrogen). We used the Consensus Disorder Prediction (CDP) tool from the Center on 
Proteolytic Pathways (CPP) (http://protease.burnham.org/www/tools/html/disorder.html).  
 This tool implements five different disorder prediction methods: COILs, 
REM465, and HOTLOOPs (from disEMBL) and GlobPlot (365) and DISOPRED (366). 
In CDP, if more than half of these applied methods calculate a residue as disordered, a 
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consensus is generated and the residue is scored as disordered. The 3D structures for 
SpeA and SmeZ were pulled from the Protein Data Bank (PDB) 
(http://www.rcsb.org/pdb/Wellcome.do) and the Molecular Modeling DataBase (MMDB) 
(http://www.ncbi.nlm.nih.gov/Structure/MMDB/mmdb.shtm). SpeA accession numbers: 
1L0X and 1L0Y, SmeZ accession numbers: 1ET6, 1EU3. The structure models were 
generated using SWISS-MODEL (367). 
 
Effect of SpeB on the functional activity of streptococcal SAgs 
 For assessment of the effect of SpeB on the ability of SAgs to induce lymphocyte 
proliferation, peripheral blood mononuclear cells (PBMC) were isolated from heparinized 
blood of healthy individuals as detailed previously (294), and stimulated with each of 
rSAg with or without pre-incubation with active rSpeB as detailed above. PBMC (105 
cells/200µl) were stimulated with serial two-fold dilutions of either the tested rSAg ± 
rSpeB or the polyclonal mitogen, phytohemagglutinin A (PHA) at 1 µg/ml conc. T cell 
proliferation was assessed by measuring [3H] thymidine uptake after 72 h of culture. 
 
Analysis of TCR Vβ  repertoire by flow cytometry 
 Each SAg has a characteristic Vβ specificity and preferentially activates T cells 
expressing certain Vβ elements. We used flow cytometry for quantitative analysis of 
preferential expansion of lymphocytes with specific TCR Vβs using the IO Test Beta 
Mark TCR Vβ Repertoire kit (Beckman Coulter; Miami, Florida). We used a CD3-PC5-
conjugate as an additional marker to enable proper gating on T lymphocytes only.  
PBMC were isolated from the blood of a healthy individual by Ficoll-Hypaque gradient 
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centrifugation, incubated at 107cells/5 ml of RPMI with 10% FCS, and stimulated with 
5ng/ml of each SAg (with or without E-64) or PHA at 1 µg/ml. After 72 h, the cells were 
cultured for additional 24 h in the presence of 10 units/ml recombinant human IL-2 to 
allow the regeneration of modulated T cell receptors.  The cells were then harvested, 
washed extensively with PBS containing 1% BSA, and stained with different antibodies 
as per the manufacturer’s instructions.  We gated on the CD3-PC5 blastogenic cells and 
performed simultaneous analysis of 3 TCR Vβs per tube using a FACSCalibur flow 
cytometer.  We analyzed the data using Cell Quest software (Becton Dickinson, 
Mountain view, California).  A minimum of 30,000 cell events was acquired for the 
analysis. 
 
Results 
 
Proteolytic degradation of individual SAgs by SpeB 
 The clinically relevant M1T1 strain harbors the genes encoding for SAgs: SpeA2, 
SpeF, SpeG, SpeH, SpeJ and SmeZ1. Using conventional methods of protein detection 
and identification, we observed that SpeF is completely degraded in the presence of SpeB 
(363). Since most of the remaining SAgs viz. SpeJ, SpeG, and SmeZ1 are secreted at 
levels much below the detection limits of conventional methods (124, 363), we extended 
these studies with the rSAgs.  
 SpeA2, SpeJ, SpeG, and SmeZ1 appear to be affected differently by the rSpeB 
(Fig 5.1A). SmeZ1 was most susceptible to proteolytic degradation by SpeB as early as 
30 min postincubation and was virtually undetectable after 8h even at the lowest SpeB 
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Figure 5.1 Differential degradation of individual rSAgs by SpeB. 
A.   Western blot analysis of the kinetics of M1T1 GAS SAg degradation by 
enzymatically active rSpeB. Each of the indicated rSAgs (200µg/ml) was incubated with 
equal volume of pre-activated r-SpeB (200µg/ml).  Aliquots (10µl) were removed at 
0.5h, 1h, 2h, 4h, 8h, and 18h post incubation and the SpeB enzymatic activity was 
stopped immediately at each time point by adding the cysteine protease inhibitor E-64 at 
a final concentration of 28 µM. Digestion of the rSAg protein was monitored by Western 
blots using SAg specific antibodies.   B.   SpeB specific degradation of superantigens can 
be inhibited with E-64. Wetsern blot analysis of His- tagged r-SAgs: SpeA2, SpeJ, SpeG, 
and SmeZ1 incubated with 200µg/ml of rSpeB for 8 h in the absence or presence of E-64. 
The blots were probed with specific anti Spe antibodies. The bands in the middle lane are 
moving lower than the rSAgs because rSpeB cleaves N terminal His tag. 
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concentration used (Fig 5.2A). Compared to SmeZ1, SpeJ was the most resistant to SpeB 
degradation even after 18h of co-incubation with the highest used dose of SpeB. Whereas 
SpeJ and SmeZ1 exhibited extreme resistance and susceptibility to SpeB, respectively, 
the susceptibility of SpeG and SpeA2 to the proteolytic activity of SpeB varied. After 8h 
of incubation, SpeG showed slight and partial degradation by 20 and 200µg/ml SpeB, 
whereas partial degradation of SpeA2 was only noted after 18h of incubation and only at 
the highest concentration of the protease (Fig 5.1A & B). In the presence of E-64, all 
SAgs were completely protected from SpeB degradation (Fig 5.1B).    
 Thus far, we have determined the differential cysteine protease activity of rSpeB 
on each of the four rSAgs individually.  In real life, however, these proteins are 
coexpressed in the GAS secretome.  We asked if the presence of a mixture of SAgs 
would have a synergistic or antagonistic effect on their susceptibility to SpeB. Because 
these rSAgs have similar molecular weights, we resolved them by two-dimensional gel 
electrophoresis before and after their incubation with the activated rSpeB.  The data 
shown in Figure 5.2A & B confirmed the higher susceptibility of SmeZ1 to rSpeB 
activity and showed that this susceptibility is not altered by the presence of the other 
three SAgs. The susceptibility of other three SAgs in the mixture showed a similar 
pattern as that seen with each one of them individually: SpeG showed partial degradation 
while SpeA2 and SpeJ remained unaffected up to 8h of incubation with rSpeB (Fig 5.2). 
 
SpeB-driven proteolytic degradation of SAgs affects their biological activity 
 Following the 8h co-incubation with SpeB, the proliferation-inducing activity of 
SmeZ1 was reduced significantly (P= 0.003) whereas that of SpeA2 remained unchanged 
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Figure 5.2 Reproducible differential degradation of mixed rSAgs by SpeB. 
 
A.   All of the indicated rSAgs (200µg/ml) were mixed together and incubated for 8h with 
0, 20 or 200µg/ml of pre-activated r-SpeB. The mixtures were resolved on 12.5% SDS-
polyacrylamide gels. Digestion of the rSAg protein was monitored by Western blots 
using SAg specific antibodies.   B.   2D-gels of mixture of rSAgs (SpeA2:A, SpeG:G, 
SpeJ:J, SmeZ1:Z) incubated for 8h with 0, 20 or 200µg/ml of pre-activated rSpeB 
(SpeB:B). The gels were stained with silver (left panels), and the silver stained spots were 
identified by MALDI-TOF MS. The gels were also blotted onto the nitrocellulose 
membrane, which were probed with anti-SmeZ1 (middle panels) or anti-SpeA2 (right 
panels) antibodies as detailed in methods. The lower right panel shows the SpeA2 spot 
with some tailing; this tailing in 2D gels is due to incomplete isoelectric focusing (also 
apparent in the silver-stained gel) and may be caused by the excess SpeB (200 µg) added 
in this gel which might have rendered the focusing less efficient than the middle panel. 
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(Fig 5.3A). In fact, the proliferation-inducing activity of SpeA2 following incubation 
with SpeB appears to have slightly increased and this was seen in several experiments 
(Fig 5.3A). The loss of SmeZ1 activity following incubation with SpeB could be stopped 
by the addition of E-64. The proliferation-inducing activity of SpeG and SpeJ was 
unaffected by SpeB (data not shown).  
 The proliferation results were supported by TCR Vβ analyses of the human T 
cells stimulated with a representative SpeB–resistant SAg, SpeA2, or a SpeB-sensitive 
SAg, SmeZ1. The skewed pattern of TCRVβ repertoire in response to stimulation with 
SpeA2 was not altered following pre-incubation with SpeB.  By contrast, the ability of 
SmeZ1 to induce the expansion of T cells bearing TCRVβ4, TCRVβ7.1 and TCRVβ8, 
was diminished when the SAg was pre-incubated with SpeB (Fig 5.3B), with a marked 
reduction in the number of activated T cells bearing TCRVβ8 elements.  
 
Specificity of SpeB degradation 
 SpeB degraded the His-tag on all the rSAgs used. This was first suggested by the 
appearance of a slightly faster migrating species in Westerns of SAgs preincubated with 
active SpeB, including those that resisted its proteolytic effects (Fig 5.1A), and later 
confirmed when we probed the blots with anti-His antibodies and were unable to detect 
any SAg bands (data not shown), yet the proteins were readily detected at their expected 
size by their specific antibodies.  These results prompted us to investigate the SpeB- 
specific cleavage sites on each of these SAgs and to explore why only SmeZ1 is degraded 
completely while other SAgs are not.  
 N-terminal sequencing of the protein fragments followed by amino acid alignment  
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Figure 5.3 SAg degradation products are not functionally active. 
 
A.   T lymphocyte proliferative activity of rSmeZ1 and rSpeA2 incubated without or with 
200µg/ml rSpeB (± E64) for 8h. The proliferation inducing activity of each SAg was 
tested over a wide range (500ng - 5pg/ml of the culture media). The results shown here, 
however, correspond to 2.5 and 10 ng/ml of SmeZ1 and SpeA2 respectively.  The data 
are representative of 3 independent experiments. Each value represents mean ± SD of 
four values. Statistical significance of the differences in the proliferation-inducing 
responses with or without incubation with rSpeB was determined by Student t test (two-
tailed).    
B.   SpeB selectively degrades SmeZ1 but spares SpeA2. Expansion profiles of 
lymphocytes with specific T cell receptor Vβ in response to stimulation with SmeZ1 and 
SpeA2 with or without incubation with 200µg/ml of rSpeB for 8h. The final 
concentrations used for stimulation of SmeZ1 and SpeA2 were 5 and 10 ng/ml of the 
culture media respectively. 
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revealed that all four SAgs were cleaved between the glutamate (E) and glycine (G) 
residues just after the histidine tag (Fig 5.4).  These two residues do not belong to the 
cloned proteins but are rather encoded by the expression vector as part of the factor Xa 
cleavage site that was engineered between the His-tag and the cloned protein to facilitate 
the removal of the His-tag. Although SmeZ1 was also initially cleaved at the same site 
(15 min post incubation with SpeB), it was completely degraded by 30 min.  
 
Bioinformatics analysis reveals a putative SpeB-target loop in SmeZ1 
 The consensus target for cleavage by SpeB has been suggested to contain a 
hydrophobic residue (isoleucine or valine) at the P2 site and a positively charged residue 
(preferably lysine) at P1 (368, 369).  Bioinformatics analysis of the primary sequence and 
the predicted secondary structure of the SAgs used in this study did not reveal a 
preferential abundance of the SpeB preferred sites in SmeZ1 when compared to the other 
SAgs. Alternatively, a plausible explanation of why SmeZ1 is totally degraded within an 
hour while SpeG, SpeA2 and SpeJ are spared could lie in the folds of the tertiary 
structures of these proteins. Accordingly, it appears that the tertiary structure of SmeZ1 
may make some ‘SpeB-vulnerable’ targets exposed whereas these may be sequestered in 
other SAgs. Indeed, it was suggested that large local motions proximate to the scissile 
bonds are required for proteolysis and that the prime determinant for limited proteolysis 
is this ability to unfold locally (370).  Accordingly, we used the CDP method (see 
experimental procedures) to predict intrinsically disordered regions in the four rSAgs. 
Subsequently, we looked for the SpeB extended specificity pattern [ILVFMYW]K in 
regions predicted to be disordered to find potential cut sites of SpeB. 
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Figure 5.4 Sites of cleavage of the various rSAgs by SpeB. 
 
Alignment of the amino acid sequences of rSpeA2, rSpeG, rSpeJ and rSmeZ1. All of the 
SAgs studied were cleaved at the N-terminal end of the first G in the protein (see arrow), 
thereby removing all extra amino acids added onto the protein as part of the His-tag 
included in this expression vector. Sequences are aligned by ClustalW tool available in 
VectorNTI suite. Amino acids likely to be in disordered areas are shown in upper case 
letters. The flexible loop encompassing the GSSYKS sequence in SmeZ1 (shown in a 
dashed box) is expected to be the most vulnerable site for SpeB cleavage. In the same 
loop, note that SpeA2 has an E instead of the K found in SmeZ1 and it is possible that 
this substitution may have rendered SpeA2 resistant to SpeB. Also, the extra P found in 
the SpeA2 but not the SmeZ1 loop, may restrict the flexibility of the loop and may 
contribute as well to its protection from SpeB proteolysis. (SpeA2 and SmeZ1 are the 
specific alleles of speA and Smez present in the M1T1 GAS). 
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The only site in disordered region was found in SmeZ1, boosting the experimental 
observation of its selective susceptibility to rSpeB. On the other hand, the homologous 
area in the other SAgs was either not in a disordered region (rSpeG and rSpeJ), or was in 
a disordered region (rSpeA2) but lacking the lysine residue and having an additional 
proline residue that adds steric hindrance which may interfere with proteolysis (Fig 5.5).  
Comparing the crystal structures for SpeA2 and SmeZ1 revealed that the areas are 
surface exposed on loops, with the difference that this loop lacks lysine in SpeA2 (Fig 
5.5). 
 
Discussion 
 SAgs play an important role in the pathogenesis of severe invasive infections 
caused by Group A Streptococcus (275, 349), and their expression is tightly regulated 
both on the transcriptional and post-translational levels (28, 363, 371). We reported 
earlier that SpeB plays a pivotal role in the post-translational degradation of GAS 
secreted protein, which results in partial loss of proliferation-inducing activity of GAS 
supernatants containing a mixture of several secreted SAgs (363). In the present study, 
we demonstrated that SAgs vary considerably in the rate and extent of their proteolytic 
degradation by SpeB: while some SAgs are highly susceptible, others are resistant to the 
degradation by SpeB up to 18 hours. 
 SpeB is a highly conserved GAS protein that, unlike some other phage-encoded 
streptococcal exotoxins, e.g., SpeA and SpeC, is encoded by chromosomal DNA. SpeB is 
secreted through the ExPortal, a unique single microdomain of the cellular membrane 
specialized to contain the Sec translocons (372) as a 40-kDa precursor that can catalyze 
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Figure 5.5 Ribbon diagram of the 3D structures of SpeA (upper) and SmeZ (lower). 
 
Each diagram shows a flexible loop that matches the region predicted by disorder 
analysis (Fig 4); however, only the SmeZ loops has a lysine moiety likely to be at the 
SpeB cleavage site.   
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its own processing to the enzymatically active 28-kDa form, also known as ‘streptopain’ 
due to its close resemblance to papain.  The enzyme is a cysteine protease belonging to a 
family of endopeptidases and shows a broad substrate specificity, including oxidized 
insulin B chain and other synthetic substrates (373).  Although it is one of the earliest 
identified and most extensively studied streptococcal proteins, little is known about its 
cleavage sites.  Most of the current knowledge about these cleavage sites comes from the 
enzyme’s effects on the natural substrates i.e pro-SpeB, immunoglobulins, C5a peptidase, 
streptococcal proteins M and H (360, 361, 368) or synthetic peptides (369), but no 
comprehensive studies have been performed to determine a consensus SpeB cleavage 
site. From the few studies performed, the preferred target for SpeB favors a hydrophobic 
residue (isoleucine or valine) at the P2 site and a positively charged residue (preferably 
lysine) at P1 (368, 369).  The only cleavage site that we could determine by N-terminal 
sequencing in our studies happens to have isoleucine (I) and glutamic acid (E) at P2 and 
P1, respectively.  However, bioinformatics analysis of SmeZ1 (and other SemZ 
homologs) revealed a conserved intrinsically disordered region containing a motif 
vulnerable to SpeB YKSG. This motif was different in SpeA2 (YETG) and was preceded 
by a proline moiety that makes susceptibility to protease unlikely. In both SpeJ and SpeG, 
the homologous motif was totally in an ordered region and expected to be folded. This 
notion that folded domains are protected from proteolysis is experimentally supported by 
the fact that tethering a histidine tag to the recombinant SAgs and incubating the tagged-
rSAgs with enzymatically active SpeB leads to a prompt degradation of the ‘foreign’ 
peptide linkers, generating products with identical N-termini, suggesting that these 
peptide linkers were exposed to the cysteine protease because they did not fit in the SAgs 
 145 
folding scheme. Accessibility of the proteolytic cleavage sites is also known to play an 
important role in the autoprocessing of pro-speB because four of the five auto-processing 
cleavage sites identified are located on accessible loops in the SpeB structure (374). 
 How does the selective degradation of SAgs affect the disease progression 
remains to be explored?  Before moving from the in vitro observations to the in vivo 
implications, we have to address the question of what physiological concentrations these 
toxins achieve during infection.  Since the concentrations of these SAgs achieved during 
infection are practically difficult to determine and are variable depending on the bacterial 
isolate and the site of bacterial infection, we decided to mix equal amounts of 
recombinant SAgs.  At 200 µg/ml, a concentration much higher than its physiological 
concentration (124), SmeZ1 could still be degraded by SpeB, and a SpeB concentration 
as low as 20µg/ml was sufficient to breakdown SmeZ1 to below detectable limits.  
However, it is not uncommon that an enzyme may fail to act properly when the substrate 
level becomes sparse.  Thus, to address the functional implications of the differential 
effects of SpeB on M1T1 SAgs, we compared its effects on the functionality of the 
susceptible rSmeZ1 vs the resistant rSpeA2.  Using in vitro biochemical and biological 
assays, we showed that the selective degradation of SmeZ1 results in a significant loss of 
its superantigenic activity and its ability stimulate specific T-cells (Fig. 5.3A & B), while 
all SpeA2 biological functions were practically unaffected. 
 The question remains: what happens during actual infections?  A very relevant 
and complex question whose answer is controlled by at least three major factors, the 
coexpression of these proteins, their regulation and their ‘available space.’ In earlier 
studies, we showed that the relative expression of SpeA2 and SpeB protein and RNA is 
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drastically and temporally reversed after animal passage (28). The differential expression 
of these proteins implies the presence of tight regulatory networks that affects their 
relative levels. High levels of SpeB expression in tissue and skin infection sites are in 
contrast with its complete shutdown in blood (73). In the initial phase of infection via 
skin or tissue, the bacteria need SpeB to break through the host tissue. Once the bacteria 
are in blood, SpeB expression can be detrimental to the bacteria as this protease degrades 
most of the bacterial anti-phagocytic proteins as well as the SAgs. (69, 375-377). 
 Selective degradation of GAS proteins by SpeB may explain why it is 
advantageous for the bacteria to down-regulate SpeB after the initial stages of infection, 
but it also explains what has been thought as “functional redundancy” of SAgic toxins in 
GAS. From an evolutionary aspect, it appears that GAS continues to acquire via 
horizontal gene transfer, more SAgs that seem to resist SpeB activity. The present study 
suggests that SpeA2 and SpeJ might be two such horizontally acquired SAgs because of 2 
reasons: 1) their location on phage or transposable elements and 2) their absence in many 
sequenced GAS strains (http://www.nmpdr.org and Aziz etal; personal communication). 
Both SpeA and SpeJ are not shared by all strains [SpeJ is present in M1 (122) and M28 
(378), and SpeA in only 20% of GAS strains (379)]. These superantigens also turn out to 
be most resistant to SpeB degradation and are able to keep their biological functions 
regardless whether SpeB is expressed or not. It is believed that non-specific immune 
responses elicited by the SAgs may allow a subset of the bacteria to escape specific 
immune defenses and make their way to host niches where they can cause chronic 
diseases such as rheumatic heart disease, glomerulonepharitis, psoriasis and pediatric 
neurological disorders (380).  
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Chapter 6. Summary and Conclusions 
 
Summary 
Overall, our study has provided valuable insight into how HLA class II allelic 
variation influences Strep SAgs responses that translates into different forms of GAS 
invasive infections being severe or non-severe. Before this study began and during its 
progress, most investigations involving HLA class II interaction with SAgs, though 
providing valuable information, revolved around demonstrating that distinct class II 
alleles differentially affect SAgs response in terms of proliferation or cytokine 
production, with only few studies addressing the molecular mechanisms for this 
phenomenon by investigating potential variability in HLA-SAg binding affinity (275, 
284, 285, 287, 289). Also, the previous studies mainly involved the early discovered 
staphylococcal SAgs (e.g. TSST-1, SEB, SEC), with only two or three Strep SAgs 
(primarily SpeB, SpeA, and SpeC) being investigated and few class II alleles that are not 
relevant to GAS pathogenesis (288, 290, 297, 381). On the other hand, our study has 
focused on translational research applications. We observed variation in different 
individuals’ susceptibility to Strep SSD, SAg-mediated disease, and examined HLA class 
II-SAg interaction in vivo and in vitro, focusing on SAgs produced by the highly 
prevalent clonal M1T1 strain and on the class II haplotypes/alleles associated with 
different infection outcomes. Furthermore, we investigated the differential presentation of 
four Strep SAgs, individually or in mixture, by eleven prevalent haplotypes and eight 
single alleles, which makes our study more comprehensive and significant. This 
extensive screening aimed at revealing novel HLA-SAg interactions that could not be 
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detected in epidemiological association studies and at answering the questions: does the 
observed differential presentation apply to a particular SAg, a SAg combination, or to all 
SAgs, and does individuals’ TCR Vβ repertoires variation play a role in controlling SAg 
response and infection outcome or is HLA class II polymorphism the main player? 
Additionally, we sought to explore the molecular mechanisms for SAg-differential 
presentation by different class II alleles. 
 Using HLA tg mice, we validated the findings of the epidemiological association 
studies and showed the dominant effect of HLA class II on SAg responses in vivo and in 
vitro, an effect that was corroborated by our screening studies. Our screening 
demonstrated that all tested SAgs, individually or mixed, were preferentially presented by 
the high-risk allele/haplotype; however, some particularly interesting results were 
observed that will be detailed later.  
 Next, we examined the binding affinity of SAgs to different class II alleles with 
the aim of providing a molecular basis for their differential presentation. Although our 
binding results revealed a general agreement between SAgs binding to and presentation 
by different class II alleles, an exception was observed in case of SmeZ1 and DQ alleles. 
We went further in our molecular mechanistic studies by investigating biochemical 
events generated in T cells (Ca2+ mobilization) when stimulated with SmeZ1 in the 
context of different DR or DQ alleles. Interestingly, the Ca2+ flux results supported the 
preferential presentation observations. These results may suggest that HLA-SAg affinity 
is only part of the process that modulate SAg responses, and that the overall avidity of the 
trimolecular complex (HLA-SAg-TCR) may determine the overall potency of the 
response. Another interesting finding of our study is that the protective alleles/haplotypes 
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were found to be superior to the high-risk counterparts in inducing the regulatory 
cytokine IL-10, which suggests that protection against Strep SSD may be mediated by an 
active rather than a passive effect. 
 
HLA-tg Mice Are Useful Animal Model for Studying SAg-mediated Diseases  
 Epidemiological studies performed on patients with clear clinical manifestations 
are effective in revealing host immunogenetic factors that influence infection outcome; 
however, the drawn associations are questionable until validated in an appropriate animal 
model. We used HLA-tg mice expressing HLA-DQ6 (SSD protective allele) or HLA-
DR4/DQ8 (SSD neutral alleles) to examine in vitro and in vivo responses to GAS SAgs. 
By using these mice, we achieved several goals. First, we overcame the poor response of 
traditional inbred mice to SAgs(296, 297). Second, the high susceptibility of tg mice to 
SAg-mediated STSS allowed us to investigate the pathophysiology of STSS (226, 227, 
300, 301). Also, expression of distinct class II alleles in specific HLA-tg mice was useful 
for delineating the effect of class II allelic variation on Strep invasive infection outcome. 
Our in vitro findings showed that DQ6 splenocytes mounted remarkably lower responses 
to M1T1 SAgs than DR4/DQ8 splenocytes. Reproducibly, DQ6 mice elicited 
significantly lower inflammatory cytokine levels (TNF-α and IFN-γ) in vitro and in vivo 
than those of the DR4/DQ8 mice, and DQ6 mice were more resistant to infection than 
DR4/DQ8 mice. Altogether, these data provide a validation for our epidemiological 
association findings and confirm the protective effect of HLA-DQ6 allele. 
 Interestingly, both tg mouse lines had comparable bacterial load in liver and 
spleen. This observation underscores the role of HLA class II as a controller of the SAg-
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induced inflammatory cytokine responses and hence the severity of invasive GAS 
infection. However, this argument needs to be further addressed at late time points of 
infection when the death rate of DR4/DQ8 mice is higher. If the DQ6 and DR4/DQ8 
mice demonstrate comparable bacteremia and tissue bacterial loads at these late stages of 
the disease, this will support our point that HLA class II polymorphism modulates the 
outcome of invasive GAS infection by governing the systemic inflammatory cytokine 
responses to SAgs rather than the bacterial clearance.  
 Also, another limitation of this study was the lack of HLA-tg mice expressing the 
high-risk alleles DR14, DQ5 or another protective allele DR15. Some of these mice are 
currently available (tg mice expressing DR14, and DR15) and the rest are being prepared, 
and we are planning to use them together with the tg mice described above to compare 
their responses to GAS SAgs in vivo and in vitro and to get a clearer picture of HLA 
allelic variation on Strep SAgs responses.   
 
Relative Contribution of HLA Class II Allelism and TCR Vβ Repertoire Variation to 
Strep SAgs Responses 
 SAg activity depends on interaction with both HLA class II molecules and TCR 
Vβ elements on APC and T cells, respectively. Therefore, in addition to the already 
demonstrated effect of HLA, SAg responses can also be influenced by the interaction 
with TCR Vβ elements. Each SAg has a unique profile of TCR Vβ specificity and 
interacts only with T cells expressing these Vβ elements. Therefore, SAg response can be 
affected by the relative abundance of SAg-specific TCR Vβ families and the frequency of 
T cells expressing those families in a given individual’s repertoire. These variables would 
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influence the number of responding T cells in a given individual. Our SAg-cross 
presentation assays clearly demonstrated that TVR Vβ repertoire variation has no effect 
on SAg response. 
 In HLA-tg mice, SAgs-cross presentation by either mouse line APC to each other 
T cells or to human T cells reproducibly demonstrated significant lower responses in the 
presence of the protective DQ6 APC as compared to DR4/DQ8 APC. Similarly, in 
humans with protective or high-risk alleles, SAg-cross presentation showed remarkably 
lower responses in the context of APC from the low responder irrespective of the T cell 
source. Furthermore, using B cell lines, homozygous for the protective alleles DR15/DQ6 
or for the high-risk alleles DR14/DQ5, to present of the same Strep SAgs to T cells from 
different individuals, reproducibly resulted in significantly lower responses in the 
presence of the cell line with the protective alleles.  
 
HLA Class II Allelic Variation Determines Not Only the Magnitude But Also the Type 
of SAg-induced Cytokine Responses 
 SAgs interact with both APC and T cells causing massive activation of large 
numbers of both cell types, which results in sudden cytokine storm. Such SAg-mediated 
cytokine responses induce the development of STSS. It was shown that individuals with 
the tendency to produce high levels of inflammatory cytokines develop severe systemic 
forms of GAS sepsis (275, 276). Our findings demonstrate that the magnitude of pro-
inflammatory cytokines produced by splenocytes or by PBMC (stimulated with the same 
SAgs) expressing the protective alleles was remarkably lower than those expressing 
neutral or high-risk alleles. Similarly, in the SAg-cross presentation studies, we found 
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that T cells from human or mice mount significantly lower level of pro-inflammatory 
cytokines if the SAgs were presented by APC expressing the protective alleles. 
Reproducibly, B cell lines homozygous for the protective haplotype (DR15/DQ6) or 
expressing single alleles from that haplotype induced lower level of pro-inflammatory 
cytokines when compared to B cell lines expressing high-risk haplotype/alleles 
(DR14/DQ5). Therefore, These data clearly indicate that of HLA class II allelic variation 
governs the magnitude of SAgs-triggered cytokine responses and thus determines the 
severity of GAS sepsis. 
 Interestingly, however, SAg-presentation by protective haplotype/alleles elicited 
high levels of the anti-inflammatory cytokine IL-10 that may have contributed to curbing 
the inflammatory responses and lowering T cell proliferation. This suggests that the 
protective effect of the DR15/DQ6 haplotype is not a passive action due to just poor SAg 
presentation. Rather, protection appears to be through active IL-10-mediated suppression 
of the inflammatory responses elicited by Strep SAgs. This view was supported by the 
fact that adding exogenous IL-10, which brought down the high-risk haplotype, induced 
SAgs-response to the same level of the protective haplotype. Although other studies have 
shown that SAgs can induce both pro- and anti-inflammatory cytokine responses (140, 
382), we are the first to report differential production of these two types of cytokines in 
response to SAg-presentation by distinct class II haplotypes. These findings provide a 
molecular basis for the protective effect of DR15/DQ6 alleles in STSS, which appears to 
be mediated by increased IL-10 production and active suppression of inflammatory 
responses.  
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Developing a Sensitive System with Minimum Variables for Elucidating the Molecular 
Basis of Differential SAg-HLA Class II Interaction 
  We tested the presentation of individual M1T1 rSAgs (SpeA-2, SpeG, SpeJ, and 
SmeZ1-1) by a panel of LBCL expressing HLA class II haplotypes that are prevalent in 
areas with high STSS incidence to find out which SAg is most affected with class II 
allelic variation. Our data showed that distinct class II haplotypes differentially presented 
all M1T1 rSAgs with the highest and lowest responses being triggered by the high-risk 
(DR14/DQ5) and the protective (DR15/DQ6) haplotype, respectively. The used BLCL 
normally express class II DR, DQ and DP isotypes. However, to delineate the 
contribution of individual alleles to SAg response single allele expressing cells are 
required. Furthermore, it is essential to eliminate any possible variability in the APC that 
may be related to any peculiar characters of the BLCL. Therefore, we generated a panel 
of BLS cell lines expressing single HLA DR or DQ alleles that are part of the high-risk, 
protective or neutral (neither high-risk nor protective) haplotypes. Such a generated panel 
would have different HLA DR or DQ alleles as the only variable contributed by the APC. 
To this end, we have established a simplified system that reduces the number of variables 
and maximizes our ability to dissect the effect of a single variable (different HLA class II 
alleles) at a time in modulating the molecular events and potency of SAgs, where the 
same SAg is presented to the same T cells by the same BLS expressing different class II 
alleles. 
 We used this system to determine whether the HLA class II effect on the SAg 
response is mediated by just one or if it requires both isotypes (DR and DQ) on the 
disease associated haplotypes. Our results showed that single class II alleles from 
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protective or high-risk haplotypes presented individual M1T1 rSAgs in a way that 
mirrored the presentation of the same rSAgs by protective or high-risk haplotypes, 
respectively. The protective DR15 or DQ6 alleles elicited proliferative and cytokine 
response that significantly lower than those elicited by the high-risk DR14 or DQ5 
alleles, while DR4, DR7, DQ2 and DQ7 elicited responses that are between these two 
extremes. Interestingly, DR14 and DQ5 were associated with the highest responses to all 
rSAgs except for SpeG, which demonstrated higher response in the presence of DQ7 than 
DQ5. This finding suggests that each SAg has its own way of interaction with class II 
alleles and that we cannot make a generalized statement about SAgs since exceptions 
always exist. Thus, we do not agree with the statement “if you have studied one SAg, you 
have studied them all”. This view will be further substantiated by the results of the 
binding studies. 
 
Possible Molecular Mechanisms Underlying the Differential Effect of HLA Class II 
Molecules on SAgs Responses 
 The stability of HLA-SAg interaction appears to be the earliest step that may 
modulate the downstream responses. Our binding studies results demonstrated that 
different binding affinity correlates with the observed functional responses. That is to say 
the protective class II alleles bind rSAg with lower affinity than that of the high-risk 
alleles. Therefore, the high-risk alleles could form greater numbers of SAg-MHC 
complexes or more stable complexes on the APC and consequently cause more 
pronounced T proliferation and cytokine production. This was found to be true for SpeG 
and SpeJ binding to different HLA DR or DQ alleles. However, SmeZ1 lacked the 
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correlation of binding to and presentation by distinct HLA DQ alleles. SmeZ1 binding to 
the high risk HLA DQ5 allele was weaker than that to the protective HLA DQ6. The 
disagreement between proliferation and binding data for SmeZ1 in the context of HLA 
DQ alleles, may suggest that the overall avidity of the trimolecular complex (HLA-SAg-
TCR) is the main governing factor. We addressed this possibility by studying Ca2+ 
mobilization in T cells following stimulation with SmeZ1 in the presence of different 
HLA DR or DQ alleles. Interestingly, presentation of SmeZ1 by the high-risk HLA DQ5 
allele induced remarkably higher Ca2+ influx than that induced by the protective HLA 
DQ6 alleles. Such finding suggests that the responses to SmeZ1 in the context of HLA 
DQ alleles may be controlled by the high affinity of TCR Vβ elements for DQ-SmeZ1 
complex rather than the mere stability of that complex. In other words, the stability of the 
HLA DQ5-SmeZ1-TCR ternary complex depends on the stability of both SmeZ1-TCR 
and DQ5-SmeZ1 interactions, with the former being relatively more important in this 
particular case. 
 Collectively, the findings presented in this dissertation emphasize the dominant 
and direct role of HLA class II as a regulator of Strep SAgs responses, which modulates 
disease severity. Furthermore, it is clear that each SAg-HLA class II allele interaction is 
distinctive. However, as mentioned earlier, along with class II polymorphism other 
factors may also affect SAg responses; including how a SAg interacts with HLA class II 
molecule (via high affinity β-chain or low affinity α-chain) and whether it can crosslink 
class II molecules. Also, the nature of class II bound peptide can affect SAg presentation. 
Different biological compartments vary in resident APC with distinct repertoires of class 
II-bound peptides; some of these peptides permit SAg presentation while others do not. 
 156 
TCR also plays an important role through its effect on the stability of the trimolecular 
complex of HLA-SAg-TCR; an effect that varies with the SAg, TCR Vβ element and in 
particular the class II allele involved. All these factors are not mutually exclusive and 
may act together to potentiate SAgs responses in different individuals and tissues.  
 Another layer of complexity is added if we consider that other host polymorphic 
genes may play a role in regulating SAg response as well as other bacterial components 
that interact with SAg and are likely to contribute to the pathogenesis of GAS sepsis as 
well.  
 
Bacterial Factors Affecting Strep SAgs Responses 
 So far, we have focused on host factors that control Strep SAgs responses. 
However, in vivo the bacteria produce many other virulence factors that interact with 
each other and with the host immune system. Therefore, in the real life situation, in 
addition to Strep SAgs, the host experiences several other GAS virulence factors 
including the major streptococcal cysteine protease SpeB whose expression results in 
partial loss of the immune-stimulating activity of the native secreted Strep SAgs 
produced by the globally disseminated M1T1 strain (363). Therefore, we examined the 
susceptibility of each of the M1T1 rSAgs to degradation by rSpeB. Our data have shown 
that SmeZ1 was degraded completely whereas SpeG and SpeA2 were more resistant and 
SpeJ was completely unaffected by the proteolytic effects of SpeB. As expected, the 
degradation of SmeZ1 abolished its immune-stimulatory activity in vitro and in vivo. We 
already know that, in invasive cases, the clonal M1T1 strain turns off SpeB to spare M 
protein and other virulence factors important for survival and evasion of host immune 
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system (29, 383). These data point to smeZ1 as a highly crucial SAg that the bacteria 
have to spare.  
 
Future Directions 
 
Examine IL-10 as the primary mediator of protective alleles suppressive effects 
 Our studies in chapter 3 and 4 suggested that IL-10 may mediate the suppressive 
effects of the protective HLA class II alleles, where addition of exogenous rIL-10 
lowered high-risk alleles-induced SAgs response to a level comparable to that of 
protective alleles. To further explore this hypothesis, we will: 
1.    Add different doses of rIL-10 and observe whether this would result in a dose- 
       dependent reduction of SAgs response when presented by high-risk alleles.  
2.    Add neutralizing anti-IL-10 Ab to culture containing APC expressing the protective 
       alleles and examine whether this would increase SAg-mediated responses to that 
       induced by high-risk alleles. 
3.    Add anti-proinflammatory cytokines Abs (e.g. Anti-INF-γ, -TNF-α and -β) to 
       cultures containing APC expressing high-risk alleles and examine whether this 
       would decrease SAg-triggered responses to a level comparable to that of the  
       protective alleles. 
4.    In vitro, assess IL-10 produced by SAgs-stimulated splenocytes from HLA-tg mice 
       expressing protective (DQ6) or neutral (DR4/DQ8) alleles. If we find significant 
       difference in IL-10 production by DQ6 than by DR4/DQ8 splenocytes, then we will 
       perform a similar set of experiments to that stated in 2 and 3.  
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5.    Assess IL-10 level in the plasma of HLA-tg mice expressing protective (DQ6) or 
      neutral (DR4/DQ8) alleles following i.v., infection with life M1T1 GAS. If DQ6 mice 
      elicit higher levels of IL-10 than DR4/DQ8 mice, then we will examine whether  
      administration of rIL-10 to DR4/DQ8 mice or anti-IL-10 to DQ6 mice would improve 
      the survival of the former or increase the death rate of the later. 
 If our in vitro and in vivo results demonstrate that addition or administration rIL-
10 in the context of high-risk alleles reduces SAg-triggered inflammatory responses to a 
level comparable to that observed in the context og high risk alleles, this would suggest 
that IL-10 may be an important contributor to the protection mediated by DR15 and DQ6 
alleles. On the other hand, if the in vitro and in vivo use of neutralizing anti-IL-10 Ab in 
the presence of protective alleles enhances SAgs responses in a way equivalent to that 
demonstrated in he presence of high-risk alleles, this would confirm our hypothesis that 
the protective effects of DR15/DQ6 alleles are mediated by an active IL-10-mediated 
suppression of the SAg-induced inflammatory responses.    
 
Study the interaction of protective and high-risk alleles in modulating SAgs 
responses 
 We will assess the impact of HLA class II hetero- vs. homozygosity with respect 
to the risk/protection status of an individual. We will generate BLS cells expressing two 
alleles from different haplotypes and determine if the effects of the protective alleles 
dominate over those of the high risk alleles or vice versa. We will use BLS cells 
expressing DRB1*1501 or DQB1*06 in conjunction with DRB1*1401 or DQB1*0503 
expressed on different cells or co-expressed on the same cells. This information is 
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relevant to real life infections in heterozygous individuals, where the effect of a particular 
allele or haplotype can be modulated in the presence of another  
 If in the presence of both DQ6 and DR14 we find >50% reduction in response 
compared to cultures with DR14 ± DQ5, this would suggest active suppression of the 
SAg response by the protective DQ6 allele. Alternatively, the effects of risk alleles are 
dominant, or that the risk and protective alleles will neutralize each other’s effect to the 
point where the response becomes comparable to that with neutral alleles. The results 
obtained from these experiments will help us determine whether individuals with 
protective alleles co-expressed with high-risk alleles are as protected against STSS. These 
distinctions are important for translating our findings to predict host susceptibility to 
severe GAS sepsis.  
 
Validate our in vitro findings using HLA-transgenic mice expressing individual or 
combinations of HLA class II alleles 
 The goal here is to create an animal model that can be used to validate in vitro 
findings, and allow us to conduct in-depth mechanistic studies in vivo. For this study we 
need a set of HLA-tg mice expressing DRB1*1501, DQA1*0102-DQB1*0602, 
DRB1*1401, DQA1*0104-DQB1*0503, DRB1*0701, DQA1*0201-DQB1*0201 and 
DRB1*0402-DQA1*0301-DQB1*0302 because these alleles are present in haplotypes 
associated with outcomes of GAS sepsis in humans as demonstrated by epidemiological 
study (275). Some of these mice are currently available (DR15, DR3, DR4, DR7) and we 
are breeding and characterizing them as well as working on generating the rest of the 
required mice. Using these mice, we will validate the in vitro data generated with the 
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BLS lines and analyze the interactive effects of protective and high-risk alleles on the 
systemic response to SAgs and on the severity of GAS sepsis in HLA-tg mice. We 
predict that the systemic inflammatory response elicited by the same dose of SAgs or 
whole bacteria will vary considerably depending on HLA class II alleles expressed by the 
mice. We expect that systemic inflammatory responses in mice expressing the high-risk-
associated class II alleles will be significantly higher than in mice expressing protective 
alleles. Further, we expect that mice expressing both protective and high-risk alleles will 
be protected from the severe systemic manifestation triggered by SAgs or whole bacteria. 
Our predictions are supported by the data generated with the HLA-tg mice used in the 
current study. If as we expect, we see a confirmation of these results in the newly 
generated mice, this will support our hypothesis of the dominance of the protective class 
II alleles 
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